
<html lang="en"     class="pb-page"  data-request-id="8db118c1-bd3d-481d-ac2e-2363eeb6b7eb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c01491;issue:issue:10.1021/jmcmar.2021.64.issue-5;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer" /></meta><meta name="dc.Creator" content="Steven P.  Langston" /></meta><meta name="dc.Creator" content="Stephen  Grossman" /></meta><meta name="dc.Creator" content="Dylan  England" /></meta><meta name="dc.Creator" content="Roushan  Afroze" /></meta><meta name="dc.Creator" content="Neil  Bence" /></meta><meta name="dc.Creator" content="Douglas  Bowman" /></meta><meta name="dc.Creator" content="Nancy  Bump" /></meta><meta name="dc.Creator" content="Ryan  Chau" /></meta><meta name="dc.Creator" content="Bei-Ching  Chuang" /></meta><meta name="dc.Creator" content="Christopher  Claiborne" /></meta><meta name="dc.Creator" content="Larry  Cohen" /></meta><meta name="dc.Creator" content="Kelly  Connolly" /></meta><meta name="dc.Creator" content="Matthew  Duffey" /></meta><meta name="dc.Creator" content="Nitya  Durvasula" /></meta><meta name="dc.Creator" content="Scott  Freeze" /></meta><meta name="dc.Creator" content="Melissa  Gallery" /></meta><meta name="dc.Creator" content="Katherine  Galvin" /></meta><meta name="dc.Creator" content="Jeffrey  Gaulin" /></meta><meta name="dc.Creator" content="Rachel  Gershman" /></meta><meta name="dc.Creator" content="Paul  Greenspan" /></meta><meta name="dc.Creator" content="Jessica  Grieves" /></meta><meta name="dc.Creator" content="Jianping  Guo" /></meta><meta name="dc.Creator" content="Nanda  Gulavita" /></meta><meta name="dc.Creator" content="Shumet  Hailu" /></meta><meta name="dc.Creator" content="Xingyue  He" /></meta><meta name="dc.Creator" content="Kara  Hoar" /></meta><meta name="dc.Creator" content="Yongbo  Hu" /></meta><meta name="dc.Creator" content="Zhigen  Hu" /></meta><meta name="dc.Creator" content="Mitsuhiro  Ito" /></meta><meta name="dc.Creator" content="Mi-Sook  Kim" /></meta><meta name="dc.Creator" content="Scott Weston  Lane" /></meta><meta name="dc.Creator" content="David  Lok" /></meta><meta name="dc.Creator" content="Anya  Lublinsky" /></meta><meta name="dc.Creator" content="William  Mallender" /></meta><meta name="dc.Creator" content="Charles  McIntyre" /></meta><meta name="dc.Creator" content="James  Minissale" /></meta><meta name="dc.Creator" content="Hirotake  Mizutani" /></meta><meta name="dc.Creator" content="Miho  Mizutani" /></meta><meta name="dc.Creator" content="Nina  Molchinova" /></meta><meta name="dc.Creator" content="Koji  Ono" /></meta><meta name="dc.Creator" content="Ashok  Patil" /></meta><meta name="dc.Creator" content="Mark  Qian" /></meta><meta name="dc.Creator" content="Jessica  Riceberg" /></meta><meta name="dc.Creator" content="Vaishali  Shindi" /></meta><meta name="dc.Creator" content="Michael D.  Sintchak" /></meta><meta name="dc.Creator" content="Keli  Song" /></meta><meta name="dc.Creator" content="Teresa  Soucy" /></meta><meta name="dc.Creator" content="Yana  Wang" /></meta><meta name="dc.Creator" content="He  Xu" /></meta><meta name="dc.Creator" content="Xiaofeng  Yang" /></meta><meta name="dc.Creator" content="Agatha  Zawadzka" /></meta><meta name="dc.Creator" content="Ji  Zhang" /></meta><meta name="dc.Creator" content="Sai M.  Pulukuri" /></meta><meta name="dc.Description" content="SUMOylation is a reversible post-translational modification that regulates protein function through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of SUMOylating ..." /></meta><meta name="Description" content="SUMOylation is a reversible post-translational modification that regulates protein function through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of SUMOylating ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 25, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01491" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 The Authors. Published by American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01491" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01491" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01491" /></link>
        
    
    

<title>Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01491" /></meta><meta property="og:title" content="Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0030.jpeg" /></meta><meta property="og:description" content="SUMOylation is a reversible post-translational modification that regulates protein function through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of SUMOylating proteins involves an enzymatic cascade, the first step of which entails the activation of a SUMO protein through an ATP-dependent process catalyzed by SUMO-activating enzyme (SAE). Here, we describe the identification of TAK-981, a mechanism-based inhibitor of SAE which forms a SUMO–TAK-981 adduct as the inhibitory species within the enzyme catalytic site. Optimization of selectivity against related enzymes as well as enhancement of mean residence time of the adduct were critical to the identification of compounds with potent cellular pathway inhibition and ultimately a prolonged pharmacodynamic effect and efficacy in preclinical tumor models, culminating in the identification of the clinical molecule TAK-981." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01491"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01491">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01491&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01491&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01491&amp;href=/doi/10.1021/acs.jmedchem.0c01491" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2501-2520</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02227" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.1c00295" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Steven P. Langston</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven P. Langston</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#97e4e3f2e1f2b9fbf6f9f0e4e3f8f9d7e3f6fcf2f3f6b9f4f8fa"><span class="__cf_email__" data-cfemail="3a494e5f4c5f14565b545d494e55547a4e5b515f5e5b14595557">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven+P.++Langston">Steven P. Langston</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5840-0005" title="Orcid link">http://orcid.org/0000-0001-5840-0005</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen Grossman</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Grossman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#13406776637b767d3d54617c60607e727d534772787677723d707c7e"><span class="__cf_email__" data-cfemail="72210617021a171c5c35001d01011f131c322613191716135c111d1f">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Grossman">Stephen Grossman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dylan England</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dylan England</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dylan++England">Dylan England</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roushan Afroze</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roushan Afroze</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roushan++Afroze">Roushan Afroze</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil Bence</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil Bence</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil++Bence">Neil Bence</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Douglas Bowman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas Bowman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas++Bowman">Douglas Bowman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nancy Bump</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nancy Bump</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nancy++Bump">Nancy Bump</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ryan Chau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ryan Chau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ryan++Chau">Ryan Chau</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bei-Ching Chuang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bei-Ching Chuang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bei-Ching++Chuang">Bei-Ching Chuang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher Claiborne</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher Claiborne</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Claiborne">Christopher Claiborne</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Larry Cohen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Larry Cohen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Larry++Cohen">Larry Cohen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kelly Connolly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kelly Connolly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kelly++Connolly">Kelly Connolly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew Duffey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew Duffey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Duffey">Matthew Duffey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nitya Durvasula</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nitya Durvasula</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nitya++Durvasula">Nitya Durvasula</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott Freeze</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott Freeze</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Freeze">Scott Freeze</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melissa Gallery</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melissa Gallery</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melissa++Gallery">Melissa Gallery</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katherine Galvin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katherine Galvin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katherine++Galvin">Katherine Galvin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey Gaulin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey Gaulin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Gaulin">Jeffrey Gaulin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rachel Gershman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rachel Gershman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rachel++Gershman">Rachel Gershman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Greenspan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Greenspan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Greenspan">Paul Greenspan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jessica Grieves</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jessica Grieves</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jessica++Grieves">Jessica Grieves</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianping Guo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianping Guo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianping++Guo">Jianping Guo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nanda Gulavita</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nanda Gulavita</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nanda++Gulavita">Nanda Gulavita</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shumet Hailu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shumet Hailu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shumet++Hailu">Shumet Hailu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xingyue He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xingyue He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xingyue++He">Xingyue He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kara Hoar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kara Hoar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kara++Hoar">Kara Hoar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yongbo Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongbo Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongbo++Hu">Yongbo Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhigen Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhigen Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhigen++Hu">Zhigen Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mitsuhiro Ito</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mitsuhiro Ito</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mitsuhiro++Ito">Mitsuhiro Ito</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mi-Sook Kim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mi-Sook Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mi-Sook++Kim">Mi-Sook Kim</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott Weston Lane</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott Weston Lane</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott+Weston++Lane">Scott Weston Lane</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Lok</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Lok</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Lok">David Lok</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anya Lublinsky</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anya Lublinsky</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anya++Lublinsky">Anya Lublinsky</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William Mallender</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William Mallender</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William++Mallender">William Mallender</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charles McIntyre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charles McIntyre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charles++McIntyre">Charles McIntyre</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Minissale</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Minissale</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Minissale">James Minissale</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hirotake Mizutani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hirotake Mizutani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hirotake++Mizutani">Hirotake Mizutani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Miho Mizutani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Miho Mizutani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Miho++Mizutani">Miho Mizutani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nina Molchinova</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nina Molchinova</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nina++Molchinova">Nina Molchinova</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Koji Ono</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Koji Ono</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Koji++Ono">Koji Ono</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ashok Patil</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ashok Patil</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ashok++Patil">Ashok Patil</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Qian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Qian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Qian">Mark Qian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jessica Riceberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jessica Riceberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jessica++Riceberg">Jessica Riceberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vaishali Shindi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vaishali Shindi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vaishali++Shindi">Vaishali Shindi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael D. Sintchak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael D. Sintchak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Sintchak">Michael D. Sintchak</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Keli Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Keli Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Keli++Song">Keli Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Teresa Soucy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Teresa Soucy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Teresa++Soucy">Teresa Soucy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yana Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yana Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yana++Wang">Yana Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">He Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">He Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=He++Xu">He Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaofeng Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaofeng Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaofeng++Yang">Xiaofeng Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Agatha Zawadzka</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Agatha Zawadzka</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Agatha++Zawadzka">Agatha Zawadzka</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ji Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ji Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ji++Zhang">Ji Zhang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Sai M. Pulukuri</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sai M. Pulukuri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sai+M.++Pulukuri">Sai M. Pulukuri</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01491&amp;href=/doi/10.1021%2Facs.jmedchem.0c01491" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2501–2520</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 25, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 October 2020</li><li><span class="item_label"><b>Published</b> online</span>25 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01491</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="https://acsopenscience.org/open-access/licensing-options/"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by-nc"><a href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a><a href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_nc-1612971093307.svg" alt="NC: Only noncommercial uses of the work are permitted" /></img><span><strong>NC: </strong>Only noncommercial uses of the work are permitted</span></a><a href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_nd-1612971093637.svg" alt="ND: No derivatives or adaptations of the work are permitted" /></img><span><strong>ND: </strong>No derivatives or adaptations of the work are permitted</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01491"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7718</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01491" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;P. Langston&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Grossman&quot;},{&quot;first_name&quot;:&quot;Dylan&quot;,&quot;last_name&quot;:&quot;England&quot;},{&quot;first_name&quot;:&quot;Roushan&quot;,&quot;last_name&quot;:&quot;Afroze&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Bence&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;Bowman&quot;},{&quot;first_name&quot;:&quot;Nancy&quot;,&quot;last_name&quot;:&quot;Bump&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;Chau&quot;},{&quot;first_name&quot;:&quot;Bei-Ching&quot;,&quot;last_name&quot;:&quot;Chuang&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Claiborne&quot;},{&quot;first_name&quot;:&quot;Larry&quot;,&quot;last_name&quot;:&quot;Cohen&quot;},{&quot;first_name&quot;:&quot;Kelly&quot;,&quot;last_name&quot;:&quot;Connolly&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Duffey&quot;},{&quot;first_name&quot;:&quot;Nitya&quot;,&quot;last_name&quot;:&quot;Durvasula&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Freeze&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;Gallery&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;Galvin&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Gaulin&quot;},{&quot;first_name&quot;:&quot;Rachel&quot;,&quot;last_name&quot;:&quot;Gershman&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Greenspan&quot;},{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;Grieves&quot;},{&quot;first_name&quot;:&quot;Jianping&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Nanda&quot;,&quot;last_name&quot;:&quot;Gulavita&quot;},{&quot;first_name&quot;:&quot;Shumet&quot;,&quot;last_name&quot;:&quot;Hailu&quot;},{&quot;first_name&quot;:&quot;Xingyue&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Kara&quot;,&quot;last_name&quot;:&quot;Hoar&quot;},{&quot;first_name&quot;:&quot;Yongbo&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Zhigen&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Mitsuhiro&quot;,&quot;last_name&quot;:&quot;Ito&quot;},{&quot;first_name&quot;:&quot;Mi-Sook&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Weston Lane&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Lok&quot;},{&quot;first_name&quot;:&quot;Anya&quot;,&quot;last_name&quot;:&quot;Lublinsky&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;Mallender&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;McIntyre&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Minissale&quot;},{&quot;first_name&quot;:&quot;Hirotake&quot;,&quot;last_name&quot;:&quot;Mizutani&quot;},{&quot;first_name&quot;:&quot;Miho&quot;,&quot;last_name&quot;:&quot;Mizutani&quot;},{&quot;first_name&quot;:&quot;Nina&quot;,&quot;last_name&quot;:&quot;Molchinova&quot;},{&quot;first_name&quot;:&quot;Koji&quot;,&quot;last_name&quot;:&quot;Ono&quot;},{&quot;first_name&quot;:&quot;Ashok&quot;,&quot;last_name&quot;:&quot;Patil&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Qian&quot;},{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;Riceberg&quot;},{&quot;first_name&quot;:&quot;Vaishali&quot;,&quot;last_name&quot;:&quot;Shindi&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Sintchak&quot;},{&quot;first_name&quot;:&quot;Keli&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Teresa&quot;,&quot;last_name&quot;:&quot;Soucy&quot;},{&quot;first_name&quot;:&quot;Yana&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;He&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Xiaofeng&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Agatha&quot;,&quot;last_name&quot;:&quot;Zawadzka&quot;},{&quot;first_name&quot;:&quot;Ji&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Sai&quot;,&quot;last_name&quot;:&quot;M. Pulukuri&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2501-2520&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01491&quot;},&quot;abstract&quot;:&quot;SUMOylation is a reversible post-translational modification that regulates protein function through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of SUMOylating proteins involves an enzymatic cascade, the first step of which entails the activation of a SUMO protein through an ATP-dependent process catalyzed by SUMO-activating enzyme (SAE). Here, we describe the identification of TAK-981, a mechanism-based inhibitor of SAE which forms a SUMO–TAK-981 adduct as the inhibitory species within the enzyme catalytic site. Optimization of selectivity against related enzymes as well as enhancement of mean residence time of the adduct were critical to the identification of compounds with potent cellular pathway inhibition and ultimately a prolonged pharmacodynamic effect and efficacy in preclinical tumor models, culminating in the identification of the clinical molecule TAK-981.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01491&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01491" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01491&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01491" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01491&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01491" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01491&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01491&amp;href=/doi/10.1021/acs.jmedchem.0c01491" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01491" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01491" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01491%26sid%3Dliteratum%253Aachs%26pmid%3D33631934%26genre%3Darticle%26aulast%3DLangston%26date%3D2021%26atitle%3DDiscovery%2Bof%2BTAK-981%252C%2Ba%2BFirst-in-Class%2BInhibitor%2Bof%2BSUMO-Activating%2BEnzyme%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D5%26spage%3D2501%26epage%3D2520%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292547" title="Adducts">Adducts</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/jmcmar.2021.64.issue-5/20210311/jmcmar.2021.64.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0030.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">SUMOylation is a reversible post-translational modification that regulates protein function through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of SUMOylating proteins involves an enzymatic cascade, the first step of which entails the activation of a SUMO protein through an ATP-dependent process catalyzed by SUMO-activating enzyme (SAE). Here, we describe the identification of TAK-981, a mechanism-based inhibitor of SAE which forms a SUMO–TAK-981 adduct as the inhibitory species within the enzyme catalytic site. Optimization of selectivity against related enzymes as well as enhancement of mean residence time of the adduct were critical to the identification of compounds with potent cellular pathway inhibition and ultimately a prolonged pharmacodynamic effect and efficacy in preclinical tumor models, culminating in the identification of the clinical molecule TAK-981.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Small ubiquitin-like modifier (SUMO) proteins are reversible post-translational modifiers of intracellular proteins. The SUMOylation of proteins occurs through a three-step enzymatic cascade involving activation, transfer, and ligation of SUMO protein to lysine residues of target proteins. The first step of the cascade is catalyzed by SUMO activating enzyme (SAE), which belongs to a small family of activating enzymes collectively known as E1s.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> SAE is a heterodimeric protein (SAE1, SAE2, or UBA2) and activates SUMO proteins through the carboxy terminus by reaction with ATP to form an acyl adenylate intermediate that is primed for acylation of a cysteine residue on the enzyme to form a thioester. The SUMO protein is subsequently transferred, through thioester exchange, to the SUMO specific conjugating enzyme E2, UBC9.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Aided by SUMO specific E3 protein ligases, the SUMO proteins are transferred to lysine residues of target proteins to form oligomers through formation of an isopeptide bond.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The enzymatic cascade is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, steps A–C. This three-step sequence is analogous to the process of ubiquitination and neddylation of cellular proteins, the first step of which is catalyzed by the homologue E1 ubiquitin activating enzyme (UAE) or Nedd8 activating enzyme (NAE), respectively.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a></div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Enzymatic Cascade for the SUMOylation of Target Proteins and Mechanism of Inhibition of Adenosine Sulfamate Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There are three SUMO family members: SUMO1, which conjugates to target proteins as a monomer, and SUMO2 and SUMO3, which modify proteins through formation of oligomeric chains.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The modification of proteins by SUMO alters their molecular surface and can have effects on the protein’s catalytic activity, cellular localization, and interaction with other proteins. In recent years, protein targets of SUMOylation have been identified that play key roles in multiple cellular pathways, including cell division and DNA repair, nuclear transport, gene transcription, chromosome structure and segregation, and immune response modulation.<a onclick="showRef(event, 'ref1 ref8'); return false;" href="javascript:void(0);" class="ref ref1 ref8">(1,8)</a></div><div class="NLM_p">Elevated levels of the components of the SUMO pathway, e.g. UBC9, are associated with poor patient outcome in certain malignancies.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Knockdown of SAE has been reported to confer synthetic lethality in cell lines and tumor models with high myc expression, and shRNAs targeting components of the SUMO pathway have demonstrated tumor growth inhibition in xenograft models.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11−14)</a> SUMOylation has also been shown to modulate innate immune responses.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> A net inhibitory effect of SUMOylation on type 1 interferon (IFN) expression has been demonstrated such that inhibiting SUMOylation by genetic means resulted in enhanced basal expression levels and sensitization of induction of type 1 IFNs by pathogenic stimuli.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a></div><div class="NLM_p last">In addition, SUMOylation has been found to suppress a type1 interferon response to innate immune sensors, and depletion of UBC9 in hematopoietic cells enhanced an inflammatory response and protection to viral infection in mouse models.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Collectively, these observations warrant the identification of potent and selective small molecule inhibitors of SAE to explore the cellular effects of SUMO pathway inhibition and potential therapeutic opportunity.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41575" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41575" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our group has previously identified a class of adenosine sulfamate (AdoS) derived inhibitors of E1 enzymes that act through a unique type of mechanism-based inhibition termed substrate assisted inhibition.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> These inhibitors were shown to act through reaction of the sulfamate moiety with a cysteine thioester of the E1 enzyme and UBL to form a UBL–inhibitor adduct within the enzyme catalytic site, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> step D, using SAE as an illustrative example. The conformation of the enzyme that binds the substrates ATP and SUMO is thought to be open, while a more closed structure resembling that captured in the crystal structure of a SUMO-adenosine vinylsulfone covalently trapped intermediate may also contribute to binding the SUMO-AdoS adduct.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a></div><div class="NLM_p">An early example of the series is the N-6 substituted adenosine sulfamate compound <b>1</b>, a nonselective E1 inhibitor, was shown to be capable of forming an inhibitor adduct with E1 UBL substrates, including UAE, NAE, and SAE, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Compound <b>1</b> was optimized through an iterative medicinal chemistry program to the selective inhibitor of NAE, Pevonedistat (TAK-924, MLN-4924), which is currently in clinical trial for solid and heme malignancies, including a phase III trial in combination with azacytidine for patients with high risk myelodysplastic syndrome (HR MDS), chronic myelomonocytic leukemia (CMML), or low-blast acute myeloid leukemia (AML) (NCT03268954).<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> Pevonedistat was shown to selectively inhibit NAE by reacting with the NAE-Nedd-8 thioester to form the Nedd-8-Pevonedistat adduct, a tight binding bisubstrate analogue, within the enzyme active site.<a onclick="showRef(event, 'ref18 ref25'); return false;" href="javascript:void(0);" class="ref ref18 ref25">(18,25)</a> The chemical class was subsequently diversified, and the UAE inhibitor TAK-243 was identified, which acts via a similar mechanism forming a ubiquitin–TAK-243 adduct that inhibits UAE and also entered clinical evaluation within oncology (NCT03816319), <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.<a onclick="showRef(event, 'ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29">(26−29)</a></div><div class="NLM_p">Despite demonstrating that compound <b>1</b> was able to form SUMO–compound <b>1</b> adduct, it proved challenging to identify a selective compound capable of demonstrating robust inhibition of the SUMO pathway in cells. Compounds reported to be inhibitors of SAE were not useful as tool compounds due to weak activity and unclear selectivity.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> While conducting an extensive scaffold hopping exercise within the adenosine sulfamate series, compound <b>2</b> was prepared and demonstrated potent SAE activity in the HTRF or transthiolation assay.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Although retaining significant activity for UAE and NAE, it was an example of a distinct chemotype, and removal the 2′-hydroxyl (adenosine numbering) gave a somewhat more selective molecule <b>3</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The homogeneous time resolved fluorescence (HTRF) assay was conducted at <i>K</i><sub>m</sub> for ATP and utilized SUMO1 as the UBL substrate. The compounds were also shown to be active at millimolar ATP concentration for both SUMO1 and SUMO2 as substrates by employing a pyrophosphate exchange assay.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Importantly, quantitative Western blot assays demonstrated robust inhibition of the SUMO pathway in cells, giving a selective reduction in the concentration of the E2 intermediate UBC9-SUMO compared to the E2-UBL conjugates for UAE and NAE, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. We were thus encouraged to utilize this scaffold as the basis of a SAR exploration to identify potent and selective inhibitors of SAE to explore the biology and potential therapeutic utility of SAE and consequently SUMO pathway inhibition both in cells and <i>in vivo</i>.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. An early adenosine sulfamate and clinical compounds for NAE and UAE.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzyme and Cell Activity of Initial Inhibitors of SAE</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0020.gif" alt="" id="GRAPHIC-d7e787-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">HTRF, IC<sub>50</sub> nM<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center">ATP-PPi, IC<sub>50</sub> nM<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="3" align="center">Western blot, IC<sub>50</sub> nM<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">SAE</th><th class="colsep0 rowsep0" align="center">UAE</th><th class="colsep0 rowsep0" align="center">NAE</th><th class="colsep0 rowsep0" align="center">SAE (SUMO1/2)</th><th class="colsep0 rowsep0" align="center">UAE</th><th class="colsep0 rowsep0" align="center">NAE</th><th class="colsep0 rowsep0" align="center">SUMO-UBC9</th><th class="colsep0 rowsep0" align="center">Ub-UBC12</th><th class="colsep0 rowsep0" align="center">Nedd 8-UBC10</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">6/50</td><td class="colsep0 rowsep0" align="left">1100</td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">410</td><td class="colsep0 rowsep0" align="left">1400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">190</td><td class="colsep0 rowsep0" align="left">11/69</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">2600</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">2600</td><td class="colsep0 rowsep0" align="left">>5000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Transthiolation assay measuring inhibition of the transfer of SUMO1 to UBC9 (the E2 for SAE) at an [ATP] approximating <i>K</i><sub>m</sub> (20 μM).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Pyrophosphate exchange assay measuring inhibition of enzyme activity for either SUMO1 or SUMO2 substrates for SAE, Ub for UAE, and Nedd-8 for NAE; all were conducted at 1 mM [ATP].</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Cellular assay conducted in HCT116 cells assessing inhibition of conjugation (transthiolation) of SUMO proteins to UBC9. Similarly, for conjugation of ubiquitin to UBC12 and conjugation of Nedd-8 to UBC-10, the UBL and E2 substrates for UAE and NAE, respectively.</p></div></div></div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Western blot demonstrating cellular pathway inhibition by compounds <b>2</b> and <b>3</b>. Inhibition of SAE and NAE in cells was assessed by immunoblot analysis of SUMO2/3-conjugated proteins, SAE enzyme, and neddylated cullin levels in HCT-116 cell lysates. Multiple SUMO2/3 conjugate bands reflect the myriad proteins serving as substrates for SUMOylation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Western blot assay served to demonstrate potent, selective pathway inhibition in cells. However, to support a medicinal chemistry program, we required a higher throughput assay that was amenable to automation. In cells, there exists a highly dynamic process of SUMOylation and deSUMOylation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> SUMO conjugated proteins, which normally have high molecular weight, are mainly localized within the nucleus. The cellular inhibition of SAE results in an apparent loss of SUMOylated proteins in the nucleus due to rapid deSUMOylation, catalyzed by SUMO specific proteases, coupled with the inability to further SUMOylate existing or newly synthesized proteins. Additionally, free SUMO levels increase and redistribute throughout the cell. An immunofluorescence assay (SUMO IF) was developed to monitor this redistribution of SUMO protein from nucleus to cytosol and quantify SAE inhibition in the HCT116 tumor cell line. Representative images are shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. The SUMO2/3 immunofluorescence assay. This assay measures the level of inhibition of the SAE by measuring the ratio of SUMO2/3 in the nuclear versus cytoplasmic cellular compartments. HCT-116 cells were seeded in 96-well plates and treated with compound <b>3</b> at the indicated concentrations for 4 h followed by staining with antihuman SUMO2/3 monoclonal antibody (MBL, clone 1E7). Imaging was performed on an IX-Ultra imager and analyzed for SUMO2/3 inner/outer ratio using MetaXpress Translocation-Enhanced module. Dose-dependent reduction of cytoplasmic SUMO2/3 positive staining reflects loss of SUMOylated proteins sequestered in this compartment under physiological conditions (DMSO). Right panel shows the dose response for compound <b>3</b> in HCT-116 cells as determined by the SUMO2/3 immunofluorescence assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Initial SAR investigation focused on two areas of the molecule: exploration of the substitution pattern of the cyclopentane core and N1-substituents of the 3-substituted pyrazole. The 2′-deoxy compound <b>3</b> improved selectivity toward NAE and UAE with only a slight decrease in activity, while epimerization of the alcohol at this position as in <b>4</b> reduced activity for all three enzymes, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Fluorination of the 2′-position was tolerated as either epimer, see <b>6</b> and <b>7</b>, and as the difluorinated compound <b>8</b>, with modest improvements in selectivity, although at the expense of cell potency and added synthetic complexity. Epimerization of the C4′-methylene sulfamate, as in <b>5</b>, to give the antirelationship relative to the nucleobase mimetic, reminiscent of the configuration for the NAE inhibitor TAK-924, reduced activity, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Exploration of the Cyclopentyl Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0021.gif" alt="" id="GRAPHIC-d7e1016-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">structure</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char=".">SAE</th><th class="colsep0 rowsep0" align="center" char=".">NAE</th><th class="colsep0 rowsep0" align="center" char=".">UAE</th><th class="colsep0 rowsep0" align="center" char=".">SUMO IFIC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">190</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">748</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">1530</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">b</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">806</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">334</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">517</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">688</td><td class="colsep0 rowsep0" align="char" char=".">492</td><td class="colsep0 rowsep0" align="char" char=".">260</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">249</td></tr></tbody></table></div></div><div class="NLM_p">An array of N1-pyrazole substituents was investigated, see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. The benzyl group was found to be preferred over alkyl groups, including linear and branched alkyl substituents. The benzyl group, as in <b>3</b>, was also preferred over phenyl, as in <b>9</b>, and the corresponding methylene cyclohexane <b>10</b>. Investigating the preferred substitution pattern around the benzyl group showed that the meta-position, as in <b>12</b>, for chloro-substitution was preferred over ortho <b>11</b> and para <b>13</b>, and typically, larger more hydrophobic groups were preferred at this position (ML-792, <b>15</b>–<b>19</b>). Methylene heterocycles with halo substitution were also found to be potent, for example the 5-chloro-2-furanyl <b>19</b>, corresponding thiophene <b>20</b>, and the 6-halo-2-pyridines (<b>21</b>, <b>22</b>), <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR Exploration of Pyrazole Substituents</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0022.gif" alt="" id="GRAPHIC-d7e1315-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">SAE</th><th class="colsep0 rowsep0" align="center" char=".">NAE</th><th class="colsep0 rowsep0" align="center" char=".">UAE</th><th class="colsep0 rowsep0" align="center" char=".">SUMO IF IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="char" char=".">67</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">468</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">cyclohexylmethyl</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">276</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">1610</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">2-Cl-benzyl</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">215</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">332</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">3-Cl-benzyl</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">242</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">4-Cl-benzyl</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">1880</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">3-F-benzyl</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">357</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">515</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ML-792</td><td class="colsep0 rowsep0" align="left">3-Br-benzyl</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">228</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">3-Me-benzyl</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">308</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">3-ethynylbenzyl</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">304</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub>-benzyl</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">695</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub>O-benzyl</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">(5-Cl-furan-2-yl)methyl</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">435</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">(5-Cl-thiophen-2-yl)methyl</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">353</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">228</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">(6-Cl-pyridine-2-yl)methyl</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">478</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">(6-Br-pyridine-2-yl)methyl</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">581</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">49</td></tr></tbody></table></div></div><div class="NLM_p">Alternative heterocycles to the 3-pyrazole were also explored. The N-substituted 3-pyrrole was found to be potent although less selective toward NAE; see <b>23</b> and <b>25</b> compared to <b>3</b> and ML-792. The N-benzyl 4-pyrazole regioisomer <b>24</b> was less potent than the 3-pyrazole, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. Heterocycles with C-benzylation were also explored, and the 4-benzylated 2-thiophene <b>26</b> showed promising potency, especially in the cellular SUMO IF assay, compared to the thiophene and furan isomers <b>27</b> and <b>28</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR Exploration of Alternative Benzyl Substituted Heterocycles</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0023.gif" alt="" id="GRAPHIC-d7e1715-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0024.gif" alt="" id="gr20" /></img><div></div></div><div class="NLM_p">ML-792 was chosen as a suitable representative compound to investigate the effects of SAE inhibition on cancer cell biology because of its potency and selectivity. The effects of ML-792 on several cancer lines have been previously reported.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> For the HCT116 cancer cell line, both an apoptotic and senescent phenotype were observed, resulting in a reduced cell proliferation in a 72 h viability assay. The next step was to explore the effects of SAE and SUMO pathway inhibition in in vivo tumor xenograft models. Selective pathway inhibition was first determined by Western blot assays showing loss of SUMO-Ubc9 thioester and SUMO-protein conjugates beyond 8 h following a single subcutaneous dose. The SUMO-ML-792 adduct from xenograft homogenates was quantified initially by mass spectrometry.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Subsequently, an antibody to the SUMO-ML-792 adduct was developed to quantify levels of adduct by immunohistochemistry (IHC). Additionally, an IHC assay was developed to assess the levels of SUMO–protein conjugates in cellular nuclei from xenograft homogenates. This facilitated observation of target engagement (presence of adduct) and SUMO pathway inhibition (loss of SUMO-protein conjugates) in the same tissue. The ratio of nuclei staining positive for SUMO-ML-792 adduct and SUMO–protein conjugates to total nuclei in HCT116 (colorectal carcinoma) xenograft homogenates is plotted in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Importantly, an inverse relationship between the persistence of SUMO–inhibitor adduct with the rate of SUMOylated protein recovery was observed. The pathway recovers between 8 and 24 h despite significant adduct remaining. This may be due to partial restoration of enzyme activity through adduct release. The effect on tumor growth was investigated, and we were gratified to observe robust, dose-dependent tumor growth inhibition in the HCT116 model on both continuous and intermittent dosing schedules, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacodynamic effects of ML-792 in HCT-116 tumor bearing female NCr nude mice. Each data point represents the averaged value across <i>n</i> = 3 mice. Error bars = SEM. At <i>t</i> = 0, mice received a single SC injection of ML-792 at 150 mg/kg. Red line = percent nuclei staining positive for SUMO2/3 conjugation normalized to vehicle-treated animals. Blue line = percent nuclei staining positive for SUMO-ML-792 adduct.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor efficacy of ML-792 at multiple dose/schedule regimens in Ncr/nude mice bearing HCT-116 tumor-bearing mice. (a) ML-792 was dosed subcutaneously at the dose and schedule indicated for each arm (<i>n</i> = 10 female NCr nude mice/arm) until the final treatment day on day 21. Schedules: BID x21 = twice per day for 21 days (days 1–21); BID BIW = twice per day/twice per week (days 1, 4, 8, 11, 15, 18, 21); BID 2on-5off = twice per day/twice per week on 2 consecutive days followed by 5 nondosing days (days 1, 2, 8, 9, 15, 16, 21).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With establishment of PD markers for both target engagement and pathway inhibition as well as robust tumor growth inhibition, we were encouraged to continue to optimize the chemical series. The dose of ML-792 required for a robust PD response and efficacy was high (150 mg/kg s.c.) and involved twice daily administration; thus, we aimed to prolong PD response to dosing frequency. The SAE enzyme is relatively long-lived, and we determined that the resynthesis rate, even in the presence of the SAE inhibitor ML-792, is comparable to cellular doubling time.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> It was thus anticipated that optimizing the binding affinity of the adduct to the enzyme would increase the residence time of the inhibitory adduct species in the enzyme active site and result in prolonged pathway inhibition.</div><div class="NLM_p">To support this approach, the SUMO IF assay was adapted to assess duration of pathway inhibition by including a compound washout step. In this format, the cells were incubated with a range of compound concentrations for 2 h. The cells were then washed to remove residual compound, and the nuclear and cytoplasmic SUMO2/3 fluorescence signal was measured immediately or 8 h following washout. As a result of pathway recovery, the SUMO2/3 fluorescence signal was shown to relocalize to the nucleus over time, and an IC<sub>50</sub> was calculated and reported at 0 and 8 h, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR Exploration of Benzylic Substitution on Thiophene</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0025.gif" alt="" id="GRAPHIC-d7e1773-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">structure</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">SAE</th><th class="colsep0 rowsep0" align="center">NAE</th><th class="colsep0 rowsep0" align="center">UAE</th><th class="colsep0 rowsep0" align="center">SUMO IF IC<sub>50</sub> (nM) (washout 0, 8 h)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ML-792</td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">228</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">10 (25, 246)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">b</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">41 (52, 650)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">b</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">68 (142, 2060)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">b</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">114</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">660 (1210, >10 000)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">b</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">216</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">55 (43, 955)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">b</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">328</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">1030 (−, −)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">b</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">50 (83, 499)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">b</td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">956</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">436</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">b</td><td class="colsep0 rowsep0" align="left">NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">4170</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> immediately following washout of compound, 0 h, or after 8 h.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Single diastereomer, undefined configuration.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Mixture of diastereomers.</p></div></div></div><div class="NLM_p">Cocrystallization of the enzyme, inhibitor, ATP, and SUMO substrate, using procedures modified from those developed for UAE and NAE, gave high resolution crystal structures of the SUMO–inhibitor adduct for both <b>2</b> and <b>3</b> within the SAE active site, see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> for compound <b>2</b>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> An internal H-bond is apparent between the amino and ketone functionalities, stabilizing the orientation of the pyrimidine and facilitating formation of an H-bond between N1 of the pyrimidine and the backbone NH of Ile96. The pyrazole nitrogen is facing the same direction as the ketone and interacting with Asn118. Replacing the pyrazole with thiophene was anticipated to lead to a similar orientation with the sulfur facing the same direction as the ketone to maximize nonbonding sulfur–oxygen interactions. The 2,4-thiophene substituted system, exemplified in compounds <b>26</b> and <b>29</b>, was chosen as an alternative starting point for further optimization because, unlike the pyrazole series, it gives the ability to incorporate heteroatoms on the benzylic methylene position which was anticipated to lead to additional H-bond interaction with Ser95, potentially helping to stabilize the adduct within the enzyme and increase residence time, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structure of SUMO1-compound <b>2</b> adduct within SAE ATP binding domain. Carbon is shown in cyan (<b>2</b>), green (SUMO), or gray (SAE); nitrogen, blue; oxygen, red; and sulfur, yellow. Secondary structure of SAE is shown in gray. Hydrogen bonds are indicated by dashed lines. PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOI">6XOI</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The 3-chloro benzyl thiophene <b>29</b> was 5–10-fold less potent than the pyrazole ML-792 in the cellular SUMO IF assay both at 0 and 8 h following washout, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Substitution of the benzylic methylene with a hydroxyl or primary amine and separation of the epimers gave one stereoisomer with significantly more activity over the other, see <b>31</b> compared to <b>30</b> and <b>33</b> compared to <b>32</b>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The more active isomer of the primary amine, compound <b>33</b>, exhibited activity approaching the cellular potency of the pyrazole ML-792 and showed good selectivity over both NAE and UAE. Methylation of the amine to the secondary or tertiary amine significantly reduced potency.</div><div class="NLM_p">Substitution of the thiophene was also investigated. Chlorination or methylation at the 5-position were tolerated with the methylated compound <b>36</b> being more potent than the unsubstituted thiophene <b>29</b>. The polar and electron withdrawing cyano group at this position <b>38</b> was significantly less active, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Combining methylation of the thiophene and hydroxylation or amination of the benzylic center yielded highly potent compounds. The more active stereoisomers exhibiting only a 2- to 3-fold drop off in potency following washout and maintaining pathway inhibition below 50 nM at 8 h. Incorporating methylation at the benzylic position to give the tertiary alcohol or corresponding primary amine was well-tolerated and again demonstrated only a small drop off in potency between 0 and 8 h for the more active isomers in the washout assay, e.g. see <b>45</b>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR Exploration Thiophene Substitution</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0026.gif" alt="" id="GRAPHIC-d7e2236-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">structure</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup>/R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center" char=".">SAE</th><th class="colsep0 rowsep0" align="center" char=".">NAE</th><th class="colsep0 rowsep0" align="center" char=".">UAE</th><th class="colsep0 rowsep0" align="center">SUMO IF IC<sub>50</sub> (nM) washout (0, 8 h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">H/H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">19 (66, 403)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">H/H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">681</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">108 (184, 1400)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">H/H</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">6260</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">OH<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a>/H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">64</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">6 (8, 21)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">OH<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a>/H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">341</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">9 (17, 70)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a>/H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">235</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">16 (19, 38)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a>/H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">861</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">10 (17, 39)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">OH<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a>/H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">340</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">14 (16, 142)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">OH<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a>/CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">343</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">12 (19, 233)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">a</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a>/CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td><td class="colsep0 rowsep0" align="left">16 (29, 101)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">b</td><td class="colsep0 rowsep0" align="left">OH<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a>/CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">616</td><td class="colsep0 rowsep0" align="left">47 (251, 361)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">More active diastereomer at this center.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last"><i>S</i>-Configuration at this center.</p></div></div></div><div class="NLM_p">The crystal structure of the adduct of the more active isomer of a tertiary alcohol analogue, compound <b>46</b>, in which the meta-chlorophenyl is replaced with 6-bromopyridyl, demonstrates the anticipated H-bond between the benzylic methylene hydroxyl group and serine 95, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>. It also specifies the desired configuration of the benzylic center as <i>S</i>. Assuming a similar preferred orientation for the benzylic amino analogues, a rationale can be put forward to explain why methylation to the secondary or tertiary amine (compounds <b>34</b>, <b>35</b> in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) is less active, as the methyl group would either preclude access to this orientation or clash with the enzyme. The internal H-bond between the pyridine substituent and tertiary alcohol suggests that cyclization of the heteroatom to the pendant aryl group may be favored.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structure of SUMO1-compound <b>46</b> adduct bound to SAE. Carbon is shown in cyan for compound <b>46</b>, green (SUMO), or gray (SAE); nitrogen, blue; oxygen, red; bromide, dark red; and sulfur, yellow. Secondary structure of SAE is shown in gray. Hydrogen bonds are indicated by dashed lines. PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOG">6XOG</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To investigate the effect of cyclization, we prepared both the isochromane and tetrahydroisoquinoline ring systems. The isochromane was indeed extremely potent and demonstrated prolonged cellular pathway inhibition; for example, ML-93 exhibited an IC<sub>50</sub> of 15 nM at the 8 h time point in the SUMO IF assay. Similar to the open chain system, one isomer is highly preferred over the other, as can be seen by comparing ML-93 with <b>47</b>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. Meta-substitution had been shown to be preferred in the open benzylic analogues. The unmethylated thiophene analogue <b>50</b> and replacement of the methyl group with chloro, as in <b>48</b>, gave compounds of similar potency. Cyclization to the isochromane effectively fixes the orientation of the meta-substituents in two distinct areas of space. The 7-chloro-isochromane <b>50</b> was found to be significantly more active than the corresponding substitution at the 5-position as in <b>51</b>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. The matched pair of <b>48</b>, the 5-membered dihydroisobenzofuran ring system <b>55</b>, was not well-tolerated with a significant loss of cell potency. The tetrahydroisoquinoline (THiQ) exemplified by TAK-981 also exhibited potent and prolonged cellular pathway inhibition with improved selectivity over NAE. Removal of the methyl or chloro-substituents (<b>58</b>, <b>59</b>) reduced cellular potency more so in the THiQ series than the isochromane series. Methylation of the THiQ nitrogen, as in <b>60</b>, also significantly reduced potency, and again, the 5-membered isoindoline ring system <b>61</b> suffered from reduced potency, e.g. comparing <b>57</b> with <b>61</b>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. A crystal structure of the SUMO–compound <b>49</b> adduct confirmed the configuration of the isochromane, and the isochromane oxygen and ser-95 are within contact distance to form an H-bond, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. The corresponding residues to Ser-95 are Lys-147 and Arg-551 in NAE and UAE, respectively, which may explain the particularly high selectivity for the basic amino-containing compounds such as TAK-981.<a onclick="showRef(event, 'ref18 ref34'); return false;" href="javascript:void(0);" class="ref ref18 ref34">(18,34)</a> The H-bonding to ser-95 may favor orientation of the isochromane and THiQ groups to form hydrophobic interactions with the enzyme and contribute to prolong binding of the adduct. The residence time of the adduct in the enzyme is thought to be particularly important for cellular potency as released adduct may be susceptible to cleavage by cellular endoproteases such as SUMO specific endoproteases (SENPs).<a onclick="showRef(event, 'ref19 ref35'); return false;" href="javascript:void(0);" class="ref ref19 ref35">(19,35)</a></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. SAR Exploration of Isochromane and Tetrahydroisoquinoline Substituents<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0027.gif" alt="" id="GRAPHIC-d7e2832-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0028.gif" alt="" id="gr21" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0029.gif" alt="" id="GRAPHIC-d7e2834-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">An asterisk indicates a more active diastereomer, undefined configuration.</p></div></div><div></div></div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Crystal structure of SAE with SUMO1-compound <b>49</b> adduct. Carbon is shown in cyan, <b>49</b>, green (SUMO), or gray (SAE); nitrogen, blue; oxygen, red; and sulfur, yellow. Secondary structure of SAE is shown in gray. Hydrogen bonds are indicated by dashed lines. PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOH">6XOH</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having established durable pathway inhibition in cells, we investigated whether this translated into a prolonged response in a solid tumor xenograft (HCT-116; colorectal carcinoma) and a hematological tumor xenograft (OCI-Ly10; DLBCL) model. A PD time course for the isochromane ML-93 and the corresponding THiQ TAK-981 compared to the initial lead ML-792 in HCT-116 is shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a and in OCI-Ly10 is shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>b. In HCT-116, the depletion of SUMO-conjugated proteins is much more sustained for ML-93 and TAK-981 than for ML-792. Even with lower dose of ML-93 (50 mg/kg) and TAK-981 (50 mg/kg in HCT116 and 25 mg/kg in LY10), we observed less than 25% recovery through 16 h. Consistently, similar improvement in the durability of the SUMO–inhibitor adduct was observed for ML-93 and TAK-981 compared to ML-792 in the HCT-116 model, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>a and OCI-Ly10 model, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>b. The adduct to SAE enzyme ratio as determined by mass spectrometry, remains close to unity even at 16 h for TAK-981, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>a. All three compounds exhibit similar relatively rapid decrease in plasma concentration to below detection by 8 h in the HCT-116 tumor bearing mice, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a and in the OCI-Ly10 tumor bearing mice, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>b. Compound ML-93 and TAK-981 showed similar potency and viability effects in the HCT116 cells cultured in vitro, as previously observed for compound ML-792, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> An efficacy study in HCT116 model demonstrated equivalent tumor growth inhibition (tumor stasis, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>a) at much lower weekly dosage for ML-93 (50 mg/kg, QDX21, total weekly dose = 350 mg/kg) and TAK-981 (50 mg/kg QDX3/week, total weekly dose = 150 mg/kg) compared to ML-792 (150 mg/kg, BID, total weekly dose = 2100 mg/kg), <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>b. Similar results and tumor regression were observed in the OCI-Ly10 model, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>c, d. This is consistent with the Ly10 cells being intrinsically more sensitive than HCT-116 for example a cellular viability EC<sub>50</sub> for TAK-981 of 4 and 63 nM in LY10 and HCT-116, respectively, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Reduction of SUMO2/3 conjugation in xenograft tumors following IV administration of SUMOylation inhibitors. Each data point represents the averaged value across <i>n</i> = 3 female Ncr nude mice. Error bars = SEM. Percent SUMO2/3 inhibition following compound administration represented as percent nuclei staining positive by IHC for SUMO2/3 conjugates/total nuclei normalized to vehicle-treated animals (time = 0 h). SUMOylation inhibitors were administered at time = 0. ML-792 was dosed at 150 mg/kg SC (dashed line/open square). ML-93 was dosed at 50 mg/kg IV (solid line/open circle). TAK-981 was dosed at 50 mg/kg IV (solid line/open triangle). (a) Reduction of SUMO2/3 conjugation at 2, 4, 8, and 16 h postinjection in HCT-116 tumors. (b) Reduction of SUMO2/3 conjugation at 2, 4, 8, 16, and 24 h postinjection in OCI-Ly10 tumors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Gain of SUMO–compound adduct in xenograft tumors following IV administration of SUMOylation inhibitors. Adduct formation in xenograft tumors following compound administration. Each data point represents the averaged value across <i>n</i> = 3 female Ncr nude mice. Error bars = SEM. (a) Single-dose ML-792 at 150 mg/kg IV (dashed line/open square), ML-93 at 50 mg/kg IV (solid line/open circle) or TAK-981 (solid line/open triangle) was administered to Ncr/nude mice bearing HCT116 tumors. Tumors were harvested 2, 4, 8, and 16 h post IV injection. Adduct/SAE ratio = quantity SUMO–compound adduct/quantity total SAE enzyme as measured by mass spectrometry. (b) Single-dose ML-792 at 150 mg/kg IV (dashed line/open square) or TAK-981 at 25 mg/kg IV (solid line/open triangle) was administered to CB17 SCID mice bearing OCI-Ly10 tumors. Tumors were harvested 2, 4, 8, 24, and 48 h post IV injection. Percent nuclei staining positive for adduct was measured by IHC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Plasma exposure following single-dose IV administration. Plasma collected at indicated time-point postinjection by cardiac blood collection followed by centrifugation. Each data point represents the averaged value across <i>n</i> = 3 female Ncr nude mice. Error bars = SEM. (a) Single-dose injection at <i>t</i> = 0 delivered to Ncr/nude mice bearing HCT-116 tumors with the indicated compounds and dosages or (b) single-dose injection at <i>t</i> = 0 delivered to CB17 SCID mice bearing OCI-Ly10 tumors with the indicated compounds and dosages. Plasma samples were collected at 0.5, 2, 4, 8, and 16 h postinjection via cardiac blood collection followed by centrifugation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Antitumor activity versus total weekly dosage in human xenograft cancer models. Line graphs = average tumor volumes over time. Error bars = SEM. Mice were randomized into groups on Day 0. Treatment started on Day 1. Tumor volume measurements were taken twice per week. Bar graphs = total weekly dose for each treatment arm. (a) Female Ncr/nude mice bearing HCT-116 tumors (∼200 mm<sup>3</sup> volume) were randomized into 5 groups (<i>n</i> = 8/group). Treatment started on Day 1. Tumor volumes were measured twice per week. Error bars represent SEM. (b) Total weekly dose administered to mice in each arm of the HCT-116 efficacy study (panel a) is calculated, demonstrating reduced compound required to achieve efficacy with TAK-981. (c) Female CB17 SCID mice bearing OCI-Ly10 tumors (∼200 mm<sup>3</sup> volume) were randomized into 5 groups (<i>n</i> = 8/group). Treatment started on Day 1. Tumor volumes were measured twice per week. Error bars represent SEM. (d) Total weekly dose administered to mice in each arm of the OCI-Ly10 efficacy study (panel c) is calculated, demonstrating reduced compound required to achieve efficacy with TAK-981. Dosing schedules: BID x21 = twice-per-day (Days 1–21); QD x2/week = twice per week (Days 1, 4, 8, 11, 15, 18); QD x21 = once-per-day (Days 1–21); QD x3/week = thrice-per-week (Days 1–21); QD x3/week = three consecutive dosing days followed by four nondosing days (Days 1, 2, 3, 8, 9, 10, 15, 16, 17).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Profiles of ML-792, ML-93, and TAK-981</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">LogD pH 7.4</th><th class="colsep0 rowsep0" align="center">p<i>K</i><sub>a</sub></th><th class="colsep0 rowsep0" align="center">CaCo2 A-B, B-A 10<sup>–6</sup> cm/s</th><th class="colsep0 rowsep0" align="center">Int CL<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a><i>E</i><sub>h</sub> human, rat</th><th class="colsep0 rowsep0" align="center">solubility<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a> μg/mL</th><th class="colsep0 rowsep0" align="center">CA<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a> 1, 2 IC<sub>50</sub> μM pH 3.5</th><th class="colsep0 rowsep0" align="center">cell viability HCT116, LY10 EC<sub>50</sub> μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ML-792</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="left">3.6, 8.8</td><td class="colsep0 rowsep0" align="left">1.2, 64</td><td class="colsep0 rowsep0" align="left">0.7, 0.8</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.05, 0.01</td><td class="colsep0 rowsep0" align="left">0.090, 0.055</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ML-93</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="left">3.5, 8.9</td><td class="colsep0 rowsep0" align="left">4.0, 64</td><td class="colsep0 rowsep0" align="left">0.9, 0.9</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">0.05, 0.01</td><td class="colsep0 rowsep0" align="left">0.110, 0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TAK-981</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="left">3.6, 7.5, 8.8</td><td class="colsep0 rowsep0" align="left">0.3, 46</td><td class="colsep0 rowsep0" align="left">0.8, 0.9</td><td class="colsep0 rowsep0" align="left">20 000</td><td class="colsep0 rowsep0" align="left">0.09, 0.02</td><td class="colsep0 rowsep0" align="left">0.063, 0.004</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Intrinsic clearance (Int CL) expressed as predicted hepatic extraction ratio <i>E</i><sub>h</sub>.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">Determined at 24 h in the presence of 10% hpβcd.</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">Carbonic anhydrase, isoform 1 and 2.</p></div></div></div><div class="NLM_p">The ADME properties of ML-93 and TAK-981 are similar to those of ML-792, exhibiting high extraction ratios in liver S9 subcellular fractions, indicating these compounds are subject to a relatively high degree of metabolism in the liver, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. The results from the permeability assay using Caco-2 cells showed high efflux ratios of >16, and the resulting low apparent permeability for all three compounds indicate these compounds are substrates of efflux transporters, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. The PK of the compounds in rat are similar, exhibiting high blood to plasma ratios, relatively short half-lives, and low exposures following an oral administration due to relatively poor oral bioavailability, <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>. The high blood to plasma partitioning may be attributed to reversible binding to carbonic anhydrase (CA), <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>, which present in high levels in red blood cells, through the sulfamate group.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> The PK profiles in blood and plasma exhibited parallel terminal phases with comparable half-lives in both matrixes, indicting the high blood to plasma partitioning of these compounds is considered to be in rapid equilibrium.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. In Vivo Profiles of ML-792, ML-93, and TAK-981<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">PK rat</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">i.v. 1 mpk</th><th class="rowsep1 colsep0" colspan="2" align="center">p.o. 10 mpk</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">AUC (μM·h) blood, plasma</th><th class="colsep0 rowsep0" align="center">CL (L/h/kg) blood, plasma</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg) blood, plasma</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h) blood, plasma</th><th class="colsep0 rowsep0" align="center">AUC (μM·h) blood, plasma</th><th class="colsep0 rowsep0" align="center">%<i>F</i> blood, plasma</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ML-792</td><td class="colsep0 rowsep0" align="left">19.1, 0.4</td><td class="colsep0 rowsep0" align="left">0.1, 5.1</td><td class="colsep0 rowsep0" align="left">0.1, 5.1</td><td class="colsep0 rowsep0" align="left">1.2, 0.9</td><td class="colsep0 rowsep0" align="left">10.8, 0.1</td><td class="colsep0 rowsep0" align="left">6.9, 7.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ML-93</td><td class="colsep0 rowsep0" align="left">12.5, 0.3</td><td class="colsep0 rowsep0" align="left">0.1, 5.2</td><td class="colsep0 rowsep0" align="left">0.2, 5.0</td><td class="colsep0 rowsep0" align="left">4.0, 1.5</td><td class="colsep0 rowsep0" align="left">24.1, 0.6</td><td class="colsep0 rowsep0" align="left">19, 18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TAK-981</td><td class="colsep0 rowsep0" align="left">31.2, 0.5</td><td class="colsep0 rowsep0" align="left">0.1, 3.7</td><td class="colsep0 rowsep0" align="left">0.2, 8.5</td><td class="colsep0 rowsep0" align="left">2.6, 2.1</td><td class="colsep0 rowsep0" align="left">32.0, 0.3</td><td class="colsep0 rowsep0" align="left">10.0, 7.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last"><i>N</i> = 3 animals, rat. mpk = mg per kg.</p></div></div></div><div class="NLM_p">Even though these compounds showed a relatively short half-life, both ML-93 and Tak-981 demonstrated a durable PD response and robust efficacy, including on intermittent dosing schedules, at greatly reduced dose compared to the initial lead ML-792. In light of this disconnect between PK and PD, driven by the tight binding nature of the inhibitor adduct to the enzyme, the team saw no requirement for improved exposure kinetics as a criterion for development as a parentally administered agent. With this in mind, the equilibrium solubility of TAK-981 compared to ML-93 was substantially higher at mildly acidic pH due to the presence of the basic THiQ system (p<i>K</i><sub>a</sub> 7.5, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). In the presence of hydroxypropylcyclodextrin (hpβcd) excipient, the equilibrium solubility at approximately 20 mg/mL was acceptable for development as an i.v. formulation.</div><div class="NLM_p">ML-93 has recently been investigated in pancreatic ductal carcinoma (PDAC), providing evidence of sensitivity to SAE inhibition and activation of MYC.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Exploration of the activity of TAK-981 in mouse models and primary cell explants revealed upregulation of Type I IFN signaling in immune cells and Type I IFN dependent activation of innate immune cells, including macrophages, NK cells and dendritic cells, as well as T cells.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In mouse syngeneic tumor models, TAK-981 was shown to promote an innate immune response capable of bridging to an adaptive antitumor immune response, representing a novel and mechanistically differentiated strategy for stimulating Type I IFN signaling and antitumor immune responses.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The activity of TAK-981 is currently being assessed in Ph1 clinical trials in adult patients with solid tumors and lymphomas (NCT03648372, NCT04074330, and NCT04381650).</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemistry</h3><div class="NLM_p">The synthetic route used to synthesize the analogues described in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> is detailed in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Benzylation of pyrazol-3-carbaldehyde provided the desired N1-benzyl pyrazole in a highly regiospecific manner. Lithium halogen metal exchange of 4-chloro-5-iodopyrimidine followed by addition of the aldehyde afforded the benzylic alcohol, which was oxidized with MnO<sub>2</sub> to provide an intermediate chloro-pyrimidine ketone (<b>I-3</b>). Displacement of the chloride with the appropriately substituted amino cyclopentane in the presence of base yielded intermediates which were further elaborated to final products by protecting group manipulation and sulfamation.</div><figure id="sch2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrazolo Analogues Described in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> details the synthetic route used to synthesize the analogues described in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. The appropriately substituted N-Boc pyrazole (<b>I-25</b>) intermediate was prepared as described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Substitution of the pyrazole was performed in an array format by one of two methods, <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Either the primary alcohol was initially sulfamated, followed by N-Boc deprotection to provide an intermediate that was selectively <i>N</i>-alkylated through parallel array, or alternatively, the Boc group was removed first to provide an intermediate that was subsequently <i>N</i>-alkylated followed by sulfamation.</div><figure id="sch3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes Employed for Pyrazolo-Substitution by Parallel Array</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a> detail the synthetic route used to prepare the benzylic alcohol or benzylic amine analogues described in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. Metal halogen exchange of the bromothiophene and reaction either with the appropriate benzaldehyde or benzylic sulfonyl imine gave the secondary alcohol or sulfonyl amine. Protecting group manipulation gave the thiophene aldehyde intermediate suitable for reaction with 4-chloro-5-iodopyrimidine, and subsequent elaboration analogous to that shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> gave the target compound, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The tertiary alcohols were prepared in a similar manner starting from the appropriate acetophenone. The alpha-methyl amines were prepared through oxidation of the secondary alcohol to the ketone, formation of the sulfonylimine, followed by reaction with methyllithium, <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Separation of the epimers was achieved through SFC or prep HPLC on the final sulfamated compounds.</div><figure id="sch4" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Key Intermediates for Benzylic Alcohol and Benzylic Amines Described in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch5" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Key Intermediates for Alpha-Methyl Benzyl Amines</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a> details the synthetic route used to prepare the isochromane and tetrahydroisoquinoline analogues described in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. Metal halogen exchange of the bromothiophene and reaction with a benzaldehyde derivatized at the ortho position with an appropriately protected alcohol. Treatment with acid deprotected the primary alcohol and facilitated cyclization to give the isochromane (<b>I-107</b>). The thiophene aldehyde was then progressed to the final compounds by an analogous route to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</div><figure id="sch6" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Key Intermediates for Isochromane and Tetrahydroisoquinoline Compounds Described in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The tetrahydroisoquinoline analogues (<b>I-117</b>) were prepared in a similar fashion by reaction with the appropriate dihydroisoquinoline and prosecution to the target compound. Separation of the epimers was achieved through SFC or prep HPLC on the final sulfamated compounds. The configuration of the more active isomer at the THiQ center was designated as <i>R</i> from a small molecule crystal structure of a late stage, presulfamation, synthetic intermediate on route to TAK-981. This was subsequently confirmed through a micro-ED crystal structure of TAK-981, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>.</div><figure id="fig13" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Crystal structure of TAK-981 solved by microelectron diffraction (microED) technique. Carbon is shown in gray; hydrogen, white; nitrogen, blue; oxygen, red; sulfur, yellow; chlorine, green. CCD accession code CCDC 2013738.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, a series of small molecule mechanism-based inhibitors of SAE have been identified and described in this report. These compounds act through a substrate assisted mechanism and demonstrate robust and selective inhibition of SAE and the SUMO pathway in cells and in vivo models. A distinct allosteric covalent inhibitor approach demonstrating in vivo activity has also recently been described.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> An iterative medicinal chemistry program optimized a nonselective compound, identified from a scaffold hopping exercise, into inhibitors that form tight binding SUMO–inhibitor adducts that exhibit extended duration of target and pathway inhibition. This work has culminated in the identification of TAK-981 which has entered clinical trials in metastatic solid tumors in combination with pembrolizumab, and in Non-Hodgkin’s lymphoma in combination with rituximab (NCT03648372, NCT04074330, and NCT04381650).</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03776" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03776" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All animal studies were conducted under the approval of the Takeda Oncology Institutional Animal Care and Use Committee and complied with all relevant ethical regulations. Mice were maintained in a specific pathogen-free facility in accordance with American Association for Laboratory Animal Science guidelines. See <a href="/doi/suppl/10.1021/acs.jmedchem.0c01491/suppl_file/jm0c01491_si_002.pdf" class="ext-link">Supporting Information</a> for in vivo protocols.</div><div id="sec4_0" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p last">NMR spectra were recorded in the solvent reported on a 400 MHz Bruker spectrometer using residual solvent peaks as the reference. Compound purity was determined by analysis of the diode array UV trace of an LC-MS spectrum using the following procedure: compounds were dissolved in DMSO, methanol, or acetonitrile, and the solutions were analyzed using a Hewlett-Packard HP1100 or Agilent 1100 Series LC system connected to a Micromass mass spectrometer using reverse phase C18 columns. One of two gradients was used to elute the compounds: either a formic acid (FA) gradient (acetonitrile containing 0–100% 0.1% formic acid in water) or an ammonium acetate (AA) gradient (acetonitrile containing 0–100% 10 mM ammonium acetate in water). All compounds were determined to be >95% pure unless otherwise noted.</div></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Synthesis of <b>2</b></h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Step 1:1-Benzyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>I-1</b>)</h4><div class="NLM_p last">A 100 mL round-bottom flask was charged with 1-pyrazole-3-carbaldehyde (250 mg, 2.60 mmol), Cs<sub>2</sub>CO<sub>3</sub> (2.12 g, 6.50 mmol), and DMF (10 mL). To the suspension was added benzyl bromide (0.33 mL, 2.70 mmol), and the reaction was stirred for 1 h. The reaction mixture was poured into water (50 mL), and the mixture was extracted with EtOAc (50 mL) three times. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to provide I-1 (372 mg, 77%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.01–9.98 (m, 1H), 7.42 (d, 1H, <i>J</i> = 2.3 Hz), 7.41–7.32 (m, 3H), 7.28–7.23 (m, 2H), 6.82 (d, 1H, <i>J</i> = 2.4 Hz), 5.40 (s, 2H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Step 2: (1-Benzyl-1<i>H</i>-pyrazol-3-yl)(4-chloropyrimidin-5-yl)methanol (<b>I-2</b>)</h4><div class="NLM_p last">4-Chloro-5-iodopyrimidine (300 mg, 1.25 mmol) was weighed into a 100 mL 2-necked round-bottom flask, and the flask was purged with argon. This starting material was dissolved in THF (10 mL), and the solution was cooled to −78 °C. To the solution was added <i>n</i>-BuLi (2.50 M in hexane; 1.0 mL, 2.5 mmol) at −78 °C, and then the mixture was stirred for 30 min. To this mixture was added dropwise a solution of 1-benzyl-1<i>H</i>-pyrazole-3-carbaldehyde (211 mg, 1.1 mmol) in THF (4 mL), and the resulting mixture was stirred for 30 min. The reaction was quenched by addition of saturated NH<sub>4</sub>Cl (50 mL) and extracted with EtOAc (50 mL) four times. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to provide <b>I-2</b> (304 mg, 85%) as a light-yellow oil. LCMS (FA): <i>m</i>/<i>z</i> = 301.4 (M+H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Step 3: (1-Benzyl-1<i>H</i>-pyrazol-3-yl)(4-chloropyrimidin-5-yl)methanone (<b>I-3</b>)</h4><div class="NLM_p last">To a solution of (1-benzyl-1<i>H</i>-pyrazol-3-yl)(4-chloropyrimidin-5-yl)methanol (285 mg, 0.95 mmol) in DCM (10 mL) was added MnO<sub>2</sub>(0.82 g, 9.5 mmol), and the mixture was stirred for 15 h at rt. The reaction was filtered through a pad of Celite, and the residual solid was washed with DCM several times. The filtrate was concentrated in vacuo, and the residue was purified on silica gel to give <b>I-3</b> (257 mg, 91%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.09 (s, 1H) 8.90 (s, 1H) 7.45 (d, 1H, <i>J</i> = 2.5 Hz) 7.32–7.41 (m, 3H) 7.22 (m, 2H) 7.02 (d, 1H, <i>J</i> = 2.5 Hz) 5.33 (s, 2H); LCMS (FA): <i>m</i>/<i>z</i> = 299.4 (M+H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Step 4: (1-Benzyl-1<i>H</i>-pyrazol-3-yl)[4-({(1<i>R</i>,3<i>R</i>,4<i>S</i>)-3-(hydroxymethyl)-4-[(triisopropylsilyl)oxy]cyclopentyl}amino)pyrimidin-5-yl]methanone (<b>I-9</b>)</h4><div class="NLM_p last">To a solution of {(1<i>R</i>,2<i>S</i>,4<i>R</i>)-4-amino-2-[(triisopropylsilyl)oxy]cyclopentyl}methanol-TFA (<b>I-8</b>, 1.04 g, 2.58 mmol) in DMF (20 mL) was added K<sub>2</sub>CO<sub>3</sub> (1.1 g, 7.7 mmol) followed by (1-benzyl-1<i>H</i>-pyrazol-3-yl)(4-chloropyrimidin-5-yl)methanone (<b>I-3</b>, 0.85 g, 2.8 mmol) at rt, and the mixture was stirred for 13 h. The reaction was then concentrated in vacuo. To the residue was added water (100 mL), and the mixture was extracted with EtOAc (100 mL) three times. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to give <b>I-9</b> (1.08 g, 75%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.66 (s, 1H), 9.25 (br d, 1H, <i>J</i> = 7.3 Hz), 8.64 (s, 1H), 7.42 (d, 1H, <i>J</i> = 2.5 Hz), 7.40–7.31 (m, 3H), 7.28–7.23 (m, 2H), 6.89 (d, 1H, <i>J</i> = 2.3 Hz), 5.39 (s, 2H), 4.87–4.76 (m, 1H), 4.32 (q, 1H, <i>J</i> = 4.7 Hz), 3.70 (t, 2H, <i>J</i> = 5.4 Hz), 2.50 (td, 1H, <i>J</i> = 13.1, 8.0 Hz), 2.24–2.14 (m, 2H), 1.92–1.81 (m, 2H), 1.32 (td, 1H, <i>J</i> = 13.1, 8.1 Hz), 1.11–1.03 (m, 21H). LCMS (FA): <i>m</i>/<i>z</i> = 550.7 (M+H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Step 5: [(1<i>R</i>,2<i>S</i>,4<i>R</i>)-4-({5-[(1-Benzyl-1<i>H</i>-pyrazol-3-yl)carbonyl]pyrimidin-4-yl}amino)-2-hydroxycyclopentyl]methyl sulfamate (<b>2</b>)</h4><div class="NLM_p last">To a solution of (1-benzyl-1<i>H</i>-pyrazol-3-yl)[4-({(1<i>R</i>,3<i>R</i>,4<i>S</i>)-3-(hydroxymethyl)-4-[(triisopropylsilyl)oxy]cyclopentyl}amino)pyrimidin-5-yl]methanone (1.0 g, 1.8 mmol) in DMF (30 mL) was added chlorosulfonamide (650 mg, 5.6 mmol) at rt, and the mixture was stirred for 20 min. The reaction was quenched by addition of saturated NaHCO<sub>3</sub> (100 mL) and water (50 mL). The mixture was extracted with EtOAc (150 mL) three times, and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to give the sulfamate intermediate [(0.91 g, 80%); LCMS (FA): <i>m</i>/<i>z</i> = 629.7 (M+H)] which was then dissolved in THF (20 mL) and HCl (4 M in water; 20 mL, 80 mmol) was added at rt. This mixture was stirred for 1 h and then quenched by addition of saturated NaHCO<sub>3</sub> (150 mL) and extracted with EtOAc (200 mL) four times. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. To the residue was added DCM and the resulting suspension was filtered through a glass frit funnel, and the residual solid was washed with DCM twice. The filtrate was concentrated in vacuo, and the residue was purified on silica gel. The purification product and solid from filtration were combined to give <b>2</b> (652 mg, 95%) as a colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.46 (s, 1H), 9.00 (d, 1H, <i>J</i> = 7.5 Hz), 8.62 (s, 1H), 8.07 (d, 1H, <i>J</i> = 2.4 Hz), 7.45 (s, 2H), 7.41–7.25 (m, 5H), 6.90 (d, 1H, <i>J</i> = 2.4 Hz), 5.50 (s, 2H), 4.92 (d, 1H, <i>J</i> = 4.6 Hz), 4.76–4.64 (m, 1H), 4.10 (dd, 1H, <i>J</i> = 9.7, 5.9 Hz), 4.01–3.92 (m, 2H), 2.41–2.30 (m, 1H), 2.19–2.07 (m, 1H), 2.00 (ddd, 1H, <i>J</i> = 11.7, 7.7, 3.8 Hz), 1.83–1.72 (m, 1H), 1.28 (dt, 1H, <i>J</i> = 12.9, 9.2 Hz). LCMS (FA): <i>m</i>/<i>z</i> = 473.5 (M+H). HRMS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>25</sub>N<sub>6</sub>O<sub>5</sub>S 473.1607, obsd 473.1608.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Synthesis of <b>26</b></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Step 1:4-(3-Bromobenzyl)thiophene-2-carbaldehyde (<b>I-42</b>)</h4><div class="NLM_p last">To a degassed solution of 2-formyl-4-thiopheneboronic acid (500 mg, 3.21 mmol), 3-bromobenzyl bromide (0.88 g, 3.53 mmol), and K<sub>2</sub>CO<sub>3</sub>(1.33 g, 9.6 mmol) in 1,4-dioxane (15 mL) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (0.185 g, 0.16 mmol). The reaction mixture was stirred at 80 °C for 1 d and then quenched with water and extracted with EtOAc. The combined organic layers were dried over Mg<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude material was purified on silica gel to provide <b>I-42</b> (631 mg, 70%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.86 (d, 1H, <i>J</i> = 1.2 Hz), 7.55 (d, 1H, <i>J</i> = 1.2 Hz), 7.42–7.32 (m, 3H), 7.20 (t, 1H, <i>J</i> = 7.7 Hz), 7.13 (d, 1H, <i>J</i> = 7.7 Hz), 3.97 (s, 2H). LCMS (FA): <i>m</i>/<i>z</i> = 282.9 (M+H).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Step 2: rac-[4-(3-Bromobenzyl)-2-thienyl](4-chloropyrimidin-5-yl)methanol (<b>I-43</b>)</h4><div class="NLM_p last">A solution of 4-chloro-5-iodopyrimidine (216 mg, 0.90 mmol) in THF (5.0 mL) was cooled to −78 °C with dry ice bath. To the solution was added dropwise 2.50 M of <i>n</i>-BuLi in hexane (0.36 mL, 0.90 mmol) at −78 °C, and the mixture was stirred for 20 min. To the mixture was added a solution of 4-(3-bromobenzyl)thiophene-2-carbaldehyde (210 mg, 0.75 mmol) in THF (2.0 mL) at −78 °C, and the resulting mixture was stirred for 30 min. The reaction was quenched by addition of saturated NH<sub>4</sub>Cl (50 mL) and extracted with EtOAc (50 mL) three times. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified on silica gel to provide <b>I-43</b> as a colorless oil (260 mg, 86%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.02 (s, 1H), 8.94 (s, 1H), 7.35 (d, 1H, <i>J</i> = 7.9 Hz), 7.32 (s, 1H), 7.17 (t, 1H, <i>J</i> = 7.7 Hz), 7.09 (d, 1H, <i>J</i> = 7.7 Hz), 6.91 (s, 1H), 6.82 (s, 1H), 6.27 (s, 1H), 3.86 (s, 2H), 2.86–2.60 (br s, 1H). LCMS (FA): <i>m</i>/<i>z</i> = 396.9 (M+H).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Step 3: [4-(3-Bromobenzyl)-2-thienyl](4-chloropyrimidin-5-yl)methanone (<b>I-44</b>)</h4><div class="NLM_p last">To a solution of rac-[4-(3-bromobenzyl)-2-thienyl](4-chloropyrimidin-5-yl)methanol (255 mg, 0.64 mmol) in DCM (10.0 mL) was added Dess–Martin periodinane (410 mg, 0.97 mmol) at rt, and the mixture was stirred for 15 min. The reaction was quenched by addition of saturated NaHCO<sub>3</sub> (50 mL) and extracted with DCM (50 mL) three times. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to afford <b>I-44</b> as a colorless oil (247 mg, 96%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.12 (s, 1H), 8.75 (s, 1H), 7.49–7.45 (m, 1H), 7.38 (d, 1H, <i>J</i> = 8.0 Hz), 7.31 (s, 1H), 7.28 (d, 1H, <i>J</i> = 1.4 Hz), 7.18 (t, 1H, <i>J</i> = 7.8 Hz), 7.09 (d, 1H, <i>J</i> = 7.8 Hz), 3.94 (s, 2H). LCMS (FA): <i>m</i>/<i>z</i> = 394.9 (M+H).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Step 4: [4-(3-Bromobenzyl)-2-thienyl][4-({(1<i>R</i>,3<i>R</i>,4<i>S</i>)-3-({[<i>tert</i>-butyl(dimethyl)silyl]oxy}methyl)-4-[(triisopropylsilyl)oxy]cyclopentyl}amino)pyrimidin-5-yl]methanone (<b>I-45</b>)</h4><div class="NLM_p last">To a solution of [4-(3-bromobenzyl)-2-thienyl](4-chloropyrimidin-5-yl)methanone (245 mg, 0.62 mmol) in DMF (10 mL) was added (1<i>R</i>,3<i>R</i>,4<i>S</i>)-3-({[<i>tert</i>-butyl(dimethyl)silyl]oxy}methyl)-4-[(triisopropylsilyl)oxy]cyclopentanamine (<b>I-31</b>, 375 mg, 0.93 mmol) followed by K<sub>2</sub>CO<sub>3</sub> (215 mg, 1.56 mmol), and the reaction was stirred for 13 h at rt. The reaction was concentrated in vacuo. To the residue was added water (50 mL) and the mixture was extracted with EtOAc (50 mL) three times. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to give <b>I-45</b> as a light yellow oil (445 mg, 94%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.78 (s, 1H), 8.69–8.56 (m, 2H), 7.42–7.30 (m, 4H), 7.18 (t, 1H, <i>J</i> = 7.7 Hz), 7.12 (d, 1H, <i>J</i> = 7.7 Hz), 4.86–4.72 (m, 1H), 4.33–4.25 (m, 1H), 3.96 (s, 2H), 3.61 (dd, 1H, <i>J</i> = 10.1, 5.4 Hz), 3.55 (dd, 1H, <i>J</i> = 10.1, 5.8 Hz), 2.49–2.36 (m, 1H), 2.24–2.08 (m, 2H), 1.77–1.66 (m, 1H), 1.34–1.17 (m, 1H), 1.06 (s, 21H), 0.88 (s, 9H), 0.03 (s, 6H).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Step 5: [4-(3-Bromobenzyl)-2-thienyl][4-({(1<i>R</i>,3<i>R</i>,4<i>S</i>)-3-(hydroxymethyl)-4-[(triisopropylsilyl)oxy]cyclopentyl}amino)pyrimidin-5-yl]methanone (<b>I-46</b>)</h4><div class="NLM_p last">To a solution of [4-(3-bromobenzyl)-2-thienyl][4-({(1<i>R</i>,3<i>R</i>,4<i>S</i>)-3-({[<i>tert</i>-butyl(dimethyl)silyl]oxy}methyl)-4-[(triisopropylsilyl)oxy]cyclopentyl}amino)pyrimidin-5-yl]methanone (150 mg, 0.20 mmol) in EtOH (8.0 mL) was added 1% HCl in EtOH solution (2.0 mL, 0.24 mmol), and the mixture was stirred for 8 h at rt. The reaction was quenched by addition of saturated NaHCO<sub>3</sub> (50 mL) and extracted with EtOAc (60 mL) three times. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to provide <b>I-46</b> as a light yellow oil (113 mg, 89%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.79 (s, 1H), 8.71 (d, 1H, <i>J</i> = 7.3 Hz), 8.66 (s, 1H), 7.40–7.32 (m, 4H), 7.19 (dd, 1H, <i>J</i> = 7.8, 7.6 Hz), 7.15–7.11 (m, 1H), 4.86–4.76 (m, 1H), 4.35–4.30 (m, 1H), 3.97 (s, 2H), 3.74–3.66 (m, 2H), 2.54–2.45 (m, 1H), 2.24–2.15 (m, 2H), 1.89–1. 81 (m, 1H), 1.75 (t, 1H, <i>J</i> = 4.8 Hz), 1.32 (dt, 1H, <i>J</i> = 13.2, 7.8 Hz), 1.10–1.04 (m, 21H). LCMS (FA): <i>m</i>/<i>z</i> = 646.1 (M+H).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step 6: {(1<i>R</i>,2<i>S</i>,4<i>R</i>)-4-[(5-{[4-(3-Bromobenzyl)-2-thienyl]carbonyl}pyrimidin-4-yl)amino]-2-[(triisopropylsilyl)oxy]cyclopentyl}methyl sulfamate (<b>I-47</b>)</h4><div class="NLM_p last">To a solution of [4-(3-bromobenzyl)-2-thienyl][4-({(1<i>R</i>,3<i>R</i>,4<i>S</i>)-3-(hydroxymethyl)-4-[(triisopropylsilyl)oxy]cyclopentyl}amino)pyrimidin-5-yl]methanone (110 mg, 0.17 mmol) in DMF (2.0 mL) was added chlorosulfonamide (39.4 mg, 0.34 mmol) at rt, and the mixture was stirred for 15 min. The reaction was cooled to 0 °C and quenched by addition of saturated NaHCO<sub>3</sub> (50 mL). The mixture was extracted with EtOAc (50 mL) three times. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to give <b>I-47</b> as a light yellow sticky oil (101 mg, 78%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.79 (s, 1H), 8.72–8.59 (m, 2H), 7.45–7.30 (m, 4H), 7.19 (t, 1H, <i>J</i> = 7.7 Hz), 7.12 (d, 1H, <i>J</i> = 7.5 Hz), 5.15 (s, 2H), 4.88–4.75 (m, 1H), 4.34 (q, 1H, <i>J</i> = 5.2 Hz), 4.27 (d, 2H, <i>J</i> = 4.7 Hz), 3.96 (s, 2H), 2.67–2.53 (m, 1H), 2.43–2.30 (m, 1H), 2.22–2.11 (m, 1H), 1.90 (dt, 1H, <i>J</i> = 13.1, 6.4 Hz), 1.46 (dt, 1H, <i>J</i> = 13.2, 6.6 Hz), 1.05 (s, 21H). LCMS (FA): <i>m</i>/<i>z</i> = 725.1 (M+H).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step 7: {(1<i>R</i>,2<i>S</i>,4<i>R</i>)-4-[(5-{[4-(3-Bromobenzyl)-2-thienyl]carbonyl}pyrimidin-4-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate (<b>26</b>)</h4><div class="NLM_p last">To a solution of {(1<i>R</i>,2<i>S</i>,4<i>R</i>)-4-[(5-{[4-(3-bromobenzyl)-2-thienyl]carbonyl}pyrimidin-4-yl)amino]-2-[(triisopropylsilyl)oxy]cyclopentyl}methyl sulfamate (95.0 mg, 0.13 mmol) in THF (2.0 mL) was added 4.0 M of HCl (2.00 mL, 8.00 mmol) at rt, and the mixture was stirred for 4 h. The reaction was quenched by addition of saturated NaHCO<sub>3</sub> (60 mL) and extracted with EtOAc (60 mL) three times. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to provide <b>26</b> as an off-white solid (66 mg, 87%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.68 (s, 1H), 8.64 (s, 1H), 8.26 (d, 1H, <i>J</i> = 7.4 Hz), 7.82 (s, 1H), 7.70 (s, 1H), 7.51 (s, 1H), 7.48–7.35 (m, 3H), 7.35–7.20 (m, 2H), 4.88 (d, 1H, <i>J</i> = 4.5 Hz), 4.77–4.62 (m, 1H), 4.09 (dd, 1H, <i>J</i> = 9.6, 6.1 Hz), 4.04–3.87 (m, 4H), 2.31 (dt, 1H, <i>J</i> = 13.6, 7.5 Hz), 2.17–2.05 (m, 1H), 2.01–1.90 (m, 1H), 1.82–1.70 (m, 1H), 1.33–1.20 (m, 1H). LCMS (FA): <i>m</i>/<i>z</i> = 569.1 (M+H). HRMS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>BrN<sub>4</sub>O<sub>5</sub>S<sub>2</sub> 567.0371, obsd 567.0370.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Synthesis of Intermediate <b>I-107</b></h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Step 1: [2-(2-{[<i>tert</i>-Butyl(dimethyl)silyl]oxy}ethyl)phenyl][5-(1,3-dioxolan-2-yl)- 2-methyl-3-thienyl]methanol (<b>I-106</b>)</h4><div class="NLM_p last">A solution of 2-(4-bromo-5-methyl-2-thienyl)-1,3-dioxolane (1.70 g, 6.82 mmol) in THF (26.6 mL) was cooled to −78 °C, and then 2.50 M of <i>n</i>-BuLi in hexane (2.94 mL, 7.35 mmol) was added and the mixture was stirred for 10 min at −78 °C. A solution of 2-(2-{[<i>tert</i>-butyl(dimethyl)silyl]oxy}ethyl)benzaldehyde (<b>I-105</b>, 1.39 g, 5.25 mmol) in THF (13.3 mL) was then added, and the reaction was stirred for 10 min at −78 °C. The reaction was quenched by adding brine and then warmed to rt. The aqueous mixture was extracted with EtOAc twice. The combined organic solvents were washed with brine, dried, and concentrated in vacuo. The residue was purified on silica gel to provide <b>I-106</b> (1.96 g, 86%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.30–7.26 (m, 2H), 7.26–7.21 (m, 2H), 7.07 (s, 1H), 6.09 (d, 1H, <i>J</i> = 2.7 Hz), 6.03 (s, 1H), 4.19–4.13 (m, 2H), 4.06–4.00 (m, 2H), 3.96–3.89 (m, 1H), 3.87–3.77 (m, 1H), 3.52 (d, 1H, <i>J</i> = 2.9 Hz), 3.06 (ddd, 1H, <i>J</i> = 14.3, 8.4, 6.2 Hz), 2.87 (dt, 1H, <i>J</i> = 13.9, 5.2 Hz), 2.37 (s, 3H), 0.86 (s, 9H), −0.00 (s, 3H), −0.01 (s, 3H).</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Step 2: 4-(3,4-Dihydro-1<i>H</i>-isochromen-1-yl)-5-methylthiophene-2-carbaldehyde (<b>I-107</b>)</h4><div class="NLM_p last">A 100 mL round-bottom flask was charged with [2-(2-{[<i>tert</i>-butyl(dimethyl)silyl]oxy}ethyl)phenyl][5-(1,3-dioxolan-2-yl)-2-methyl-3-thienyl]methanol (1.96 g, 4.51 mmol) and TFA (6.60 mL, 85.7 mmol) at rt. The resulting purple solution was stirred at rt overnight. The reaction mixture was carefully poured into saturated aqueous NaHCO<sub>3</sub> (50 mL). The layers were separated, and the aqueous layer was extracted three times with EtOAc. The combined organic layers were washed with brine, then dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified on silica gel to yield <b>I-107</b> (1.03 g, 89%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.73 (s, 1H), 7.41 (s, 1H), 7.27–7.19 (m, 2H), 7.18–7.12 (m, 1H), 6.75 (d, 1H, <i>J</i> = 7.7 Hz), 5.86 (s, 1H), 4.21 (ddd, 1H, <i>J</i> = 11.3, 5.5, 3.7 Hz), 3.97 (ddd, 1H, <i>J</i> = 11.4, 9.7, 4.0 Hz), 3.16 (ddd, 1H, <i>J</i> = 15.9, 9.4, 5.4 Hz), 2.85 (dt, 1H, <i>J</i> = 16.6, 3.6 Hz), 2.59 (s, 3H).</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Synthesis of Intermediate <b>I-117</b></h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Step 1: 1-[5-(1,3-Dioxolan-2-yl)-3-thienyl]-1,2,3,4-tetrahydroisoquinoline (<b>I-115</b>)</h4><div class="NLM_p last">A solution of 3,4-dihydroisoquinoline (500 mg, 3.81 mmol) in THF (15.4 mL) was cooled at −30 °C. To this solution was added dropwise boron trifluoride etherate (0.53 mL, 4.19 mmol) at −30 °C, and the mixture was stirred for 20 min. Into a separate 50 mL 2-neck flask 2.50 M of <i>n</i>-BuLi in hexane (1.83 mL, 4.57 mmol) was added at −78 °C followed by a solution of 2-(4-bromo-2-thienyl)-1,3-dioxolane (1.08 g, 4.57 mmol) in THF (10 mL). After 5 min, lithiated thiophene suspension was added to the above solution of dihydroisoquinoline BF<sub>3</sub>–OEt<sub>2</sub> complex at −78 °C. The reaction was stirred for 20 min at −78 °C and then quenched by addition of water. The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to provide <b>I-115</b> (513 mg) and some impurities as a red amorphous solid. This mixture was used for the next step without further purification.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Step 2: <i>tert</i>-Butyl 1-[5-(1,3-Dioxolan-2-yl)-3-thienyl]-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (<b>I-116</b>)</h4><div class="NLM_p last">The crude mixture from step 1was dissolved in MeCN (6.97 mL), to which was added (Boc)<sub>2</sub>O (1.25 g, 5.72 mmol) and DMAP (2.33 mg, 19.1 μmol) at rt. After stirring for 2 h, the reaction was quenched by adding water. The layers were separated, and the aqueous layer was extracted with EtOAc twice. The combined organics were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to provide <b>I-116</b> (393 mg, 27% for 2 steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.26–7.03 (m, 6H), 6.82 (s, 1H), 6.01 (s, 1H), 4.17–3.93 (m, 5H), 3.20–3.04 (m, 1H), 3.04–2.86 (m, 1H), 2.79–2.68 (m, 1H), 1.57–1.46 (m, 9H); LCMS (FA): <i>m</i>/<i>z</i> = 388.3 (M+H).</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Step 3: <i>tert</i>-Butyl 1-(5-Formyl-3-thienyl)-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (<b>I-117</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 1-[5-(1,3-dioxolan-2-yl)-3-thienyl]-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (393 mg, 1.01 mmol) in acetone (7.72 mL) was added 500 mg of Dowex 50WX-2-200 (H) (acid resin), and the mixture was shaken for 18 h at rt. The reaction was filtered through a glass frit funnel and the residual resin was rinsed with acetone several times. To the filtrate was added saturated aqueous NaHCO<sub>3</sub> (25 mL) and the mixture was concentrated to half volume in vacuo. The residue was diluted with EtOAc; the layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on silica gel to provide <b>I-117</b> as a colorless amorphous solid (319 mg, 91%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.84 (s, 1H), 7.64 (s, 1H), 7.30–7.07 (m, 5H), 6.48–6.23 (br s, 1H), 4.09–3.88 (m, 1H), 3.22–3.06 (m, 1H), 3.05–2.89 (m, 1H), 2.81–2.69 (m, 1H), 1.52 (s, 9H).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01491" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20463" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20463" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01491?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01491</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings file and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01491/suppl_file/jm0c01491_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Protocols for the in vitro and cell assays and in vivo experiments, synthetic methods for the remaining examples, HPLC traces of final compound, protein synthesis and purification methodology, and X-ray crystallographic and microelectron diffraction protocols (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01491/suppl_file/jm0c01491_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01491/suppl_file/jm0c01491_si_001.csv">jm0c01491_si_001.csv (6.99 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01491/suppl_file/jm0c01491_si_002.pdf">jm0c01491_si_002.pdf (4.33 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB depositions are available for SAE SUMO adducts of compounds <b>2</b>, <b>46</b>, <b>49</b>, and TAK-981. The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01491" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61356" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61356" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven P. Langston</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5840-0005" title="Orcid link">http://orcid.org/0000-0001-5840-0005</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a6d5d2c3d0c388cac7c8c1d5d2c9c8e6d2c7cdc3c2c788c5c9cb"><span class="__cf_email__" data-cfemail="3447405142511a58555a5347405b5a7440555f5150551a575b59">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Grossman</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ce9dbaabbea6aba0e089bca1bdbda3afa08e9aafa5abaaafe0ada1a3"><span class="__cf_email__" data-cfemail="510225342139343f7f16233e22223c303f1105303a3435307f323e3c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dylan England</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roushan Afroze</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Bence</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas Bowman</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nancy Bump</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan Chau</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bei-Ching Chuang</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Claiborne</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Larry Cohen</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kelly Connolly</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Duffey</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nitya Durvasula</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Freeze</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa Gallery</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine Galvin</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Gaulin</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachel Gershman</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Greenspan</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica Grieves</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianping Guo</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nanda Gulavita</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shumet Hailu</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xingyue He</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kara Hoar</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongbo Hu</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhigen Hu</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mitsuhiro Ito</span> - <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mi-Sook Kim</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Weston Lane</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Lok</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anya Lublinsky</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William Mallender</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles McIntyre</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Minissale</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hirotake Mizutani</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Miho Mizutani</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nina Molchinova</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Koji Ono</span> - <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, Fujisawa, Kanagawa 251-0012, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashok Patil</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Qian</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica Riceberg</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vaishali Shindi</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Sintchak</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keli Song</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teresa Soucy</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yana Wang</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">He Xu</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaofeng Yang</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agatha Zawadzka</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ji Zhang</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sai M. Pulukuri</span> - <span class="hlFld-Affiliation affiliation">Millennium
Pharmaceuticals, a wholly owned subsidiary
of Takeda Pharmaceuticals Company Ltd., Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank Dr. Dennis Huszar for reading the manuscript. We would like to thank Drs. John Ringeling, John Donovan, and Saurabh Menon for advice on assay development. We would also like to thank NanoImaging Inc. for performing the microED data collection.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BID x21</td><td class="NLM_def"><p class="first last">twice per day for 21 days</p></td></tr><tr><td class="NLM_term">BID BIW</td><td class="NLM_def"><p class="first last">twice per day/twice per week</p></td></tr><tr><td class="NLM_term">BID 2on-5off</td><td class="NLM_def"><p class="first last">twice per day on 2 consecutive days, followed by 5 nondosing days</p></td></tr><tr><td class="NLM_term">CA</td><td class="NLM_def"><p class="first last">carbonic anhydrase</p></td></tr><tr><td class="NLM_term">QD x21</td><td class="NLM_def"><p class="first last">once per day for 21 consecutive days</p></td></tr><tr><td class="NLM_term">QD x3/week</td><td class="NLM_def"><p class="first last">Three consecutive dosing days followed by 4 nondosing days</p></td></tr><tr><td class="NLM_term">SC</td><td class="NLM_def"><p class="first last">subcutaneously</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">IHC</td><td class="NLM_def"><p class="first last">immunohistochemistry</p></td></tr><tr><td class="NLM_term">IF</td><td class="NLM_def"><p class="first last">immunofluorescence</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">type 1 interferon</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenously</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe combined immune deficiency</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31262" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31262" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 41 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geiss-Friedlander, R.</span></span> <span> </span><span class="NLM_article-title">Concepts in sumoylation: a decade on</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1038/nrm2293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnrm2293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=18000527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=947-956&issue=12&author=R.+Geiss-Friedlander&title=Concepts+in+sumoylation%3A+a+decade+on&doi=10.1038%2Fnrm2293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Concepts in sumoylation: a decade on</span></div><div class="casAuthors">Geiss-Friedlander, Ruth; Melchior, Frauke</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">947-956</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A decade has passed since SUMO (small ubiquitin-related modifier) was discovered to be a reversible post-translational protein modifier.  During this time many enzymes that participate in regulated SUMO conjugation and deconjugation pathways have been identified and characterized.  In parallel, the search for SUMO substrates has produced a long list of targets, which appear to be involved in most cellular functions.  Sumoylation is a highly dynamic process and its outcomes are extremely diverse, ranging from changes in localization to altered activity and, in some cases, stability of the modified protein.  At 1st glance, these effects have nothing in common; however, it seems that they all result from changes in the mol. interactions of the sumoylated proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXaaIwX1UoerVg90H21EOLACvtfcHk0lj5xhIuWZ33iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsbrN&md5=aaab4fe48e4cff67e778648b5f416b1d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2293%26sid%3Dliteratum%253Aachs%26aulast%3DGeiss-Friedlander%26aufirst%3DR.%26atitle%3DConcepts%2520in%2520sumoylation%253A%2520a%2520decade%2520on%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26issue%3D12%26spage%3D947%26epage%3D956%26doi%3D10.1038%2Fnrm2293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. W.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1038/nrm2673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnrm2673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=19352404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=319-331&issue=5&author=B.+A.+Schulmanauthor=J.+W.+Harper&title=Ubiquitin-like+protein+activation+by+E1+enzymes%3A+the+apex+for+downstream+signalling+pathways&doi=10.1038%2Fnrm2673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signaling pathways</span></div><div class="casAuthors">Schulman, Brenda A.; Harper, J. Wade</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-331</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The attachment of ubiquitin or ubiquitin-like proteins (known as UBLs) to their targets through multienzyme cascades is a central mechanism in modulating protein functions.  This process is initiated by a family of mechanistically and structurally related E1 (or activating) enzymes.  These activate UBLs through C-terminal adenylylation and thiol transfer, and coordinate the use of UBLs in specific downstream pathways by charging cognate E2 (or conjugating) enzymes, which then interact with the downstream ubiquitination machinery to coordinate the modification of the target.  A broad understanding of how E1 enzymes activate UBLs and how they selectively coordinate UBLs with downstream function has come from enzymic, structural, and genetic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqRrsEHwtC8rVg90H21EOLACvtfcHk0lj5xhIuWZ33iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFGrsL8%253D&md5=ac268f8312c97c2663ce89b54ea3d1ac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrm2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2673%26sid%3Dliteratum%253Aachs%26aulast%3DSchulman%26aufirst%3DB.%2BA.%26aulast%3DHarper%26aufirst%3DJ.%2BW.%26atitle%3DUbiquitin-like%2520protein%2520activation%2520by%2520E1%2520enzymes%253A%2520the%2520apex%2520for%2520downstream%2520signalling%2520pathways%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2009%26volume%3D10%26issue%3D5%26spage%3D319%26epage%3D331%26doi%3D10.1038%2Fnrm2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gareau, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. D.</span></span> <span> </span><span class="NLM_article-title">The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1038/nrm3011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnrm3011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=21102611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGru7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=861-871&author=J.+R.+Gareauauthor=C.+D.+Lima&title=The+SUMO+pathway%3A+emerging+mechanisms+that+shape+specificity%2C+conjugation+and+recognition&doi=10.1038%2Fnrm3011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition</span></div><div class="casAuthors">Gareau, Jaclyn R.; Lima, Christopher D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">861-871</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Proteins of the small ubiquitin-related modifier (SUMO) family are conjugated to proteins to regulate such cellular processes as nuclear transport, transcription, chromosome segregation and DNA repair.  Recently, numerous insights into regulatory mechanisms of the SUMO modification pathway have emerged.  Although SUMO-conjugating enzymes can discriminate between SUMO targets, many substrates possess characteristics that facilitate their modification.  Other post-translational modifications also regulate SUMO conjugation, suggesting that SUMO signalling is integrated with other signal transduction pathways.  A better understanding of SUMO regulatory mechanisms will lead to improved approaches for analyzing the function of SUMO and substrate conjugation in distinct cellular pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN0COL6nhikLVg90H21EOLACvtfcHk0lj5xhIuWZ33iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGru7zP&md5=48e56d75fa04204c8589a42746e21bf3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3011%26sid%3Dliteratum%253Aachs%26aulast%3DGareau%26aufirst%3DJ.%2BR.%26aulast%3DLima%26aufirst%3DC.%2BD.%26atitle%3DThe%2520SUMO%2520pathway%253A%2520emerging%2520mechanisms%2520that%2520shape%2520specificity%252C%2520conjugation%2520and%2520recognition%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D861%26epage%3D871%26doi%3D10.1038%2Fnrm3011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernier-Villamor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matunis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. D.</span></span> <span> </span><span class="NLM_article-title">Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00630-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2FS0092-8674%2802%2900630-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=11853669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVSksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2002&pages=345-356&issue=3&author=V.+Bernier-Villamorauthor=D.+A.+Sampsonauthor=M.+J.+Matunisauthor=C.+D.+Lima&title=Structural+basis+for+E2-mediated+SUMO+conjugation+revealed+by+a+complex+between+ubiquitin-conjugating+enzyme+Ubc9+and+RanGAP1&doi=10.1016%2FS0092-8674%2802%2900630-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1</span></div><div class="casAuthors">Bernier-Villamor, Victor; Sampson, Deborah A.; Matunis, Michael J.; Lima, Christopher D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-356</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">E2 enzymes catalyze attachment of ubiquitin and ubiquitin-like proteins to lysine residues directly or through E3-mediated reactions.  The small ubiquitin-like modifier SUMO regulates nuclear transport, stress response, and signal transduction in eukaryotes and is essential for cell-cycle progression in yeast.  In contrast to most ubiquitin conjugation, the SUMO E2 enzyme Ubc9 is sufficient for substrate recognition and lysine modification of known SUMO targets.  Crystallog. anal. of a complex between mammalian Ubc9 and a C-terminal domain of RanGAP1 at 2.5 Å reveals structural determinants for recognition of consensus SUMO modification sequences found within SUMO-conjugated proteins.  Structure-based mutagenesis and biochem. anal. of Ubc9 and RanGAP1 reveal distinct motifs required for substrate binding and SUMO modification of p53, IκBα, and RanGAP1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEE-4uiRTY97Vg90H21EOLACvtfcHk0lgV5VMHoEUFqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVSksbw%253D&md5=b774c5af1eff7415654ba378b1ceeee6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900630-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900630-X%26sid%3Dliteratum%253Aachs%26aulast%3DBernier-Villamor%26aufirst%3DV.%26aulast%3DSampson%26aufirst%3DD.%2BA.%26aulast%3DMatunis%26aufirst%3DM.%2BJ.%26aulast%3DLima%26aufirst%3DC.%2BD.%26atitle%3DStructural%2520basis%2520for%2520E2-mediated%2520SUMO%2520conjugation%2520revealed%2520by%2520a%2520complex%2520between%2520ubiquitin-conjugating%2520enzyme%2520Ubc9%2520and%2520RanGAP1%26jtitle%3DCell%26date%3D2002%26volume%3D108%26issue%3D3%26spage%3D345%26epage%3D356%26doi%3D10.1016%2FS0092-8674%2802%2900630-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. S.</span></span> <span> </span><span class="NLM_article-title">Protein modification by SUMO</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.074118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1146%2Fannurev.biochem.73.011303.074118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=15189146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslags7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=355-382&author=E.+S.+Johnson&title=Protein+modification+by+SUMO&doi=10.1146%2Fannurev.biochem.73.011303.074118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Protein modification by SUMO</span></div><div class="casAuthors">Johnson, Erica S.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">355-382</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Small ubiquitin-related modifier (SUMO) family proteins function by becoming covalently attached to other proteins as post-translational modifications.  SUMO modifies many proteins that participate in diverse cellular processes, including transcriptional regulation, nuclear transport, maintenance of genome integrity, and signal transduction.  Reversible attachment of SUMO is controlled by an enzyme pathway that is analogous to the ubiquitin pathway.  The functional consequences of SUMO attachment vary greatly from substrate to substrate, and in many cases are not understood at the mol. level.  Frequently SUMO alters interactions of substrates with other proteins or with DNA, but SUMO can also act by blocking ubiquitin attachment sites.  An unusual feature of SUMO modification is that, for most substrates, only a small fraction of the substrate is sumoylated at any given time.  This review discusses our current understanding of how SUMO conjugation is controlled, as well as the roles of SUMO in a no. of biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2cgvMqPC8f7Vg90H21EOLACvtfcHk0lgV5VMHoEUFqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslags7k%253D&md5=2a78d67692e278552125c4da373c0cc2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.074118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.074118%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DE.%2BS.%26atitle%3DProtein%2520modification%2520by%2520SUMO%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D355%26epage%3D382%26doi%3D10.1146%2Fannurev.biochem.73.011303.074118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hershko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciechanover, A.</span></span> <span> </span><span class="NLM_article-title">The ubiquitin system</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.67.1.425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1146%2Fannurev.biochem.67.1.425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=9759494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADyaK1cXlsFOmsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1998&pages=425-479&author=A.+Hershkoauthor=A.+Ciechanover&title=The+ubiquitin+system&doi=10.1146%2Fannurev.biochem.67.1.425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitin system</span></div><div class="casAuthors">Hershko, Avram; Ciechanover, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">425-479</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with ∼298 refs.  The selective degrdn. of many short-lived proteins in eukaryotic cells is carried out by the ubiquitin system.  In this pathway, proteins are targeted for degrdn. by covalent ligation to ubiquitin, a highly conserved small protein.  Ubiquitin-mediated degrdn. of regulatory proteins plays important roles in the control of numerous processes, including cell-cycle progression, signal transduction, transcriptional regulation, receptor down-regulation, and endocytosis.  The ubiquitin system has been implicated in the immune response, development, and programmed cell death.  Abnormalities in ubiquitin-mediated processes have been shown to cause pathol. conditions, including malignant transformation.  In this review we discuss recent information on functions and mechanisms of the ubiquitin system.  Since the selectivity of protein degrdn. is detd. mainly at the stage of ligation to ubiquitin, special attention is focused on what we know, and would like to know, about the mode of action of ubiquitin-protein ligation systems and about signals in proteins recognized by these systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqo5VhDx0kSLVg90H21EOLACvtfcHk0lgV5VMHoEUFqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlsFOmsLc%253D&md5=7c3c0a6df9c07baf55b5000eae13ef49</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.67.1.425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.67.1.425%26sid%3Dliteratum%253Aachs%26aulast%3DHershko%26aufirst%3DA.%26aulast%3DCiechanover%26aufirst%3DA.%26atitle%3DThe%2520ubiquitin%2520system%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1998%26volume%3D67%26spage%3D425%26epage%3D479%26doi%3D10.1146%2Fannurev.biochem.67.1.425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, E. T.</span></span> <span> </span><span class="NLM_article-title">Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">12036</span>– <span class="NLM_lpage">12042</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.17.12036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1074%2Fjbc.274.17.12036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10207026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADyaK1MXislGltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=12036-12042&issue=17&author=L.+Gongauthor=E.+T.+Yeh&title=Identification+of+the+activating+and+conjugating+enzymes+of+the+NEDD8+conjugation+pathway&doi=10.1074%2Fjbc.274.17.12036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway</span></div><div class="casAuthors">Gong, Limin; Yeh, Edward T. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">12036-12042</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">NEDD8 is a ubiquitin-like mol. that can be covalently conjugated to a limited no. of cellular proteins, such as Cdc53/cullin.  We have previously reported that the C terminus of NEDD8 is efficiently processed to expose Gly-76, which is required for conjugation to target proteins.  A combination of data base searches and polymerase chain reaction cloning was used to identify a cDNA encoding human UBA3, which is 38% identical to the yeast homolog, 22% identical to human UBA2, and 19% identical to the C-terminal region of human UBE1.  The human UBA3 gene is located on chromosome 3p13 and gave rise to a 2.2-kilobase pair transcript that was detected in all tissues.  Human UBA3 could be pptd. with glutathione S-transferase (GST)-NEDD8, but not with GST-ubiquitin or GST-sentrin-1.  Moreover, human UBA3 could form a β-mercaptoethanol-sensitive conjugate with NEDD8 in the presence of APP-BP1, a protein with sequence homol. to the N-terminal half of ubiquitin-activating enzyme.  We have also cloned human UBC12 and demonstrated that it could form a thiol ester linkage with NEDD8 in the presence of the activating enzyme complex.  Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway should allow for a more detailed study of the role of NEDD8 modification in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvNB8GF3Q9j7Vg90H21EOLACvtfcHk0lgV5VMHoEUFqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXislGltrg%253D&md5=2fa85c6110831986455948a921c79bc7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.17.12036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.17.12036%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DL.%26aulast%3DYeh%26aufirst%3DE.%2BT.%26atitle%3DIdentification%2520of%2520the%2520activating%2520and%2520conjugating%2520enzymes%2520of%2520the%2520NEDD8%2520conjugation%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26issue%3D17%26spage%3D12036%26epage%3D12042%26doi%3D10.1074%2Fjbc.274.17.12036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergink, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jentsch, S.</span></span> <span> </span><span class="NLM_article-title">Principles of ubiquitin and SUMO modifications in DNA repair</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>458</i></span> (<span class="NLM_issue">7237</span>),  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1038/nature07963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnature07963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=19325626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1KltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=461-467&issue=7237&author=S.+Berginkauthor=S.+Jentsch&title=Principles+of+ubiquitin+and+SUMO+modifications+in+DNA+repair&doi=10.1038%2Fnature07963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of ubiquitin and SUMO modifications in DNA repair</span></div><div class="casAuthors">Bergink, Steven; Jentsch, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">7237</span>),
    <span class="NLM_cas:pages">461-467</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  With the discovery in the late 1980s that the DNA-repair gene RAD6 encodes a ubiquitin-conjugating enzyme, it became clear that protein modification by ubiquitin conjugation has a much broader significance than had previously been assumed.  Now, two decades later, ubiquitin and its cousin SUMO are implicated in a range of human diseases, including breast cancer and Fanconi anemia, giving fresh momentum to studies focused on the relationships between ubiquitin, SUMO and DNA-repair pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt4pGq8VIfgrVg90H21EOLACvtfcHk0lgb2uRGm2Yisw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1KltLY%253D&md5=22fdbf1b69d65a9b7a846816654e976e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature07963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07963%26sid%3Dliteratum%253Aachs%26aulast%3DBergink%26aufirst%3DS.%26aulast%3DJentsch%26aufirst%3DS.%26atitle%3DPrinciples%2520of%2520ubiquitin%2520and%2520SUMO%2520modifications%2520in%2520DNA%2520repair%26jtitle%3DNature%26date%3D2009%26volume%3D458%26issue%3D7237%26spage%3D461%26epage%3D467%26doi%3D10.1038%2Fnature07963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F. X.</span></span> <span> </span><span class="NLM_article-title">Ubc9 expression predicts chemoresistance in breast cancer</span>. <i>Aizheng</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.5732/cjc.011.10084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.5732%2Fcjc.011.10084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=21880185" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=638-644&issue=9&author=S.+F.+Chenauthor=C.+Gongauthor=M.+Luoauthor=H.+R.+Yaoauthor=Y.+J.+Zengauthor=F.+X.+Su&title=Ubc9+expression+predicts+chemoresistance+in+breast+cancer&doi=10.5732%2Fcjc.011.10084"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.5732%2Fcjc.011.10084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5732%252Fcjc.011.10084%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DGong%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DH.%2BR.%26aulast%3DZeng%26aufirst%3DY.%2BJ.%26aulast%3DSu%26aufirst%3DF.%2BX.%26atitle%3DUbc9%2520expression%2520predicts%2520chemoresistance%2520in%2520breast%2520cancer%26jtitle%3DAizheng%26date%3D2011%26volume%3D30%26issue%3D9%26spage%3D638%26epage%3D644%26doi%3D10.5732%2Fcjc.011.10084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seeler, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejean, A.</span></span> <span> </span><span class="NLM_article-title">SUMO and the robustness of cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnrc.2016.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=28134258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVaru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=184-197&issue=3&author=J.+S.+Seelerauthor=A.+Dejean&title=SUMO+and+the+robustness+of+cancer&doi=10.1038%2Fnrc.2016.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">SUMO and the robustness of cancer</span></div><div class="casAuthors">Seeler, Jacob-Sebastian; Dejean, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-197</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Post-translational protein modification by small ubiquitin-like modifier (SUMO), termed sumoylation, is an important mechanism in cellular responses to stress and one that appears to be upregulated in many cancers.  Here, we examine the role of sumoylation in tumorigenesis as a possibly necessary safeguard that protects the stability and functionality of otherwise easily misregulated gene expression programs and signalling pathways of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquyShx1EBV0LVg90H21EOLACvtfcHk0lgb2uRGm2Yisw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVaru78%253D&md5=1dbd9cf2e98fa41ee2319bd8056d9dc8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.143%26sid%3Dliteratum%253Aachs%26aulast%3DSeeler%26aufirst%3DJ.%2BS.%26aulast%3DDejean%26aufirst%3DA.%26atitle%3DSUMO%2520and%2520the%2520robustness%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26issue%3D3%26spage%3D184%26epage%3D197%26doi%3D10.1038%2Fnrc.2016.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahle, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerbrey, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlabach, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez-Vidana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solimini, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, T. F.</span></span> <span> </span><span class="NLM_article-title">A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>335</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1126/science.1212728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1126%2Fscience.1212728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=22157079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC38XntlGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2012&pages=348-353&author=J.+D.+Kesslerauthor=K.+T.+Kahleauthor=T.+Sunauthor=K.+L.+Meerbreyauthor=M.+R.+Schlabachauthor=E.+M.+Schmittauthor=S.+O.+Skinnerauthor=Q.+Xuauthor=M.+Z.+Liauthor=Z.+C.+Hartmanauthor=M.+Raoauthor=P.+Yuauthor=R.+Dominguez-Vidanaauthor=A.+C.+Liangauthor=N.+L.+Soliminiauthor=R.+J.+Bernardiauthor=B.+Yuauthor=T.+Hsuauthor=I.+Goldingauthor=J.+Luoauthor=C.+K.+Osborneauthor=C.+J.+Creightonauthor=S.+G.+Hilsenbeckauthor=R.+Schiffauthor=C.+A.+Shawauthor=S.+J.+Elledgeauthor=T.+F.+Westbrook&title=A+SUMOylation-dependent+transcriptional+subprogram+is+required+for+Myc-driven+tumorigenesis&doi=10.1126%2Fscience.1212728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis</span></div><div class="casAuthors">Kessler, Jessica D.; Kahle, Kristopher T.; Sun, Tingting; Meerbrey, Kristen L.; Schlabach, Michael R.; Schmitt, Earlene M.; Skinner, Samuel O.; Xu, Qikai; Li, Mamie Z.; Hartman, Zachary C.; Rao, Mitchell; Yu, Peng; Dominguez-Vidana, Rocio; Liang, Anthony C.; Solimini, Nicole L.; Bernardi, Ronald J.; Yu, Bing; Hsu, Tiffany; Golding, Ido; Luo, Ji; Osborne, C. Kent; Creighton, Chad J.; Hilsenbeck, Susan G.; Schiff, Rachel; Shaw, Chad A.; Elledge, Stephen J.; Westbrook, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">6066</span>),
    <span class="NLM_cas:pages">348-353</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Myc is an oncogenic transcription factor frequently dysregulated in human cancer.  To identify pathways supporting the Myc oncogenic program, we used a genome-wide RNA interference screen to search for Myc-synthetic lethal genes and uncovered a role for the SUMO-activating enzyme (SAE1/2).  Loss of SAE1/2 enzymic activity drives synthetic lethality with Myc.  Inactivation of SAE2 leads to mitotic catastrophe and cell death upon Myc hyperactivation.  Mechanistically, SAE2 inhibition switches a transcriptional subprogram of Myc from activated to repressed.  A subset of these SUMOylation-dependent Myc switchers (SMS genes) is required for mitotic spindle function and to support the Myc oncogenic program.  SAE2 is required for growth of Myc-dependent tumors in mice, and gene expression analyses of Myc-high human breast cancers suggest that low SAE1 and SAE2 abundance in the tumors correlates with longer metastasis-free survival of the patients.  Thus, inhibition of SUMOylation may merit investigation as a possible therapy for Myc-driven human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTfA0iuQ_f_7Vg90H21EOLACvtfcHk0lgb2uRGm2Yisw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntlGhtg%253D%253D&md5=b25fdbcaae0d4c96d01876ed3d00bb65</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.1212728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1212728%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DJ.%2BD.%26aulast%3DKahle%26aufirst%3DK.%2BT.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DMeerbrey%26aufirst%3DK.%2BL.%26aulast%3DSchlabach%26aufirst%3DM.%2BR.%26aulast%3DSchmitt%26aufirst%3DE.%2BM.%26aulast%3DSkinner%26aufirst%3DS.%2BO.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DM.%2BZ.%26aulast%3DHartman%26aufirst%3DZ.%2BC.%26aulast%3DRao%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DDominguez-Vidana%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DA.%2BC.%26aulast%3DSolimini%26aufirst%3DN.%2BL.%26aulast%3DBernardi%26aufirst%3DR.%2BJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DGolding%26aufirst%3DI.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DC.%2BA.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26aulast%3DWestbrook%26aufirst%3DT.%2BF.%26atitle%3DA%2520SUMOylation-dependent%2520transcriptional%2520subprogram%2520is%2520required%2520for%2520Myc-driven%2520tumorigenesis%26jtitle%3DScience%26date%3D2012%26volume%3D335%26spage%3D348%26epage%3D353%26doi%3D10.1126%2Fscience.1212728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riceberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulukuri, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N.</span></span> <span> </span><span class="NLM_article-title">Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e0123882</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0123882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1371%2Fjournal.pone.0123882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=25860128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVylsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&issue=4&author=X.+Heauthor=J.+Ricebergauthor=S.+M.+Pulukuriauthor=S.+Grossmanauthor=V.+Shindeauthor=P.+Shahauthor=J.+E.+Brownellauthor=L.+Dickauthor=J.+Newcombauthor=N.+Bence&title=Characterization+of+the+loss+of+SUMO+pathway+function+on+cancer+cells+and+tumor+proliferation&doi=10.1371%2Fjournal.pone.0123882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the loss of sumo pathway function on cancer cells and tumor proliferation</span></div><div class="casAuthors">He, Xingyue; Riceberg, Jessica; Pulukuri, Sai M.; Grossman, Steve; Shinde, Vaishali; Shah, Pooja; Brownell, James E.; Dick, Larry; Newcomb, John; Bence, Neil</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0123882/1-e0123882/19</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">SUMOylation is a post-translational ubiquitin-like protein modification pathway that regulates important cellular processes including chromosome structure, kinetochore function, chromosome segregation, nuclear and sub-nuclear organization, transcription and DNA damage repair.  There is increasing evidence that the SUMO pathway is dysregulated in cancer, raising the possibility that modulation of this pathway may have therapeutic potential.  To investigate the importance of the SUMO pathway in the context of cancer cell proliferation and tumor growth, we applied lentivirus-based short hairpin RNAs (shRNA) to knockdown SUMO pathway genes in human cancer cells. shRNAs for SAE2 and UBC9 reduced SUMO conjugation activity and inhibited proliferation of human cancer cells.  To expand upon these observations, we generated doxycycline inducible conditional shRNA cell lines for SAE2 to achieve acute and reversible SAE2 knockdown.  Conditional SAE2 knockdown in U2OS and HCT116 cells slowed cell growth in vitro, and SAE2 knockdown induced multiple terminal outcomes including apoptosis, endoreduplication and senescence.  Multinucleated cells became senescent and stained pos. for the senescence marker, SA-β Gal, and displayed elevated levels of p53 and p21.  In an attempt to explain these phenotypes, we confirmed that loss of SUMO pathway activity leads to a loss of SUMOylated Topoisomerase IIα and the appearance of chromatin bridges which can impair proper cytokinesis and lead to multinucleation.  Furthermore, knockdown of SAE2 induces disruption of PML nuclear bodies which may further promote apoptosis or senescence.  In an in vivo HCT116 xenograft tumor model, conditional SAE2 knockdown strongly impaired tumor growth.  These data demonstrate that the SUMO pathway is required for cancer cell proliferation in vitro and tumor growth in vivo, implicating the SUMO pathway as a potential cancer therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7KVD_INIZILVg90H21EOLACvtfcHk0ljslKjp9saMCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVylsbvL&md5=1e7ac33d55c7df5cb1412df49c3e9338</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0123882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0123882%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DRiceberg%26aufirst%3DJ.%26aulast%3DPulukuri%26aufirst%3DS.%2BM.%26aulast%3DGrossman%26aufirst%3DS.%26aulast%3DShinde%26aufirst%3DV.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DBence%26aufirst%3DN.%26atitle%3DCharacterization%2520of%2520the%2520loss%2520of%2520SUMO%2520pathway%2520function%2520on%2520cancer%2520cells%2520and%2520tumor%2520proliferation%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D4%26doi%3D10.1371%2Fjournal.pone.0123882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1186/s13045-015-0164-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1186%2Fs13045-015-0164-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=25622682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=1-10&author=X.+Liuauthor=Y.+Xuauthor=Z.+Pangauthor=F.+Guoauthor=Q.+Qinauthor=T.+Yinauthor=Y.+Sangauthor=C.+Fengauthor=X.+Liauthor=L.+Jiangauthor=P.+Shuauthor=Y.+Wang&title=Knockdown+of+SUMO-activating+enzyme+subunit+2+%28SAE2%29+suppresses+cancer+malignancy+and+enhances+chemotherapy+sensitivity+in+small+cell+lung+cancer&doi=10.1186%2Fs13045-015-0164-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy</span></div><div class="casAuthors">Wu, Jingjing; Fu, Jiaping; Zhang, Mingzhi; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-4</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Monoclonal antibodies against CD20 mol. have been leading the revolution of lymphoma treatment.  In addn. to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clin. development are being developed and are rapidly migrating to clin. application.  One area of active development is NK cell activators, such as AFM13.  This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDJHDzKZXTOrVg90H21EOLACvtfcHk0ljslKjp9saMCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFymtQ%253D%253D&md5=fd933124d358677979fc145146116b2c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs13045-015-0164-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-015-0164-y%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPang%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DSang%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DShu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DKnockdown%2520of%2520SUMO-activating%2520enzyme%2520subunit%25202%2520%2528SAE2%2529%2520suppresses%2520cancer%2520malignancy%2520and%2520enhances%2520chemotherapy%2520sensitivity%2520in%2520small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2015%26volume%3D8%26spage%3D1%26epage%3D10%26doi%3D10.1186%2Fs13045-015-0164-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biederstadt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneeweis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckenhuber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenhof, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orben, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, U.</span></span> <span> </span><span class="NLM_article-title">SUMO pathway inhibition targets an aggressive pancreatic cancer subtype</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1472</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2018-317856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1136%2Fgutjnl-2018-317856" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=1472-1482&author=A.+Biederstadtauthor=Z.+Hassanauthor=C.+Schneeweisauthor=M.+Schickauthor=L.+Schneiderauthor=A.+Muckenhuberauthor=Y.+Hongauthor=G.+Siegersauthor=L.+Nilssonauthor=M.+Wirthauthor=Z.+Dantesauthor=K.+Steigerauthor=K.+Schunckauthor=S.+Langstonauthor=H.+P.+Lenhofauthor=A.+Coluccioauthor=F.+Orbenauthor=J.+Slawskaauthor=A.+Schergerauthor=D.+Saurauthor=S.+Mullerauthor=R.+Radauthor=W.+Weichertauthor=J.+Nilssonauthor=M.+Reichertauthor=G.+Schneiderauthor=U.+Keller&title=SUMO+pathway+inhibition+targets+an+aggressive+pancreatic+cancer+subtype&doi=10.1136%2Fgutjnl-2018-317856"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2018-317856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2018-317856%26sid%3Dliteratum%253Aachs%26aulast%3DBiederstadt%26aufirst%3DA.%26aulast%3DHassan%26aufirst%3DZ.%26aulast%3DSchneeweis%26aufirst%3DC.%26aulast%3DSchick%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DL.%26aulast%3DMuckenhuber%26aufirst%3DA.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DSiegers%26aufirst%3DG.%26aulast%3DNilsson%26aufirst%3DL.%26aulast%3DWirth%26aufirst%3DM.%26aulast%3DDantes%26aufirst%3DZ.%26aulast%3DSteiger%26aufirst%3DK.%26aulast%3DSchunck%26aufirst%3DK.%26aulast%3DLangston%26aufirst%3DS.%26aulast%3DLenhof%26aufirst%3DH.%2BP.%26aulast%3DColuccio%26aufirst%3DA.%26aulast%3DOrben%26aufirst%3DF.%26aulast%3DSlawska%26aufirst%3DJ.%26aulast%3DScherger%26aufirst%3DA.%26aulast%3DSaur%26aufirst%3DD.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DRad%26aufirst%3DR.%26aulast%3DWeichert%26aufirst%3DW.%26aulast%3DNilsson%26aufirst%3DJ.%26aulast%3DReichert%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DKeller%26aufirst%3DU.%26atitle%3DSUMO%2520pathway%2520inhibition%2520targets%2520an%2520aggressive%2520pancreatic%2520cancer%2520subtype%26jtitle%3DGut%26date%3D2020%26volume%3D8%26spage%3D1472%26epage%3D1482%26doi%3D10.1136%2Fgutjnl-2018-317856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adorisio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fierabracci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muscari, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liberati, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayroldi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delfino, D. V.</span></span> <span> </span><span class="NLM_article-title">SUMO proteins: Guardians of immune system</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1016/j.jaut.2017.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.jaut.2017.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=28919255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWitrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2017&pages=21-28&author=S.+Adorisioauthor=A.+Fierabracciauthor=I.+Muscariauthor=A.+M.+Liberatiauthor=E.+Ayroldiauthor=G.+Miglioratiauthor=T.+T.+Thuyauthor=C.+Riccardiauthor=D.+V.+Delfino&title=SUMO+proteins%3A+Guardians+of+immune+system&doi=10.1016%2Fj.jaut.2017.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">SUMO proteins: Guardians of immune system</span></div><div class="casAuthors">Adorisio, Sabrina; Fierabracci, Alessandra; Muscari, Isabella; Liberati, Anna Marina; Ayroldi, Emira; Migliorati, Graziella; Thuy, Trinh Thi; Riccardi, Carlo; Delfino, Domenico V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Autoimmunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-28</span>CODEN:
                <span class="NLM_cas:coden">JOAUEP</span>;
        ISSN:<span class="NLM_cas:issn">0896-8411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Small ubiquitin-like modifier (SUMO) proteins belong to the ubiquitin-like family and act to change the function of target proteins through post-translational modifications.  Through their interactions with innate immune pathways, SUMOs promote an efficient immune response to pathogenic challenge avoiding, at the same time, an excess of immune response that could lead to the development of autoimmune diseases.  This report discusses the general functions of SUMO proteins; highlights SUMO involvement in the innate immune response through their role in NF-κB and interferon pathways; the involvement of SUMO proteins in autoimmune diseases; and reviews bacterial, viral, and parasitic interactions with SUMO pathways.  In conclusion, we speculate that targeting SUMOs could represent a new therapeutic strategy against infections and autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdivj0kCCqJLVg90H21EOLACvtfcHk0liYHhExJ7rcMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWitrnJ&md5=29a6a2431f7aac67f1659e09cde2547c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2017.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2017.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DAdorisio%26aufirst%3DS.%26aulast%3DFierabracci%26aufirst%3DA.%26aulast%3DMuscari%26aufirst%3DI.%26aulast%3DLiberati%26aufirst%3DA.%2BM.%26aulast%3DAyroldi%26aufirst%3DE.%26aulast%3DMigliorati%26aufirst%3DG.%26aulast%3DThuy%26aufirst%3DT.%2BT.%26aulast%3DRiccardi%26aufirst%3DC.%26aulast%3DDelfino%26aufirst%3DD.%2BV.%26atitle%3DSUMO%2520proteins%253A%2520Guardians%2520of%2520immune%2520system%26jtitle%3DJ.%2520Autoimmun.%26date%3D2017%26volume%3D84%26spage%3D21%26epage%3D28%26doi%3D10.1016%2Fj.jaut.2017.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Decque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffre, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magalhaes, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossec, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blecher-Gonen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapaquette, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joubert, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeler, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amit, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amigorena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejean, A.</span></span> <span> </span><span class="NLM_article-title">Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1038/ni.3342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fni.3342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=26657003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSgtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=140-149&issue=2&author=A.+Decqueauthor=O.+Joffreauthor=J.+G.+Magalhaesauthor=J.+C.+Cossecauthor=R.+Blecher-Gonenauthor=P.+Lapaquetteauthor=A.+Silvinauthor=N.+Manelauthor=P.+E.+Joubertauthor=J.+S.+Seelerauthor=M.+L.+Albertauthor=I.+Amitauthor=S.+Amigorenaauthor=A.+Dejean&title=Sumoylation+coordinates+the+repression+of+inflammatory+and+anti-viral+gene-expression+programs+during+innate+sensing&doi=10.1038%2Fni.3342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing</span></div><div class="casAuthors">Decque, Adrien; Joffre, Olivier; Magalhaes, Joao G.; Cossec, Jack-Christophe; Blecher-Gonen, Ronnie; Lapaquette, Pierre; Silvin, Aymeric; Manel, Nicolas; Joubert, Pierre-Emmanuel; Seeler, Jacob-Sebastian; Albert, Matthew L.; Amit, Ido; Amigorena, Sebastian; Dejean, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-149</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Innate sensing of pathogens initiates inflammatory cytokine responses that need to be tightly controlled.  We found here that after engagement of Toll-like receptors (TLRs) in myeloid cells, deficient sumoylation caused increased secretion of transcription factor NF-κB-dependent inflammatory cytokines and a massive type I interferon signature.  In mice, diminished sumoylation conferred susceptibility to endotoxin shock and resistance to viral infection.  Overprodn. of several NF-κB-dependent inflammatory cytokines required expression of the type I interferon receptor, which identified type I interferon as a central sumoylation-controlled hub for inflammation.  Mechanistically, the small ubiquitin-like modifier SUMO operated from a distal enhancer of the gene encoding interferon-β (Ifnb1) to silence both basal and stimulus-induced activity of the Ifnb1 promoter.  Therefore, sumoylation restrained inflammation by silencing Ifnb1 expression and by strictly suppressing an unanticipated priming by type I interferons of the TLR-induced prodn. of inflammatory cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnGzeVo1dSU7Vg90H21EOLACvtfcHk0liYHhExJ7rcMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSgtrfF&md5=d2f6be017daac62c3eeb57d167a13b8a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fni.3342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3342%26sid%3Dliteratum%253Aachs%26aulast%3DDecque%26aufirst%3DA.%26aulast%3DJoffre%26aufirst%3DO.%26aulast%3DMagalhaes%26aufirst%3DJ.%2BG.%26aulast%3DCossec%26aufirst%3DJ.%2BC.%26aulast%3DBlecher-Gonen%26aufirst%3DR.%26aulast%3DLapaquette%26aufirst%3DP.%26aulast%3DSilvin%26aufirst%3DA.%26aulast%3DManel%26aufirst%3DN.%26aulast%3DJoubert%26aufirst%3DP.%2BE.%26aulast%3DSeeler%26aufirst%3DJ.%2BS.%26aulast%3DAlbert%26aufirst%3DM.%2BL.%26aulast%3DAmit%26aufirst%3DI.%26aulast%3DAmigorena%26aufirst%3DS.%26aulast%3DDejean%26aufirst%3DA.%26atitle%3DSumoylation%2520coordinates%2520the%2520repression%2520of%2520inflammatory%2520and%2520anti-viral%2520gene-expression%2520programs%2520during%2520innate%2520sensing%26jtitle%3DNat.%2520Immunol.%26date%3D2016%26volume%3D17%26issue%3D2%26spage%3D140%26epage%3D149%26doi%3D10.1038%2Fni.3342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowl, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D. B.</span></span> <span> </span><span class="NLM_article-title">SUMO2 and SUMO3 redundantly prevent a noncanonical type I interferon response</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">6798</span>– <span class="NLM_lpage">6803</span>, <span class="refDoi"> DOI: 10.1073/pnas.1802114115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1073%2Fpnas.1802114115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=29891701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbmt1Crsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=6798-6803&issue=26&author=J.+T.+Crowlauthor=D.+B.+Stetson&title=SUMO2+and+SUMO3+redundantly+prevent+a+noncanonical+type+I+interferon+response&doi=10.1073%2Fpnas.1802114115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">SUMO2 and SUMO3 redundantly prevent a noncanonical type I interferon response</span></div><div class="casAuthors">Crowl John T; Stetson Daniel B</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6798-6803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Detection of nucleic acids by innate immune sensors triggers the production of type I interferons (IFNs).  While IFNs are essential for host defense against viral infection, dysregulated production of IFNs underlies numerous autoinflammatory diseases.  We have found that the loss of sumoylation results in a potent, spontaneous IFN response.  Vertebrates possess three small ubiquitin-like modifiers (SUMOs) that can be conjugated onto target proteins and alter protein function in diverse but still poorly characterized ways.  We demonstrate that regulation of IFN by sumoylation is redundantly mediated by both SUMO2 and SUMO3, but not SUMO1, revealing a previously unknown function of SUMO2/3.  Remarkably, this IFN response is independent of all known IFN-inducing pathways and does not require either of the canonical IFN-associated transcription factors IRF3 or IRF7.  Taken together, our findings demonstrate that SUMO2 and SUMO3 are specific and essential negative regulators of a noncanonical mechanism of IFN induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqfLtnKg3oakodMGTatQ7LfW6udTcc2ebaqstRKMbNQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbmt1Crsg%253D%253D&md5=9424d47505eb615f8eb86a2ab294ed35</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1802114115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1802114115%26sid%3Dliteratum%253Aachs%26aulast%3DCrowl%26aufirst%3DJ.%2BT.%26aulast%3DStetson%26aufirst%3DD.%2BB.%26atitle%3DSUMO2%2520and%2520SUMO3%2520redundantly%2520prevent%2520a%2520noncanonical%2520type%2520I%2520interferon%2520response%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D26%26spage%3D6798%26epage%3D6803%26doi%3D10.1073%2Fpnas.1802114115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraj, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spelman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sells, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visiers, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span> <span> </span><span class="NLM_article-title">Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2009.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.molcel.2009.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=20129059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFKgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=102-111&issue=1&author=J.+E.+Brownellauthor=M.+D.+Sintchakauthor=J.+M.+Gavinauthor=H.+Liaoauthor=F.+J.+Bruzzeseauthor=N.+J.+Bumpauthor=T.+A.+Soucyauthor=M.+A.+Milhollenauthor=X.+Yangauthor=A.+L.+Burkhardtauthor=J.+Maauthor=H.+K.+Lokeauthor=T.+Lingarajauthor=D.+Wuauthor=K.+B.+Hammanauthor=J.+J.+Spelmanauthor=C.+A.+Cullisauthor=S.+P.+Langstonauthor=S.+Vyskocilauthor=T.+B.+Sellsauthor=W.+D.+Mallenderauthor=I.+Visiersauthor=P.+Liauthor=C.+F.+Claiborneauthor=M.+Rolfeauthor=J.+B.+Bolenauthor=L.+R.+Dick&title=Substrate-assisted+inhibition+of+ubiquitin-like+protein-activating+enzymes%3A+the+NEDD8+E1+inhibitor+MLN4924+forms+a+NEDD8-AMP+mimetic+in+situ&doi=10.1016%2Fj.molcel.2009.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ</span></div><div class="casAuthors">Brownell, James E.; Sintchak, Michael D.; Gavin, James M.; Liao, Hua; Bruzzese, Frank J.; Bump, Nancy J.; Soucy, Teresa A.; Milhollen, Michael A.; Yang, Xiaofeng; Burkhardt, Anne L.; Ma, Jingya; Loke, Huay-Keng; Lingaraj, Trupti; Wu, Dongyun; Hamman, Kristin B.; Spelman, James J.; Cullis, Courtney A.; Langston, Steven P.; Vyskocil, Stepan; Sells, Todd B.; Mallender, William D.; Visiers, Irache; Li, Ping; Claiborne, Christopher F.; Rolfe, Mark; Bolen, Joseph B.; Dick, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The NEDD8-activating enzyme (NAE) initiates a protein homeostatic pathway essential for cancer cell growth and survival.  MLN4924 is a selective inhibitor of NAE currently in clin. trials for the treatment of cancer.  Here, we show that MLN4924 is a mechanism-based inhibitor of NAE and creates a covalent NEDD8-MLN4924 adduct catalyzed by the enzyme.  The NEDD8-MLN4924 adduct resembles NEDD8 adenylate, the first intermediate in the NAE reaction cycle, but cannot be further utilized in subsequent intraenzyme reactions.  The stability of the NEDD8-MLN4924 adduct within the NAE active site blocks enzyme activity, thereby accounting for the potent inhibition of the NEDD8 pathway by MLN4924.  Importantly, we have detd. that compds. resembling MLN4924 demonstrate the ability to form analogous adducts with other ubiquitin-like proteins (UBLs) catalyzed by their cognate-activating enzymes.  These findings reveal insights into the mechanism of E1s and suggest a general strategy for selective inhibition of UBL conjugation pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrGGYI7bTPerVg90H21EOLACvtfcHk0lgrgjoOOoW-3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFKgsbw%253D&md5=b080f6ec40864164ab2252f629975456</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2009.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2009.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DLiao%26aufirst%3DH.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DBump%26aufirst%3DN.%2BJ.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBurkhardt%26aufirst%3DA.%2BL.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLoke%26aufirst%3DH.%2BK.%26aulast%3DLingaraj%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DHamman%26aufirst%3DK.%2BB.%26aulast%3DSpelman%26aufirst%3DJ.%2BJ.%26aulast%3DCullis%26aufirst%3DC.%2BA.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DSells%26aufirst%3DT.%2BB.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DVisiers%26aufirst%3DI.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DDick%26aufirst%3DL.%2BR.%26atitle%3DSubstrate-assisted%2520inhibition%2520of%2520ubiquitin-like%2520protein-activating%2520enzymes%253A%2520the%2520NEDD8%2520E1%2520inhibitor%2520MLN4924%2520forms%2520a%2520NEDD8-AMP%2520mimetic%2520in%2520situ%26jtitle%3DMol.%2520Cell%26date%3D2010%26volume%3D37%26issue%3D1%26spage%3D102%26epage%3D111%26doi%3D10.1016%2Fj.molcel.2009.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span> <span> </span><span class="NLM_article-title">Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">40867</span>– <span class="NLM_lpage">40877</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.279984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1074%2Fjbc.M111.279984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=21969368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=40867-40877&issue=47&author=J.+J.+Chenauthor=C.+A.+Tsuauthor=J.+M.+Gavinauthor=M.+A.+Milhollenauthor=F.+J.+Bruzzeseauthor=W.+D.+Mallenderauthor=M.+D.+Sintchakauthor=N.+J.+Bumpauthor=X.+Yangauthor=J.+Maauthor=H.+K.+Lokeauthor=Q.+Xuauthor=P.+Liauthor=N.+F.+Benceauthor=J.+E.+Brownellauthor=L.+R.+Dick&title=Mechanistic+studies+of+substrate-assisted+inhibition+of+ubiquitin-activating+enzyme+by+adenosine+sulfamate+analogues&doi=10.1074%2Fjbc.M111.279984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues</span></div><div class="casAuthors">Chen, Jesse J.; Tsu, Christopher A.; Gavin, James M.; Milhollen, Michael A.; Bruzzese, Frank J.; Mallender, William D.; Sintchak, Michael D.; Bump, Nancy J.; Yang, Xiaofeng; Ma, Jingya; Loke, Huay-Keng; Xu, Qing; Li, Ping; Bence, Neil F.; Brownell, James E.; Dick, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">40867-40877</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ubiquitin-activating enzyme (UAE or E1) activates ubiquitin via an adenylate intermediate and catalyzes its transfer to a ubiquitin-conjugating enzyme (E2).  MLN4924 is an adenosine sulfamate analog that was identified as a selective, mechanism-based inhibitor of NEDD8-activating enzyme (NAE), another E1 enzyme, by forming a NEDD8-MLN4924 adduct that tightly binds at the active site of NAE, a novel mechanism termed substrate-assisted inhibition.  In the present study, substrate-assisted inhibition of human UAE (Ube1) by another adenosine sulfamate analog, 5'-O-sulfamoyl-N6-[(1S)-2,3-dihydro-1H-inden-1-yl]-adenosine (Compd. I), a nonselective E1 inhibitor, was characterized.  Compd. I inhibited UAE-dependent ATP-PPi exchange activity, caused loss of UAE thioester, and inhibited E1-E2 transthiolation in a dose-dependent manner.  Mechanistic studies on Compd. I and its purified ubiquitin adduct demonstrate that the proposed substrate-assisted inhibition via covalent adduct formation is entirely consistent with the three-step ubiquitin activation process and that the adduct is formed via nucleophilic attack of UAE thioester by the sulfamate group of Compd. I after completion of step 2.  Kinetic and affinity anal. of Compd. I, MLN4924, and their purified ubiquitin adducts suggest that both the rate of adduct formation and the affinity between the adduct and E1 contribute to the overall potency.  Because all E1s are thought to use a similar mechanism to activate their cognate ubiquitin-like proteins, the substrate-assisted inhibition by adenosine sulfamate analogs represents a promising strategy to develop potent and selective E1 inhibitors that can modulate diverse biol. pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiclhUT_b-7Vg90H21EOLACvtfcHk0lgrgjoOOoW-3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE&md5=2362ac83bb8acf0de63162bac731c6e7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.279984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.279984%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DTsu%26aufirst%3DC.%2BA.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBump%26aufirst%3DN.%2BJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLoke%26aufirst%3DH.%2BK.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBence%26aufirst%3DN.%2BF.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DDick%26aufirst%3DL.%2BR.%26atitle%3DMechanistic%2520studies%2520of%2520substrate-assisted%2520inhibition%2520of%2520ubiquitin-activating%2520enzyme%2520by%2520adenosine%2520sulfamate%2520analogues%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26issue%3D47%26spage%3D40867%26epage%3D40877%26doi%3D10.1074%2Fjbc.M111.279984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capili, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cisar, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S.</span></span> <span> </span><span class="NLM_article-title">Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1748</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1021/ja9088549</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9088549" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVSiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=1748-1749&issue=6&author=X.+Luauthor=S.+K.+Olsenauthor=A.+D.+Capiliauthor=J.+S.+Cisarauthor=C.+D.+Limaauthor=D.+S.+Tan&title=Designed+semisynthetic+protein+inhibitors+of+Ub%2FUbl+E1+activating+enzymes&doi=10.1021%2Fja9088549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Semisynthetic Protein Inhibitors of Ub/Ubl E1 Activating Enzymes</span></div><div class="casAuthors">Lu, Xuequan; Olsen, Shaun K.; Capili, Allan D.; Cisar, Justin S.; Lima, Christopher D.; Tan, Derek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1748-1749</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Semisynthetic, mechanism-based protein inhibitors of ubiquitin (Ub) and ubiquitin-like modifier (Ubl) activating enzymes (E1s) have been developed to target E1-catalyzed adenylation and thioesterification of the Ub/Ubl C-terminus during the processes of protein SUMOylation and ubiquitination.  The inhibitors were generated by intein-mediated expressed protein ligation using a truncated Ub/Ubl protein (SUMO residues 1-94; Ub residues 1-71) with a C-terminal thioester and synthetic tripeptides having a C-terminal adenosine analog and an N-terminal cysteine residue.  SUMO-AMSN (4a) and Ub-AMSN (4b) contain a sulfamide group as a nonhydrolyzable mimic of the phosphate group in the cognate Ub/Ubl-AMP adenylate intermediate in the first half-reaction, and these constructs selectively inhibit SUMO E1 and Ub E1, resp., in a dose-dependent manner.  SUMO-AVSN (5a) and Ub-AVSN (5b) contain an electrophilic vinyl sulfonamide designed to trap the incoming E1 cysteine nucleophile (Uba2 Cys173 in SUMO E1; Uba1 Cys593 in Ub E1) in the second half-reaction, and these constructs selectively, covalently, and stably cross-link to SUMO E1 and Ub E1, resp., in a cysteine nucleophile-dependent manner.  These inhibitors are powerful tools to probe outstanding mechanistic questions in E1 function and can also be used to study the biol. functions of E1 enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFrlstIrtwC7Vg90H21EOLACvtfcHk0lg0XF9yPZljkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVSiurY%253D&md5=2c7015f7594aa5fb6f540c8679101fce</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fja9088549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9088549%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26aulast%3DCapili%26aufirst%3DA.%2BD.%26aulast%3DCisar%26aufirst%3DJ.%2BS.%26aulast%3DLima%26aufirst%3DC.%2BD.%26aulast%3DTan%26aufirst%3DD.%2BS.%26atitle%3DDesigned%2520semisynthetic%2520protein%2520inhibitors%2520of%2520Ub%252FUbl%2520E1%2520activating%2520enzymes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26issue%3D6%26spage%3D1748%26epage%3D1749%26doi%3D10.1021%2Fja9088549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capili, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. D.</span></span> <span> </span><span class="NLM_article-title">Active site remodelling accompanies thioester bond formation in the SUMO E1</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span> (<span class="NLM_issue">7283</span>),  <span class="NLM_fpage">906</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1038/nature08765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnature08765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=20164921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFemsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=906-912&issue=7283&author=S.+K.+Olsenauthor=A.+D.+Capiliauthor=X.+Luauthor=D.+S.+Tanauthor=C.+D.+Lima&title=Active+site+remodelling+accompanies+thioester+bond+formation+in+the+SUMO+E1&doi=10.1038%2Fnature08765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Active site remodelling accompanies thioester bond formation in the SUMO E1</span></div><div class="casAuthors">Olsen, Shaun K.; Capili, Allan D.; Lu, Xuequan; Tan, Derek S.; Lima, Christopher D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7283</span>),
    <span class="NLM_cas:pages">906-912</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">E1 enzymes activate ubiquitin (Ub) and ubiquitin-like (Ubl) proteins in two steps by carboxy-terminal adenylation and thioester bond formation to a conserved catalytic cysteine in the E1 Cys domain.  The structural basis for these intermediates remains unknown.  Here we report crystal structures for human SUMO E1 in complex with SUMO adenylate and tetrahedral intermediate analogs at 2.45 and 2.6 Å, resp.  These structures show that side chain contacts to ATP·Mg are released after adenylation to facilitate a 130 degree rotation of the Cys domain during thioester bond formation that is accompanied by remodeling of key structural elements including the helix that contains the E1 catalytic cysteine, the crossover and re-entry loops, and refolding of two helixes that are required for adenylation.  These changes displace side chains required for adenylation with side chains required for thioester bond formation.  Mutational and biochem. analyses indicate these mechanisms are conserved in other E1s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9k1BOu5nwaLVg90H21EOLACvtfcHk0lg0XF9yPZljkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFemsr8%253D&md5=1c21dabaaa4d831db0bb9bb343ffe555</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature08765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08765%26sid%3Dliteratum%253Aachs%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26aulast%3DCapili%26aufirst%3DA.%2BD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DD.%2BS.%26aulast%3DLima%26aufirst%3DC.%2BD.%26atitle%3DActive%2520site%2520remodelling%2520accompanies%2520thioester%2520bond%2520formation%2520in%2520the%2520SUMO%2520E1%26jtitle%3DNature%26date%3D2010%26volume%3D463%26issue%3D7283%26spage%3D906%26epage%3D912%26doi%3D10.1038%2Fnature08765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faessel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedarati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezube, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span> <span> </span><span class="NLM_article-title">Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1111/bjh.13323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1111%2Fbjh.13323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=25733005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2015&pages=534-543&issue=4&author=R.+T.+Swordsauthor=H.+P.+Erbaauthor=D.+J.+DeAngeloauthor=D.+L.+Bixbyauthor=J.+K.+Altmanauthor=M.+Marisauthor=Z.+Huaauthor=S.+J.+Blakemoreauthor=H.+Faesselauthor=F.+Sedaratiauthor=B.+J.+Dezubeauthor=F.+J.+Gilesauthor=B.+C.+Medeiros&title=Pevonedistat+%28MLN4924%29%2C+a+First-in-Class+NEDD8-activating+enzyme+inhibitor%2C+in+patients+with+acute+myeloid+leukaemia+and+myelodysplastic+syndromes%3A+a+phase+1+study&doi=10.1111%2Fbjh.13323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study</span></div><div class="casAuthors">Swords, Ronan T.; Erba, Harry P.; DeAngelo, Daniel J.; Bixby, Dale L.; Altman, Jessica K.; Maris, Michael; Hua, Zhaowei; Blakemore, Stephen J.; Faessel, Helene; Sedarati, Farhad; Dezube, Bruce J.; Giles, Francis J.; Medeiros, Bruno C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">534-543</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : This trial was conducted to det. the dose-limiting toxicities (DLTs) and max. tolerated dose (MTD) of the first in class NEDD8-activating enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).  Pevonedistat was administered via a 60-min i.v. infusion on days 1, 3 and 5 (schedule A, n = 27), or days 1, 4, 8 and 11 (schedule B, n = 26) every 21-days.  Dose escalation proceeded using a std. '3 + 3' design.  Responses were assessed according to published guidelines.  The MTD for schedules A and B were 59 and 83 mg/m2, resp.  On schedule A, hepatotoxicity was dose limiting.  Multi-organ failure (MOF) was dose limiting on schedule B. The overall complete (CR) and partial (PR) response rate in patients treated at or below the MTD was 17% (4/23, 2 CRs, 2 PRs) for schedule A and 10% (2/19, 2 PRs) for schedule B. Pevonedistat plasma concns. peaked after infusion followed by elimination in a biphasic pattern.  Pharmacodynamic studies of biol. correlates of NAE inhibition demonstrated target-specific activity of pevonedistat.  In conclusion, administration of the first-in-class agent, pevonedistat, was feasible in patients with MDS and AML and modest clin. activity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKvj57_N1VFrVg90H21EOLACvtfcHk0lhikP-rCVUgxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOntLY%253D&md5=435529c5ec061a767d00a3feb6589bb1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13323%26sid%3Dliteratum%253Aachs%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DMaris%26aufirst%3DM.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DBlakemore%26aufirst%3DS.%2BJ.%26aulast%3DFaessel%26aufirst%3DH.%26aulast%3DSedarati%26aufirst%3DF.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26atitle%3DPevonedistat%2520%2528MLN4924%2529%252C%2520a%2520First-in-Class%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukaemia%2520and%2520myelodysplastic%2520syndromes%253A%2520a%2520phase%25201%2520study%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D169%26issue%3D4%26spage%3D534%26epage%3D543%26doi%3D10.1111%2Fbjh.13323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span>; <span class="NLM_string-name">Langston, S. P.</span>; <span class="NLM_string-name">Vyskocil, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Potent NAE Inhibitor: Pevonedistat</span>. In  <i>Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Vol. 2</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, F. A.-M.</span>, <span class="NLM_string-name">Pesti, J. A..</span>, <span class="NLM_string-name">Vaidyanathan, R.</span></span>, Eds.; <span class="NLM_publisher-name">ACS Symposium Series</span>: <span class="NLM_year">2016</span>; Vol.  <span class="NLM_volume">1240</span>, pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1240.ch001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=1-11&author=H.+Mizutani&author=S.+P.+Langston&author=S.+Vyskocilauthor=F.+A.-M.+Ahmed&author=J.+A..+Pesti&author=R.+Vaidyanathan&title=Comprehensive+Accounts+of+Pharmaceutical+Research+and+Development%3A+From+Discovery+to+Late-Stage+Process+Development+Vol.+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1240.ch001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Fbk-2016-1240.ch001%26sid%3Dliteratum%253Aachs%26aulast%3DMizutani%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520a%2520Potent%2520NAE%2520Inhibitor%253A%2520Pevonedistat%26btitle%3DComprehensive%2520Accounts%2520of%2520Pharmaceutical%2520Research%2520and%2520Development%253A%2520From%2520Discovery%2520to%2520Late-Stage%2520Process%2520Development%2520Vol.%25202%26aulast%3DAhmed%26aufirst%3DF.%2BA.-M.%26pub%3DACS%2520Symposium%2520Series%26date%3D2016%26volume%3D1240%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams-Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span> <span> </span><span class="NLM_article-title">MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-03-272567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1182%2Fblood-2010-03-272567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=20525923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2qsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=1515-1523&issue=9&author=M.+A.+Milhollenauthor=T.+Traoreauthor=J.+Adams-Duffyauthor=M.+P.+Thomasauthor=A.+J.+Bergerauthor=L.+Dangauthor=L.+R.+Dickauthor=J.+J.+Garnseyauthor=E.+Koenigauthor=S.+P.+Langstonauthor=M.+Manfrediauthor=U.+Narayananauthor=M.+Rolfeauthor=L.+M.+Staudtauthor=T.+A.+Soucyauthor=J.+Yuauthor=J.+Zhangauthor=J.+B.+Bolenauthor=P.+G.+Smith&title=MLN4924%2C+a+NEDD8-activating+enzyme+inhibitor%2C+is+active+in+diffuse+large+B-cell+lymphoma+models%3A+rationale+for+treatment+of+NF-%7Bkappa%7DB-dependent+lymphoma&doi=10.1182%2Fblood-2010-03-272567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma</span></div><div class="casAuthors">Milhollen, Michael A.; Traore, Tary; Adams-Duffy, Jennifer; Thomas, Michael P.; Berger, Allison J.; Dang, Lenny; Dick, Lawrence R.; Gamsey, James J.; Koenig, Erik; Langston, Steven P.; Manfredi, Mark; Narayanan, Usha; Rolfe, Mark; Staudt, Louis M.; Soucy, Teresa A.; Yu, Jie; Zhang, Julie; Bolen, Joseph B.; Smith, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1515-1523</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">MLN4924 is a potent and selective small mol. NEDD8-activating enzyme (NAE) inhibitor.  In most cancer cells tested, inhibition of NAE leads to induction of DNA rereplication, resulting in DNA damage and cell death.  However, in preclin. models of activated B cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), we show that MLN4924 induces an alternative mechanism of action.  Treatment of ABC DLBCL cells with MLN4924 resulted in rapid accumulation of pIκBα, decrease in nuclear p65 content, redn. of nuclear factor-κB (NF-κB) transcriptional activity, and G1 arrest, ultimately resulting in apoptosis induction, events consistent with potent NF-κB pathway inhibition.  Treatment of germinal-center B cell-like (GCB) DLBCL cells resulted in an increase in cellular Cdt-1 and accumulation of cells in S-phase, consistent with cells undergoing DNA rereplication.  In vivo administration of MLN4924 to mice bearing human xenograft tumors of ABC- and GCB-DLBCL blocked NAE pathway biomarkers and resulted in complete tumor growth inhibition.  In primary human tumor models of ABC-DLBCL, MLN4924 treatment resulted in NF-κB pathway inhibition accompanied by tumor regressions.  This work describes a novel mechanism of targeted NF-κB pathway modulation in DLBCL and provides strong rationale for clin. development of MLN4924 against NF-κB-dependent lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Ez4BtgNx0LVg90H21EOLACvtfcHk0lhikP-rCVUgxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2qsbzO&md5=6100194d48b30325e94b3b0cdb77fae0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-03-272567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-03-272567%26sid%3Dliteratum%253Aachs%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DAdams-Duffy%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DKoenig%26aufirst%3DE.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DNarayanan%26aufirst%3DU.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26atitle%3DMLN4924%252C%2520a%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520is%2520active%2520in%2520diffuse%2520large%2520B-cell%2520lymphoma%2520models%253A%2520rationale%2520for%2520treatment%2520of%2520NF-%257Bkappa%257DB-dependent%2520lymphoma%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26issue%3D9%26spage%3D1515%26epage%3D1523%26doi%3D10.1182%2Fblood-2010-03-272567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doucette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talreja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span> <span> </span><span class="NLM_article-title">An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>458</i></span> (<span class="NLM_issue">7239</span>),  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1038/nature07884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnature07884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=19360080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=732-736&issue=7239&author=T.+A.+Soucyauthor=P.+G.+Smithauthor=M.+A.+Milhollenauthor=A.+J.+Bergerauthor=J.+M.+Gavinauthor=S.+Adhikariauthor=J.+E.+Brownellauthor=K.+E.+Burkeauthor=D.+P.+Cardinauthor=S.+Critchleyauthor=C.+A.+Cullisauthor=A.+Doucetteauthor=J.+J.+Garnseyauthor=J.+L.+Gaulinauthor=R.+E.+Gershmanauthor=A.+R.+Lublinskyauthor=A.+McDonaldauthor=H.+Mizutaniauthor=U.+Narayananauthor=E.+J.+Olhavaauthor=S.+Pelusoauthor=M.+Rezaeiauthor=M.+D.+Sintchakauthor=T.+Talrejaauthor=M.+P.+Thomasauthor=T.+Traoreauthor=S.+Vyskocilauthor=G.+S.+Weatherheadauthor=J.+Yuauthor=J.+Zhangauthor=L.+R.+Dickauthor=C.+F.+Claiborneauthor=M.+Rolfeauthor=J.+B.+Bolenauthor=S.+P.+Langston&title=An+inhibitor+of+NEDD8-activating+enzyme+as+a+new+approach+to+treat+cancer&doi=10.1038%2Fnature07884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</span></div><div class="casAuthors">Soucy, Teresa A.; Smith, Peter G.; Milhollen, Michael A.; Berger, Allison J.; Gavin, James M.; Adhikari, Sharmila; Brownell, James E.; Burke, Kristine E.; Cardin, David P.; Critchley, Stephen; Cullis, Courtney A.; Doucette, Amanda; Garnsey, James J.; Gaulin, Jeffrey L.; Gershman, Rachel E.; Lublinsky, Anna R.; McDonald, Alice; Mizutani, Hirotake; Narayanan, Usha; Olhava, Edward J.; Peluso, Stephane; Rezaei, Mansoureh; Sintchak, Michael D.; Talreja, Tina; Thomas, Michael P.; Traore, Tary; Vyskocil, Stepan; Weatherhead, Gabriel S.; Yu, Jie; Zhang, Julie; Dick, Lawrence R.; Claiborne, Christopher F.; Rolfe, Mark; Bolen, Joseph B.; Langston, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">7239</span>),
    <span class="NLM_cas:pages">732-736</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. development of an inhibitor of cellular proteasome function suggests that compds. targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies.  NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome.  Substrates of cullin-RING ligases have important roles in cellular processes assocd. with cancer cell growth and survival pathways.  Here we describe MLN4924, a potent and selective inhibitor of NAE.  MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumor cells by a new mechanism of action, the deregulation of S-phase DNA synthesis.  MLN4924 suppressed the growth of human tumor xenografts in mice at compd. exposures that were well tolerated.  Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8fx7OnZtYjbVg90H21EOLACvtfcHk0lhYB5hogkvrLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D&md5=365d4b4feac3994849050e00f1aae5e0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature07884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07884%26sid%3Dliteratum%253Aachs%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DAdhikari%26aufirst%3DS.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DK.%2BE.%26aulast%3DCardin%26aufirst%3DD.%2BP.%26aulast%3DCritchley%26aufirst%3DS.%26aulast%3DCullis%26aufirst%3DC.%2BA.%26aulast%3DDoucette%26aufirst%3DA.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DGaulin%26aufirst%3DJ.%2BL.%26aulast%3DGershman%26aufirst%3DR.%2BE.%26aulast%3DLublinsky%26aufirst%3DA.%2BR.%26aulast%3DMcDonald%26aufirst%3DA.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DNarayanan%26aufirst%3DU.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DPeluso%26aufirst%3DS.%26aulast%3DRezaei%26aufirst%3DM.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DTalreja%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DWeatherhead%26aufirst%3DG.%2BS.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26atitle%3DAn%2520inhibitor%2520of%2520NEDD8-activating%2520enzyme%2520as%2520a%2520new%2520approach%2520to%2520treat%2520cancer%26jtitle%3DNature%26date%3D2009%26volume%3D458%26issue%3D7239%26spage%3D732%26epage%3D736%26doi%3D10.1038%2Fnature07884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciavarri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riceberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulukuri, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuranda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenspan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/nm.4474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnm.4474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=29334375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=186-193&issue=2&author=M.+L.+Hyerauthor=M.+A.+Milhollenauthor=J.+Ciavarriauthor=P.+Flemingauthor=T.+Traoreauthor=D.+Sappalauthor=J.+Huckauthor=J.+Shiauthor=J.+Gavinauthor=J.+Brownellauthor=Y.+Yangauthor=B.+Stringerauthor=R.+Griffinauthor=F.+Bruzzeseauthor=T.+Soucyauthor=J.+Duffyauthor=C.+Rabinoauthor=J.+Ricebergauthor=K.+Hoarauthor=A.+Lublinskyauthor=S.+Menonauthor=M.+Sintchakauthor=N.+Bumpauthor=S.+M.+Pulukuriauthor=S.+Langstonauthor=S.+Tirrellauthor=M.+Kurandaauthor=P.+Veibyauthor=J.+Newcombauthor=P.+Liauthor=J.+T.+Wuauthor=J.+Poweauthor=L.+R.+Dickauthor=P.+Greenspanauthor=K.+Galvinauthor=M.+Manfrediauthor=C.+Claiborneauthor=B.+S.+Amidonauthor=N.+F.+Bence&title=A+small-molecule+inhibitor+of+the+ubiquitin+activating+enzyme+for+cancer+treatment&doi=10.1038%2Fnm.4474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment</span></div><div class="casAuthors">Hyer, Marc L.; Milhollen, Michael A.; Ciavarri, Jeff; Fleming, Paul; Traore, Tary; Sappal, Darshan; Huck, Jessica; Shi, Judy; Gavin, James; Brownell, Jim; Yang, Yu; Stringer, Bradley; Griffin, Robert; Bruzzese, Frank; Soucy, Teresa; Duffy, Jennifer; Rabino, Claudia; Riceberg, Jessica; Hoar, Kara; Lublinsky, Anya; Menon, Saurabh; Sintchak, Michael; Bump, Nancy; Pulukuri, Sai M.; Langston, Steve; Tirrell, Stephen; Kuranda, Mike; Veiby, Petter; Newcomb, John; Li, Ping; Wu, Jing Tao; Powe, Josh; Dick, Lawrence R.; Greenspan, Paul; Galvin, Katherine; Manfredi, Mark; Claiborne, Chris; Amidon, Benjamin S.; Bence, Neil F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-193</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis.  The therapeutic potential of this pathway has been validated by the clin. successes of a no. of UPS modulators, including proteasome inhibitors and immunomodulatory imide drugs (IMiDs).  Here we identified TAK-243 (formerly known as MLN7243) as a potent, mechanism-based small-mol. inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade.  TAK-243 treatment caused depletion of cellular ubiquitin conjugates, resulting in disruption of signaling events, induction of proteotoxic stress, and impairment of cell cycle progression and DNA damage repair pathways.  TAK-243 treatment caused death of cancer cells and, in primary human xenograft studies, demonstrated antitumor activity at tolerated doses.  Due to its specificity and potency, TAK-243 allows for interrogation of ubiquitin biol. and for assessment of UAE inhibition as a new approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0GCsna-MdUrVg90H21EOLACvtfcHk0lhYB5hogkvrLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D&md5=06010b7eb1cc59cf3687b9c52844eb96</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnm.4474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4474%26sid%3Dliteratum%253Aachs%26aulast%3DHyer%26aufirst%3DM.%2BL.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DCiavarri%26aufirst%3DJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DSappal%26aufirst%3DD.%26aulast%3DHuck%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DGavin%26aufirst%3DJ.%26aulast%3DBrownell%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DStringer%26aufirst%3DB.%26aulast%3DGriffin%26aufirst%3DR.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DSoucy%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DRabino%26aufirst%3DC.%26aulast%3DRiceberg%26aufirst%3DJ.%26aulast%3DHoar%26aufirst%3DK.%26aulast%3DLublinsky%26aufirst%3DA.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DPulukuri%26aufirst%3DS.%2BM.%26aulast%3DLangston%26aufirst%3DS.%26aulast%3DTirrell%26aufirst%3DS.%26aulast%3DKuranda%26aufirst%3DM.%26aulast%3DVeiby%26aufirst%3DP.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%2BT.%26aulast%3DPowe%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGreenspan%26aufirst%3DP.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DClaiborne%26aufirst%3DC.%26aulast%3DAmidon%26aufirst%3DB.%2BS.%26aulast%3DBence%26aufirst%3DN.%2BF.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520the%2520ubiquitin%2520activating%2520enzyme%2520for%2520cancer%2520treatment%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26issue%3D2%26spage%3D186%26epage%3D193%26doi%3D10.1038%2Fnm.4474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciavarri, J.</span>; <span class="NLM_string-name">Langston, S.</span></span>, <span> </span><span class="NLM_article-title">The Discovery of First-in-Class Inhibitors of the Nedd8-Activating Enzyme (NAE) and the Ubiquitin-Activating Enzyme (UAE)</span>. In  <i>Comprehensive Medicinal Chemistry III</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span>, <span class="NLM_string-name">Rotella, D.</span>, <span class="NLM_string-name">Ward, S.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Oxford</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">8</span>, pp  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">112</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2FB978-0-12-409547-2.12459-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=95-112&author=J.+Ciavarri&author=S.+Langstonauthor=S.+Chackalamannil&author=D.+Rotella&author=S.+Ward&title=Comprehensive+Medicinal+Chemistry+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-409547-2.12459-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-409547-2.12459-X%26sid%3Dliteratum%253Aachs%26aulast%3DCiavarri%26aufirst%3DJ.%26atitle%3DThe%2520Discovery%2520of%2520First-in-Class%2520Inhibitors%2520of%2520the%2520Nedd8-Activating%2520Enzyme%2520%2528NAE%2529%2520and%2520the%2520Ubiquitin-Activating%2520Enzyme%2520%2528UAE%2529%26btitle%3DComprehensive%2520Medicinal%2520Chemistry%2520III%26aulast%3DChackalamannil%26aufirst%3DS.%26pub%3DElsevier%26date%3D2017%26volume%3D8%26spage%3D95%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statsyuk, A. V.</span></span> <span> </span><span class="NLM_article-title">Development of activity-based probes for ubiquitin and ubiquitin-like protein signaling pathways</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">16948</span>– <span class="NLM_lpage">16962</span>, <span class="refDoi"> DOI: 10.1021/ja4099643</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja4099643" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=16948-16962&issue=45&author=H.+Anauthor=A.+V.+Statsyuk&title=Development+of+activity-based+probes+for+ubiquitin+and+ubiquitin-like+protein+signaling+pathways&doi=10.1021%2Fja4099643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Activity-Based Probes for Ubiquitin and Ubiquitin-like Protein Signaling Pathways</span></div><div class="casAuthors">An, Heeseon; Statsyuk, Alexander V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">16948-16962</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ubiquitin and ubiquitin-like (UBL) proteins regulate a vast variety of cellular functions.  Some UBL proteins are present in all cell types, while others are expressed only in certain cells or under certain environmental conditions.  This highlights the central role of UBL systems in regulation of ubiquitous as well as specific cellular functions.  UBL proteins share little amino acid sequence identity to each other, yet they share similar 3D shapes, which is exemplified by the β-grasp fold.  Central to UBL protein signaling pathways are UBL protein-activating E1 enzymes that activate the C-terminus of UBL proteins for subsequent conjugation to the protein substrates.  Due to their crit. roles in biol., E1 enzymes have been recognized as emerging drug targets to treat human diseases.  In spite of their biol. significance, however, methods to discover UBL proteins and to monitor the intracellular activity of E1 enzymes are lacking.  Thus, there is a crit. need for methods to evaluate the intracellular mechanisms of action of E1 enzyme inhibitors.  Here we describe the development of a mechanism-based small-mol. probe, ABP1, that can be used to discover and to detect active UBL proteins, and to monitor the intracellular activity of E1 enzymes inside intact cells.  The developed probe can also be used to profile the selectivity of E1 enzyme-targeting drugs in vitro and inside intact cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodWCWohwWsNrVg90H21EOLACvtfcHk0lhYB5hogkvrLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrrM&md5=d6e53c87761a79d3ac8636a44d09b017</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fja4099643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja4099643%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DH.%26aulast%3DStatsyuk%26aufirst%3DA.%2BV.%26atitle%3DDevelopment%2520of%2520activity-based%2520probes%2520for%2520ubiquitin%2520and%2520ubiquitin-like%2520protein%2520signaling%2520pathways%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26issue%3D45%26spage%3D16948%26epage%3D16962%26doi%3D10.1021%2Fja4099643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statsyuk, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotriffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindelin, H.</span></span> <span> </span><span class="NLM_article-title">Dissecting the Specificity of Adenosyl Sulfamate Inhibitors Targeting the Ubiquitin-Activating Enzyme</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1120</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1016/j.str.2017.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.str.2017.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=28578874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptFClurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1120-1129&issue=7&author=M.+Misraauthor=M.+Kuhnauthor=M.+Lobelauthor=H.+Anauthor=A.+V.+Statsyukauthor=C.+Sotrifferauthor=H.+Schindelin&title=Dissecting+the+Specificity+of+Adenosyl+Sulfamate+Inhibitors+Targeting+the+Ubiquitin-Activating+Enzyme&doi=10.1016%2Fj.str.2017.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting the Specificity of Adenosyl Sulfamate Inhibitors Targeting the Ubiquitin-Activating Enzyme</span></div><div class="casAuthors">Misra, Mohit; Kuhn, Maximilian; Loebel, Mark; An, Heeseon; Statsyuk, Alexander V.; Sotriffer, Christoph; Schindelin, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1120-1129.e3</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Targeting the activating enzymes (E1) of ubiquitin (Ub) and ubiquitin-like modifiers (Ubls) has emerged as a promising anti-cancer strategy, possibly overcoming the ineffectiveness of proteasome inhibitors against solid tumors.  Here, we report crystal structures of the yeast ubiquitin E1 (Uba1) with three adenosyl sulfamate inhibitors exhibiting different E1 specificities, which are all covalently linked to ubiquitin.  The structures illustrate how the chem. diverse inhibitors are accommodated within the adenylation active site.  When compared with the previously reported structures of various E1 enzymes, our structures provide the basis of the preferences of these inhibitors for different Ub/Ubl-activating enzymes.  In vitro inhibition assays and mol. dynamics simulations validated the specificities of the inhibitors as deduced from the structures.  Taken together, the structures establish a framework for the development of addnl. compds. targeting E1 enzymes, which will display higher potency and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRazXmQXgL4LVg90H21EOLACvtfcHk0ljXNlehWmHBgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptFClurc%253D&md5=78ff180520852f9baab732964a09d613</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2017.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2017.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DM.%26aulast%3DLobel%26aufirst%3DM.%26aulast%3DAn%26aufirst%3DH.%26aulast%3DStatsyuk%26aufirst%3DA.%2BV.%26aulast%3DSotriffer%26aufirst%3DC.%26aulast%3DSchindelin%26aufirst%3DH.%26atitle%3DDissecting%2520the%2520Specificity%2520of%2520Adenosyl%2520Sulfamate%2520Inhibitors%2520Targeting%2520the%2520Ubiquitin-Activating%2520Enzyme%26jtitle%3DStructure%26date%3D2017%26volume%3D25%26issue%3D7%26spage%3D1120%26epage%3D1129%26doi%3D10.1016%2Fj.str.2017.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodeoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span> <span> </span><span class="NLM_article-title">Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2009.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.chembiol.2009.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=19246003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFagtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=133-140&issue=2&author=I.+Fukudaauthor=A.+Itoauthor=G.+Hiraiauthor=S.+Nishimuraauthor=H.+Kawasakiauthor=H.+Saitohauthor=K.+Kimuraauthor=M.+Sodeokaauthor=M.+Yoshida&title=Ginkgolic+acid+inhibits+protein+SUMOylation+by+blocking+formation+of+the+E1-SUMO+intermediate&doi=10.1016%2Fj.chembiol.2009.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Ginkgolic Acid Inhibits Protein SUMOylation by Blocking Formation of the E1-SUMO Intermediate</span></div><div class="casAuthors">Fukuda, Isao; Ito, Akihiro; Hirai, Go; Nishimura, Shinichi; Kawasaki, Hisashi; Saitoh, Hisato; Kimura, Ken-ichi; Sodeoka, Mikiko; Yoshida, Minoru</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-140</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Protein modification by small ubiquitin-related modifier proteins (SUMOs) controls diverse cellular functions.  Dysregulation of SUMOylation or deSUMOylation processes has been implicated in the development of cancer and neurodegenerative diseases.  However, no small-mol. inhibiting protein SUMOylation has been reported so far.  Here, we report inhibition of SUMOylation by ginkgolic acid and its analog, anacardic acid.  Ginkgolic acid and anacardic acid inhibit protein SUMOylation both in vitro and in vivo without affecting in vivo ubiquitination.  Binding assays with a fluorescently labeled probe showed that ginkgolic acid directly binds E1 and inhibits the formation of the E1-SUMO intermediate.  These studies will provide not only a useful tool for investigating the roles of SUMO conjugations in a variety of pathways in cells, but also a basis for the development of drugs targeted against diseases involving aberrant SUMOylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoilR5o6aqeKrVg90H21EOLACvtfcHk0ljXNlehWmHBgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFagtbw%253D&md5=64eca326e5b3426a8d1b807bea9a5b48</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2009.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2009.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DI.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DHirai%26aufirst%3DG.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DSaitoh%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DSodeoka%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DM.%26atitle%3DGinkgolic%2520acid%2520inhibits%2520protein%2520SUMOylation%2520by%2520blocking%2520formation%2520of%2520the%2520E1-SUMO%2520intermediate%26jtitle%3DChem.%2520Biol.%26date%3D2009%26volume%3D16%26issue%3D2%26spage%3D133%26epage%3D140%26doi%3D10.1016%2Fj.chembiol.2009.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirohama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koshino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of protein SUMOylation by davidiin, an ellagitannin from Davidia involucrata</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1038/ja.2013.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fja.2013.142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=24424345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvV2ltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=335-338&issue=4&author=M.+Takemotoauthor=Y.+Kawamuraauthor=M.+Hirohamaauthor=Y.+Yamaguchiauthor=H.+Handaauthor=H.+Saitohauthor=Y.+Nakaoauthor=M.+Kawadaauthor=K.+Khalidauthor=H.+Koshinoauthor=K.+Kimuraauthor=A.+Itoauthor=M.+Yoshida&title=Inhibition+of+protein+SUMOylation+by+davidiin%2C+an+ellagitannin+from+Davidia+involucrata&doi=10.1038%2Fja.2013.142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of protein SUMOylation by davidiin, an ellagitannin from Davidia involucrata</span></div><div class="casAuthors">Takemoto, Misao; Kawamura, Yumi; Hirohama, Mikako; Yamaguchi, Yuki; Handa, Hiroshi; Saitoh, Hisato; Nakao, Yoichi; Kawada, Manabu; Khalid, Khan; Koshino, Hiroyuki; Kimura, Ken-ichi; Ito, Akihiro; Yoshida, Minoru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-338</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein sumoylation regulates numerous biol. processes including transcription, the cell cycle, DNA repair, and innate immunity.  Like ubiquitination, sumoylation is reversible; the desumoylation process is mediated by SUMO-specific proteases.  Abnormal sumoylation is implicated in various diseases including neurodegenerative disease, viral infection, and cancer.  Therefore, enzymes responsible for the SUMO conjugation pathway represent potential targets for drug discovery.  To date, several natural products including ginkgolic acid, anacardic acid, kerriamycin B7, and spectromycin B18, as well as synthetic compds. have been reported to inhibit protein sumoylation.  Here, the authors report another natural product that functions as a sumoylation inhibitor: davidiin (I), an ellagitannin purified from the plant D. involucrata.  Although most known sumoylation inhibitors function in the micromolar range, I was particularly potent, inhibiting at sub-micromolar concns.  Purified I inhibited the in vitro sumoylation of RanGAP1-C2 protein in a dose-dependent manner, and its IC50 value was 0.15 μM.  In addn., I reduced the level of sumoylation of p53 protein in a dose-dependent manner.  Importantly, I did not influence the cellular level of ubiquitinated proteins.  These results indicated that I inhibits protein sumoylation both in vitro and in vivo without affecting protein ubiquitination.  Next, the authors sought to identify the target of I.  High-level expression of genes involved in sumoylation is frequently obsd. in cancer.  In addn., SUMO E1 has an important role in Myc-driven tumorigenesis.  Accordingly, the authors tested the effects of I on the proliferation of cancer cells.  I inhibited cell proliferation of several cancer cells in a dose-dependent manner with similar GI50 values (gastric cancer MKN-45 cells: 8.3 μM, prostate cancer DU-145 cells: 11.6 μM, and lung cancer NCI-H460 cells: 16.4 μM).  Recent studies showed that I inhibited the growth of hepatocellular carcinoma cells by down-regulating EZH2 (enhancer of zeste homolog 2), the enzymic subunit of the Polycomb-repressive complex 2 that catalyzes histone H3 Lys-27 methylation, which is highly expressed in a variety of human cancers.  Importantly in this regard, EZH2 is SUMOylated in cells.  Here, the authors showed that I inhibited the cell growth of several cancer cells including DU-145 cells, in which EZH2 is overexpressed.  Thus, although the mol. mechanism by which I inhibits cancer cell growth remains to be elucidated, these observations suggest that the antitumor activity of I is mediated, at least in part, by inhibition of sumoylation of proteins, including EZH2.  Analyses of the structure-activity relations of I should facilitate development of novel anti-cancer agents targeting protein sumoylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLeUTKQAnSALVg90H21EOLACvtfcHk0ljJmZd2Ba_SWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvV2ltrc%253D&md5=51ec85a5148b6e6fb68a28bf923c5e65</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fja.2013.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2013.142%26sid%3Dliteratum%253Aachs%26aulast%3DTakemoto%26aufirst%3DM.%26aulast%3DKawamura%26aufirst%3DY.%26aulast%3DHirohama%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DSaitoh%26aufirst%3DH.%26aulast%3DNakao%26aufirst%3DY.%26aulast%3DKawada%26aufirst%3DM.%26aulast%3DKhalid%26aufirst%3DK.%26aulast%3DKoshino%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520protein%2520SUMOylation%2520by%2520davidiin%252C%2520an%2520ellagitannin%2520from%2520Davidia%2520involucrata%26jtitle%3DJ.%2520Antibiot.%26date%3D2014%26volume%3D67%26issue%3D4%26spage%3D335%26epage%3D338%26doi%3D10.1038%2Fja.2013.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uramoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span> <span> </span><span class="NLM_article-title">Kerriamycin B inhibits protein SUMOylation</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1038/ja.2009.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fja.2009.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=19265871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlt1Smtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2009&pages=221-224&issue=4&author=I.+Fukudaauthor=A.+Itoauthor=M.+Uramotoauthor=H.+Saitohauthor=H.+Kawasakiauthor=H.+Osadaauthor=M.+Yoshida&title=Kerriamycin+B+inhibits+protein+SUMOylation&doi=10.1038%2Fja.2009.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Kerriamycin B inhibits protein SUMOylation</span></div><div class="casAuthors">Fukuda, Isao; Ito, Akihiro; Uramoto, Masakazu; Saitoh, Hisato; Kawasaki, Hisashi; Osada, Hiroyuki; Yoshida, Minoru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-224</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors report a novel activity of kerriamycin B that inhibits protein SUMOylation, which will provide useful information about the role of SUMOylation in cells and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4vd7M4mI--bVg90H21EOLACvtfcHk0ljJmZd2Ba_SWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlt1Smtr8%253D&md5=267d0861d4124ce1dc926fa9eb2d0dde</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fja.2009.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2009.10%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DI.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DUramoto%26aufirst%3DM.%26aulast%3DSaitoh%26aufirst%3DH.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DOsada%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26atitle%3DKerriamycin%2520B%2520inhibits%2520protein%2520SUMOylation%26jtitle%3DJ.%2520Antibiot.%26date%3D2009%26volume%3D62%26issue%3D4%26spage%3D221%26epage%3D224%26doi%3D10.1038%2Fja.2009.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riceberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minissale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xega, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightcap, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulukuri, S. M.</span></span> <span> </span><span class="NLM_article-title">Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1164</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnchembio.2463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=28892090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKltbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=1164-1171&issue=11&author=X.+Heauthor=J.+Ricebergauthor=T.+Soucyauthor=E.+Koenigauthor=J.+Minissaleauthor=M.+Galleryauthor=H.+Bernardauthor=X.+Yangauthor=H.+Liaoauthor=C.+Rabinoauthor=P.+Shahauthor=K.+Xegaauthor=Z.+H.+Yanauthor=M.+Sintchakauthor=J.+Bradleyauthor=H.+Xuauthor=M.+Duffeyauthor=D.+Englandauthor=H.+Mizutaniauthor=Z.+Huauthor=J.+Guoauthor=R.+Chauauthor=L.+R.+Dickauthor=J.+E.+Brownellauthor=J.+Newcombauthor=S.+Langstonauthor=E.+S.+Lightcapauthor=N.+Benceauthor=S.+M.+Pulukuri&title=Probing+the+roles+of+SUMOylation+in+cancer+cell+biology+by+using+a+selective+SAE+inhibitor&doi=10.1038%2Fnchembio.2463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor</span></div><div class="casAuthors">He, Xingyue; Riceberg, Jessica; Soucy, Teresa; Koenig, Erik; Minissale, James; Gallery, Melissa; Bernard, Hugues; Yang, Xiaofeng; Liao, Hua; Rabino, Claudia; Shah, Pooja; Xega, Kristina; Yan, Zhong-hua; Sintchak, Mike; Bradley, John; Xu, He; Duffey, Matt; England, Dylan; Mizutani, Hirotake; Hu, Zhigen; Guo, Jianping; Chau, Ryan; Dick, Lawrence R.; Brownell, James E.; Newcomb, John; Langston, Steve; Lightcap, Eric S.; Bence, Neil; Pulukuri, Sai M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1164-1171</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Small ubiquitin-like modifier (SUMO) family proteins regulate target-protein functions by post-translational modification.  However, a potent and selective inhibitor targeting the SUMO pathway has been lacking.  Here we describe ML-792, a mechanism-based SUMO-activating enzyme (SAE) inhibitor with nanomolar potency in cellular assays.  ML-792 selectively blocks SAE enzyme activity and total SUMOylation, thus decreasing cancer cell proliferation.  Moreover, we found that induction of the MYC oncogene increased the ML-792-mediated viability effect in cancer cells, thus indicating a potential application of SAE inhibitors in treating MYC-amplified tumors.  Using ML-792, we further explored the crit. roles of SUMOylation in mitotic progression and chromosome segregation.  Furthermore, expression of an SAE catalytic-subunit (UBA2) S95N M97T mutant rescued SUMOylation loss and the mitotic defect induced by ML-792, thus confirming the selectivity of ML-792.  As a potent and selective SAE inhibitor, ML-792 provides rapid loss of endogenously SUMOylated proteins, thereby facilitating novel insights into SUMO biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNkvcAW2wXqLVg90H21EOLACvtfcHk0ljJmZd2Ba_SWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKltbfJ&md5=62ee63218ec5f40923370294780a0f7f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2463%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DRiceberg%26aufirst%3DJ.%26aulast%3DSoucy%26aufirst%3DT.%26aulast%3DKoenig%26aufirst%3DE.%26aulast%3DMinissale%26aufirst%3DJ.%26aulast%3DGallery%26aufirst%3DM.%26aulast%3DBernard%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiao%26aufirst%3DH.%26aulast%3DRabino%26aufirst%3DC.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DXega%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DZ.%2BH.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DBradley%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DDuffey%26aufirst%3DM.%26aulast%3DEngland%26aufirst%3DD.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DChau%26aufirst%3DR.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DLangston%26aufirst%3DS.%26aulast%3DLightcap%26aufirst%3DE.%2BS.%26aulast%3DBence%26aufirst%3DN.%26aulast%3DPulukuri%26aufirst%3DS.%2BM.%26atitle%3DProbing%2520the%2520roles%2520of%2520SUMOylation%2520in%2520cancer%2520cell%2520biology%2520by%2520using%2520a%2520selective%2520SAE%2520inhibitor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D11%26spage%3D1164%26epage%3D1171%26doi%3D10.1038%2Fnchembio.2463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkison, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of a human ubiquitin E1-ubiquitin complex reveals conserved functional elements essential for activity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">18337</span>– <span class="NLM_lpage">18352</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA118.003975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1074%2Fjbc.RA118.003975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=30279270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12ksrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=18337-18352&issue=47&author=Z.+Lvauthor=K.+M.+Williamsauthor=L.+Yuanauthor=J.+H.+Atkisonauthor=S.+K.+Olsen&title=Crystal+structure+of+a+human+ubiquitin+E1-ubiquitin+complex+reveals+conserved+functional+elements+essential+for+activity&doi=10.1074%2Fjbc.RA118.003975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a human ubiquitin E1-ubiquitin complex reveals conserved functional elements essential for activity</span></div><div class="casAuthors">Lv, Zongyang; Williams, Katelyn M.; Yuan, Lingmin; Atkison, James H.; Olsen, Shaun K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">18337-18352</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ubiquitin (Ub) signaling plays a key regulatory role in nearly every aspect of eukaryotic biol. and is initiated by E1 enzymes that activate and transfer Ub to E2 Ub-conjugating enzymes.  Despite Ub E1's fundamental importance to the cell and its attractiveness as a target for therapeutic intervention in cancer and other diseases, its only available structural information is derived from yeast orthologs of human ubiquitin-like modifier-activating enzyme 1 (hUBA1).  To illuminate structural differences between yeast and hUBA1 structures that might be exploited for the development of small-mol. therapeutics, we detd. the first crystal structure of a hUBA1-Ub complex.  Using structural anal., mol. modeling, and biochem. anal., we demonstrate that hUBA1 shares a conserved overall structure and mechanism with previously characterized yeast orthologs, but displays subtle structural differences, particularly within the active site.  Computational anal. revealed four potential ligand-binding hot spots on the surface of hUBA1 that might serve as targets to inhibit hUBA1 at the level of Ub activation or E2 recruitment or that might potentially be used in approaches such as protein-targeting chimeric mols.  Taken together, our work enhances our understanding of the hUBA1 mechanism, provides an improved framework for the development of small-mol. inhibitors of UBA1, and serves as a stepping stone for structural studies that involve the enzymes of the human Ub system at the level of both E1 and E2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRhwD_aDGQ4rVg90H21EOLACvtfcHk0lic4jCGw3HKMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12ksrzO&md5=760049e734451c2ed5b4aa1bbf8ce54c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.003975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.003975%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DZ.%26aulast%3DWilliams%26aufirst%3DK.%2BM.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DAtkison%26aufirst%3DJ.%2BH.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520a%2520human%2520ubiquitin%2520E1-ubiquitin%2520complex%2520reveals%2520conserved%2520functional%2520elements%2520essential%2520for%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26issue%3D47%26spage%3D18337%26epage%3D18352%26doi%3D10.1074%2Fjbc.RA118.003975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minissale, J.</span>; <span class="NLM_string-name">Burkhardt, A.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Minissale%2C+J.%3B+Burkhardt%2C+A.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DMinissale%26aufirst%3DJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shank, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doose, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streeter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialer, M.</span></span> <span> </span><span class="NLM_article-title">Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase</span>. <i>Epilepsy Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">2–3</span>),  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/j.eplepsyres.2005.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.eplepsyres.2005.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=15715969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtF2hsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2005&pages=103-112&issue=2%E2%80%933&author=R.+P.+Shankauthor=D.+R.+Dooseauthor=A.+J.+Streeterauthor=M.+Bialer&title=Plasma+and+whole+blood+pharmacokinetics+of+topiramate%3A+the+role+of+carbonic+anhydrase&doi=10.1016%2Fj.eplepsyres.2005.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase</span></div><div class="casAuthors">Shank, Richard P.; Doose, Dennis R.; Streeter, Anthony J.; Bialer, Meir</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">103-112</span>CODEN:
                <span class="NLM_cas:coden">EPIRE8</span>;
        ISSN:<span class="NLM_cas:issn">0920-1211</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Topiramate (TPM) is a broad-spectrum antiepileptic drug with various mechanisms of action including an inhibitory effect on some isoenzymes of carbonic anhydrase (CA).  Binding to CA-I and CA-II, which are highly concd. in erythrocytes, may affect drug pharmacokinetics.  Consequently, the objectives of this study were: (a) to comparatively assess TPM pharmacokinetics in healthy subjects, based on plasma and whole blood data, by simultaneously measuring TPM concns. in plasma and whole blood following different therapeutic doses; (b) to rigorously establish the affinity of TPM for CA-I and CA-II in order to gain insight into how binding to these isoenzymes in erythrocytes influences TPM pharmacokinetics.  TPM (100, 200 and 400 mg, single dose) was given in a randomized three-way crossover design to 27 healthy subjects and the drug concns. in plasma and whole blood were simultaneously measured for 168 h after dosing.  The pharmacokinetics of TPM in plasma was linear, but TPM clearance from whole blood increased with increasing dose.  At low therapeutic concns., the blood-to-plasma ratio for TPM decreased from 8 to 2 as its concn. increased, indicating a substantial and saturable binding of TPM to erythrocytes.  The kinetics (dissocn. binding const. -Kd and max. binding rate -Bmax) of the binding of TPM to erythrocytes was detd. from the measured concns. of TPM in whole blood and plasma.  This anal. indicated the existence of two binding sites with Kd values of 0.54 and 140 μM, and Bmax values of 22 and 124 μmol/L of erythrocyte vol., resp.  These Bmax values are similar to literature values for the molar concn. of human CA-II (14-25 μmol/L) and CA-I (115-125 μmol/L).  TPM inhibition const. (Ki) values for the inhibition of purified human CA obtained using assays based on CO2 hydration or 4-nitrophenylacetate hydrolysis were 0.62 and 0.49 μM for CA-II, and 91 and 93 μM for CA-I.  The results of these studies indicate that virtually all of the binding of TPM to erythrocytes is attributable to CA-I and CA-II.  Because CA-I and CA-II are highly concd. in erythrocytes, a large portion of TPM in whole blood is bound and serves as a depot.  This contributes to the lower oral clearance (CL/F), apparent vol. of distribution (Vss/F) and longer half-life (t 1/2) that TPM has in blood compared to the CL/F, Vss/F and t 1/2, estd. from plasma data.  The difference between TPM blood and plasma pharmacokinetics was more profound at low doses (≤100 mg/day).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEtCEepha3NLVg90H21EOLACvtfcHk0lic4jCGw3HKMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtF2hsrk%253D&md5=c0691a2ff9425f452f04539c1988038c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.eplepsyres.2005.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eplepsyres.2005.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DShank%26aufirst%3DR.%2BP.%26aulast%3DDoose%26aufirst%3DD.%2BR.%26aulast%3DStreeter%26aufirst%3DA.%2BJ.%26aulast%3DBialer%26aufirst%3DM.%26atitle%3DPlasma%2520and%2520whole%2520blood%2520pharmacokinetics%2520of%2520topiramate%253A%2520the%2520role%2520of%2520carbonic%2520anhydrase%26jtitle%3DEpilepsy%2520Res.%26date%3D2005%26volume%3D63%26issue%3D2%25E2%2580%25933%26spage%3D103%26epage%3D112%26doi%3D10.1016%2Fj.eplepsyres.2005.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winum, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scozzafava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supuran, C. T.</span></span> <span> </span><span class="NLM_article-title">Sulfamates and their therapeutic potential</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1002/med.20021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1002%2Fmed.20021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=15478125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlWhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=186-228&issue=2&author=J.+Y.+Winumauthor=A.+Scozzafavaauthor=J.+L.+Monteroauthor=C.+T.+Supuran&title=Sulfamates+and+their+therapeutic+potential&doi=10.1002%2Fmed.20021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfamates and their therapeutic potential</span></div><div class="casAuthors">Winum, Jean-Yves; Scozzafava, Andrea; Montero, Jean-Louis; Supuran, Claudiu T.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-228</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Starting from the very simple mol. sulfamic acid, O-substituted-, N-substituted-, or di-/tri-substituted sulfamates may be obtained, which show specific biol. activities which were or started to be exploited for the design of many types of therapeutic agents.  Among them, sulfamate inhibitors of aminoacyl-tRNA synthetases (aaRSs) were recently reported, constituting completely new classes of antibiotics, useful in the fight of drug-resistant infections.  Anti-viral agents incorporating sulfamate moieties have also been obtained, with at least two types of such derivs. investigated: the nucleoside/nucleotide human immunodeficiency virus (HIV) reverse transcriptase inhibitors, and the HIV protease inhibitors (PIs).  In the increasing armamentarium of anti-cancer drugs, the sulfamates occupy a special position, with at least two important targets evidenced so far: the steroid sulfatases (STSs) and the carbonic anhydrases (CAs).  An impressing no. of inhibitors of STSs of the sulfamate type have been reported in the last years, with several compds., such as 667 COUMATE among others, progressing to clin. trials for the treatment of hormone-dependent tumors (breast and prostate cancers).  This field is rapidly evolving, with many types of new inhibitors being constantly reported and designed in such a way as to increase their anti-tumor properties, and decrease undesired features (for example, estrogenicity, a problem encountered with the first generation such inhibitors, such as EMATE).  Among the many isoenzymes of CAs, at least two, CA IX and CA XII, are highly overexpressed in tumors, being generally absent in the normal tissues.  Inhibition of tumor-assocd. CAs was hypothesized to lead to novel therapeutic approaches for the treatment of cancer.  Many sulfamates act as very potent (low nanomolar) CA inhibitors.  The x-ray crystal structure of the best-studied isoenzyme, CA II, with three sulfamates (sulfamic acid, topiramate, and EMATE) has recently been reported, which allowed for a rationale drug design of new inhibitors.  Indeed, low nanomolar CA IX inhibitors of the sulfamate type have been reported, although such compds. also act as efficient inhibitors of isoenzymes CA I and II, which are not assocd. with tumors.  A large no. of anti-convulsant sulfamates have been described, with one such compd., topiramate, being widely used clin. as anti-epileptic drug.  By taking into consideration a side effect of topiramate, an anti-epileptic drug leading to wt. loss in some patients, it has recently been proposed to use this drug and related sulfamates for the treatment of obesity.  The rationale of this use is based on the inhibition of the mitochondrial CA isoenzyme, CA V, involved in lipogenesis.  Some sulfamates were also shown to possess potent inhibitory activity against acyl CoA:cholesterol acyltransferase, an enzyme involved in cholesterol metab.  One such agent, avasimibe, is in advanced clin. trials for the treatment of hyperlipidemia and atherosclerosis.  Thus, the sulfamate moiety offers very attractive possibilities for the drug design of various pharmacol. agents, which are on one hand due to the relative ease with which such compds. are synthesized, and on the other one, due to the fact that biol. activity of most of them is impressive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIqLDcmtZep7Vg90H21EOLACvtfcHk0lic4jCGw3HKMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlWhsL4%253D&md5=d9d2f31b7cdf47a11d204227813c0f2a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fmed.20021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20021%26sid%3Dliteratum%253Aachs%26aulast%3DWinum%26aufirst%3DJ.%2BY.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DMontero%26aufirst%3DJ.%2BL.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DSulfamates%2520and%2520their%2520therapeutic%2520potential%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2005%26volume%3D25%26issue%3D2%26spage%3D186%26epage%3D228%26doi%3D10.1002%2Fmed.20021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lightcap, Y. P.</span>; <span class="NLM_string-name">Grossman, S.</span>; <span class="NLM_string-name">Song, K.</span>; <span class="NLM_string-name">Khattar, M.</span>; <span class="NLM_string-name">Xega, K.</span>; <span class="NLM_string-name">He, X.</span>; <span class="NLM_string-name">Gavin, J. G.</span>; <span class="NLM_string-name">Imaichi, H.</span>; <span class="NLM_string-name">Garnsey, J. J.</span>; <span class="NLM_string-name">Koenig, E.</span>; <span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Lu, Z.</span>; <span class="NLM_string-name">Shah, P.</span>; <span class="NLM_string-name">Hatton, B. A.</span>; <span class="NLM_string-name">Riceberg, J.</span>; <span class="NLM_string-name">Shinde, V.</span>; <span class="NLM_string-name">Li, C.</span>; <span class="NLM_string-name">Minissale, J.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">England, D.</span>; <span class="NLM_string-name">Klinghoffer, R. A.</span>; <span class="NLM_string-name">Langston, S.</span>; <span class="NLM_string-name">Galvin, K.</span>; <span class="NLM_string-name">Shapiro, G.</span>; <span class="NLM_string-name">Pulukuri, S. M.</span>; <span class="NLM_string-name">Fuchs, S. Y.</span>; <span class="NLM_string-name">Huszar, D.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lightcap%2C+Y.+P.%3B+Grossman%2C+S.%3B+Song%2C+K.%3B+Khattar%2C+M.%3B+Xega%2C+K.%3B+He%2C+X.%3B+Gavin%2C+J.+G.%3B+Imaichi%2C+H.%3B+Garnsey%2C+J.+J.%3B+Koenig%2C+E.%3B+Zhang%2C+H.%3B+Lu%2C+Z.%3B+Shah%2C+P.%3B+Hatton%2C+B.+A.%3B+Riceberg%2C+J.%3B+Shinde%2C+V.%3B+Li%2C+C.%3B+Minissale%2C+J.%3B+Yang%2C+X.%3B+England%2C+D.%3B+Klinghoffer%2C+R.+A.%3B+Langston%2C+S.%3B+Galvin%2C+K.%3B+Shapiro%2C+G.%3B+Pulukuri%2C+S.+M.%3B+Fuchs%2C+S.+Y.%3B+Huszar%2C+D.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DLightcap%26aufirst%3DY.%2BP." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span> <i>TAK-981: A first-in-class SUMOylation inhibitor in phase 1 clinical trials promotes a Type I interferon response and antitumor immunity in preclinical models</i>, Session DDT01; <span class="NLM_publisher-name">American Association for Cancer Research</span>: <span class="NLM_publisher-loc">Atlanta, GA</span>, Mar 29–Apr 03, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Huszar&title=TAK-981%3A+A+first-in-class+SUMOylation+inhibitor+in+phase+1+clinical+trials+promotes+a+Type+I+interferon+response+and+antitumor+immunity+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHuszar%26aufirst%3DD.%26btitle%3DTAK-981%253A%2520A%2520first-in-class%2520SUMOylation%2520inhibitor%2520in%2520phase%25201%2520clinical%2520trials%2520promotes%2520a%2520Type%2520I%2520interferon%2520response%2520and%2520antitumor%2520immunity%2520in%2520preclinical%2520models%26pub%3DAmerican%2520Association%2520for%2520Cancer%2520Research%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldana-Masangkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colayco, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobkova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divlianska, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergienko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakih, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.chembiol.2018.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=30581133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2ksL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=278-288&issue=2&author=Y.+J.+Liauthor=L.+Duauthor=J.+Wangauthor=R.+Vegaauthor=T.+D.+Leeauthor=Y.+Miaoauthor=G.+Aldana-Masangkayauthor=E.+R.+Samuelsauthor=B.+Liauthor=S.+X.+Ouyangauthor=S.+A.+Colaycoauthor=E.+V.+Bobkovaauthor=D.+B.+Divlianskaauthor=E.+Sergienkoauthor=T.+D.+Y.+Chungauthor=M.+Fakihauthor=Y.+Chen&title=Allosteric+Inhibition+of+Ubiquitin-like+Modifications+by+a+Class+of+Inhibitor+of+SUMO-Activating+Enzyme&doi=10.1016%2Fj.chembiol.2018.10.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme</span></div><div class="casAuthors">Li, Yi-Jia; Du, Li; Wang, Jianghai; Vega, Ramir; Lee, Terry D.; Miao, Yunan; Aldana-Masangkay, Grace; Samuels, Eric R.; Li, Baozong; Ouyang, S. Xiaohu; Colayco, Sharon A.; Bobkova, Ekaterina V.; Divlianska, Daniela B.; Sergienko, Eduard; Chung, Thomas D. Y.; Fakih, Marwan; Chen, Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-288.e6</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ubiquitin-like (Ubl) post-translational modifications are potential targets for therapeutics.  However, the only known mechanism for inhibiting a Ubl-activating enzyme is through targeting its ATP-binding site.  Here we identify an allosteric inhibitory site in the small ubiquitin-like modifier (SUMO)-activating enzyme (E1).  This site was unexpected because both it and analogous sites are deeply buried in all previously solved structures of E1s of ubiquitin-like modifiers (Ubl).  The inhibitor not only suppresses SUMO E1 activity, but also enhances its degrdn. in vivo, presumably due to a conformational change induced by the compd.  In addn., the lead compd. increased the expression of miR-34b and reduced c-Myc levels in lymphoma and colorectal cancer cell lines and a colorectal cancer xenograft mouse model.  Identification of this first-in-class inhibitor of SUMO E1 is a major advance in modulating Ubl modifications for therapeutic aims.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiIbJhcJwpzrVg90H21EOLACvtfcHk0li_87csJmzSjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2ksL7N&md5=ec87586d0834746bfdd8521d7a11725a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DVega%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DAldana-Masangkay%26aufirst%3DG.%26aulast%3DSamuels%26aufirst%3DE.%2BR.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DS.%2BX.%26aulast%3DColayco%26aufirst%3DS.%2BA.%26aulast%3DBobkova%26aufirst%3DE.%2BV.%26aulast%3DDivlianska%26aufirst%3DD.%2BB.%26aulast%3DSergienko%26aufirst%3DE.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DFakih%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DAllosteric%2520Inhibition%2520of%2520Ubiquitin-like%2520Modifications%2520by%2520a%2520Class%2520of%2520Inhibitor%2520of%2520SUMO-Activating%2520Enzyme%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D2%26spage%3D278%26epage%3D288%26doi%3D10.1016%2Fj.chembiol.2018.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkison, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessions, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divlianska, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-07015-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fs41467-018-07015-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=29317637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVakur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-12&author=Z.+Lvauthor=L.+Yuanauthor=J.+H.+Atkisonauthor=K.+M.+Williamsauthor=R.+Vegaauthor=E.+H.+Sessionsauthor=D.+B.+Divlianskaauthor=C.+Daviesauthor=Y.+Chenauthor=S.+K.+Olsen&title=Molecular+mechanism+of+a+covalent+allosteric+inhibitor+of+SUMO+E1+activating+enzyme&doi=10.1038%2Fs41467-018-07015-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme</span></div><div class="casAuthors">Lv, Zongyang; Yuan, Lingmin; Atkison, James H.; Williams, Katelyn M.; Vega, Ramir; Sessions, E. Hampton; Divlianska, Daniela B.; Davies, Christopher; Chen, Yuan; Olsen, Shaun K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">E1 enzymes activate ubiquitin (Ub) and ubiquitin-like modifiers (Ubls) in the first step of Ub/Ubl conjugation cascades and represent potential targets for therapeutic intervention in cancer and other life-threatening diseases.  Here, we report the crystal structure of the E1 enzyme for the Ubl SUMO in complex with a recently discovered and highly specific covalent allosteric inhibitor (COH000).  The structure reveals that COH000 targets a cryptic pocket distinct from the active site that is completely buried in all previous SUMO E1 structures and that COH000 binding to SUMO E1 is accompanied by a network of structural changes that altogether lock the enzyme in a previously unobserved inactive conformation.  These structural changes include disassembly of the active site and a 180° rotation of the catalytic cysteine-contg. SCCH domain, relative to conformational snapshots of SUMO E1 poised to catalyze adenylation.  Altogether, our study provides a mol. basis for the inhibitory mechanism of COH000 and its SUMO E1 specificity, and also establishes a framework for potential development of mols. targeting E1 enzymes for other Ubls at a cryptic allosteric site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmPuzjKgi2DrVg90H21EOLACvtfcHk0li_87csJmzSjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVakur3O&md5=b86e1882ba6f772e9477a1fe3431f342</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-07015-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-07015-1%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DZ.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DAtkison%26aufirst%3DJ.%2BH.%26aulast%3DWilliams%26aufirst%3DK.%2BM.%26aulast%3DVega%26aufirst%3DR.%26aulast%3DSessions%26aufirst%3DE.%2BH.%26aulast%3DDivlianska%26aufirst%3DD.%2BB.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26atitle%3DMolecular%2520mechanism%2520of%2520a%2520covalent%2520allosteric%2520inhibitor%2520of%2520SUMO%2520E1%2520activating%2520enzyme%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fs41467-018-07015-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Stepan Vyskocil, David Cardin, Jeffrey Ciavarri, Joe Conlon, Courtney Cullis, Dylan England, Rachel Gershman, Kenneth Gigstad, Krista Gipson, Alexandra Gould, Paul Greenspan, Robert Griffin, Nanda Gulavita, Sean Harrison, Zhigen Hu, Yongbo Hu, Akito Hata, Jian Huang, Shih-Chung Huang, Dave Janowick, Matthew Jones, Vihren Kolev, Steven P. Langston, Hong Myung Lee, Gang Li, David Lok, Liting Ma, Doanh Mai, Jenna Malley, Atsushi Matsuda, Hirotake Mizutani, Miho Mizutani, Nina Molchanova, Elise Nunes, Sandeep Pusalkar, Christelle Renou, Scott Rowland, Yosuke Sato, Michael Shaw, Luhua Shen, Zhan Shi, Robert Skene, Francois Soucy, Steve Stroud, He Xu, Tianlin Xu, Adnan O. Abu-Yousif, <span class="NLM_string-name hlFld-ContribAuthor">Ji Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6902-6923. <a href="https://doi.org/10.1021/acs.jmedchem.1c00374" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00374%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BNovel%252BCarbocyclic%252BPyrimidine%252BCyclic%252BDinucleotide%252BSTING%252BAgonists%252Bfor%252BAntitumor%252BImmunotherapy%252BUsing%252BSystemic%252BIntravenous%252BRoute%26aulast%3DVyskocil%26aufirst%3DStepan%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01032021%26date%3D17052021%26volume%3D64%26issue%3D10%26spage%3D6902%26epage%3D6923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessie S.  Kroonen</span>, <span class="hlFld-ContribAuthor ">Alwine B.  Kruisselbrink</span>, <span class="hlFld-ContribAuthor ">Inge H.  Briaire-de Bruijn</span>, <span class="hlFld-ContribAuthor ">Olaejirinde O.  Olaofe</span>, <span class="hlFld-ContribAuthor ">Judith V. M. G.  Bovée</span>, <span class="hlFld-ContribAuthor ">Alfred C. O.  Vertegaal</span>. </span><span class="cited-content_cbyCitation_article-title">SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (15)
                                     , 3823. <a href="https://doi.org/10.3390/cancers13153823" title="DOI URL">https://doi.org/10.3390/cancers13153823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13153823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13153823%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DSUMOylation%252BIs%252BAssociated%252Bwith%252BAggressive%252BBehavior%252Bin%252BChondrosarcoma%252Bof%252BBone%26aulast%3DKroonen%26aufirst%3DJessie%2BS.%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D15%26spage%3D3823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiuying  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianhui  Rong</span>. </span><span class="cited-content_cbyCitation_article-title">SUMOylation as a Therapeutic Target for Myocardial Infarction. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cardiovascular Medicine</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.3389/fcvm.2021.701583" title="DOI URL">https://doi.org/10.3389/fcvm.2021.701583</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcvm.2021.701583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcvm.2021.701583%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cardiovascular%2520Medicine%26atitle%3DSUMOylation%252Bas%252Ba%252BTherapeutic%252BTarget%252Bfor%252BMyocardial%252BInfarction%26aulast%3DZhao%26aufirst%3DWei%26date%3D2021%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iman F.  Fergani</span>, <span class="hlFld-ContribAuthor ">Luciana R.  Frick</span>. </span><span class="cited-content_cbyCitation_article-title">Wrestling and Wrapping: A Perspective on SUMO Proteins in Schwann Cells. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2021,</strong> <em>11 </em>
                                    (7)
                                     , 1055. <a href="https://doi.org/10.3390/biom11071055" title="DOI URL">https://doi.org/10.3390/biom11071055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom11071055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom11071055%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DWrestling%252Band%252BWrapping%25253A%252BA%252BPerspective%252Bon%252BSUMO%252BProteins%252Bin%252BSchwann%252BCells%26aulast%3DFergani%26aufirst%3DIman%2BF.%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D7%26spage%3D1055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0030.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Enzymatic Cascade for the SUMOylation of Target Proteins and Mechanism of Inhibition of Adenosine Sulfamate Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. An early adenosine sulfamate and clinical compounds for NAE and UAE.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Western blot demonstrating cellular pathway inhibition by compounds <b>2</b> and <b>3</b>. Inhibition of SAE and NAE in cells was assessed by immunoblot analysis of SUMO2/3-conjugated proteins, SAE enzyme, and neddylated cullin levels in HCT-116 cell lysates. Multiple SUMO2/3 conjugate bands reflect the myriad proteins serving as substrates for SUMOylation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. The SUMO2/3 immunofluorescence assay. This assay measures the level of inhibition of the SAE by measuring the ratio of SUMO2/3 in the nuclear versus cytoplasmic cellular compartments. HCT-116 cells were seeded in 96-well plates and treated with compound <b>3</b> at the indicated concentrations for 4 h followed by staining with antihuman SUMO2/3 monoclonal antibody (MBL, clone 1E7). Imaging was performed on an IX-Ultra imager and analyzed for SUMO2/3 inner/outer ratio using MetaXpress Translocation-Enhanced module. Dose-dependent reduction of cytoplasmic SUMO2/3 positive staining reflects loss of SUMOylated proteins sequestered in this compartment under physiological conditions (DMSO). Right panel shows the dose response for compound <b>3</b> in HCT-116 cells as determined by the SUMO2/3 immunofluorescence assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmacodynamic effects of ML-792 in HCT-116 tumor bearing female NCr nude mice. Each data point represents the averaged value across <i>n</i> = 3 mice. Error bars = SEM. At <i>t</i> = 0, mice received a single SC injection of ML-792 at 150 mg/kg. Red line = percent nuclei staining positive for SUMO2/3 conjugation normalized to vehicle-treated animals. Blue line = percent nuclei staining positive for SUMO-ML-792 adduct.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor efficacy of ML-792 at multiple dose/schedule regimens in Ncr/nude mice bearing HCT-116 tumor-bearing mice. (a) ML-792 was dosed subcutaneously at the dose and schedule indicated for each arm (<i>n</i> = 10 female NCr nude mice/arm) until the final treatment day on day 21. Schedules: BID x21 = twice per day for 21 days (days 1–21); BID BIW = twice per day/twice per week (days 1, 4, 8, 11, 15, 18, 21); BID 2on-5off = twice per day/twice per week on 2 consecutive days followed by 5 nondosing days (days 1, 2, 8, 9, 15, 16, 21).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structure of SUMO1-compound <b>2</b> adduct within SAE ATP binding domain. Carbon is shown in cyan (<b>2</b>), green (SUMO), or gray (SAE); nitrogen, blue; oxygen, red; and sulfur, yellow. Secondary structure of SAE is shown in gray. Hydrogen bonds are indicated by dashed lines. PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOI">6XOI</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structure of SUMO1-compound <b>46</b> adduct bound to SAE. Carbon is shown in cyan for compound <b>46</b>, green (SUMO), or gray (SAE); nitrogen, blue; oxygen, red; bromide, dark red; and sulfur, yellow. Secondary structure of SAE is shown in gray. Hydrogen bonds are indicated by dashed lines. PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOG">6XOG</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Crystal structure of SAE with SUMO1-compound <b>49</b> adduct. Carbon is shown in cyan, <b>49</b>, green (SUMO), or gray (SAE); nitrogen, blue; oxygen, red; and sulfur, yellow. Secondary structure of SAE is shown in gray. Hydrogen bonds are indicated by dashed lines. PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOH">6XOH</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Reduction of SUMO2/3 conjugation in xenograft tumors following IV administration of SUMOylation inhibitors. Each data point represents the averaged value across <i>n</i> = 3 female Ncr nude mice. Error bars = SEM. Percent SUMO2/3 inhibition following compound administration represented as percent nuclei staining positive by IHC for SUMO2/3 conjugates/total nuclei normalized to vehicle-treated animals (time = 0 h). SUMOylation inhibitors were administered at time = 0. ML-792 was dosed at 150 mg/kg SC (dashed line/open square). ML-93 was dosed at 50 mg/kg IV (solid line/open circle). TAK-981 was dosed at 50 mg/kg IV (solid line/open triangle). (a) Reduction of SUMO2/3 conjugation at 2, 4, 8, and 16 h postinjection in HCT-116 tumors. (b) Reduction of SUMO2/3 conjugation at 2, 4, 8, 16, and 24 h postinjection in OCI-Ly10 tumors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Gain of SUMO–compound adduct in xenograft tumors following IV administration of SUMOylation inhibitors. Adduct formation in xenograft tumors following compound administration. Each data point represents the averaged value across <i>n</i> = 3 female Ncr nude mice. Error bars = SEM. (a) Single-dose ML-792 at 150 mg/kg IV (dashed line/open square), ML-93 at 50 mg/kg IV (solid line/open circle) or TAK-981 (solid line/open triangle) was administered to Ncr/nude mice bearing HCT116 tumors. Tumors were harvested 2, 4, 8, and 16 h post IV injection. Adduct/SAE ratio = quantity SUMO–compound adduct/quantity total SAE enzyme as measured by mass spectrometry. (b) Single-dose ML-792 at 150 mg/kg IV (dashed line/open square) or TAK-981 at 25 mg/kg IV (solid line/open triangle) was administered to CB17 SCID mice bearing OCI-Ly10 tumors. Tumors were harvested 2, 4, 8, 24, and 48 h post IV injection. Percent nuclei staining positive for adduct was measured by IHC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Plasma exposure following single-dose IV administration. Plasma collected at indicated time-point postinjection by cardiac blood collection followed by centrifugation. Each data point represents the averaged value across <i>n</i> = 3 female Ncr nude mice. Error bars = SEM. (a) Single-dose injection at <i>t</i> = 0 delivered to Ncr/nude mice bearing HCT-116 tumors with the indicated compounds and dosages or (b) single-dose injection at <i>t</i> = 0 delivered to CB17 SCID mice bearing OCI-Ly10 tumors with the indicated compounds and dosages. Plasma samples were collected at 0.5, 2, 4, 8, and 16 h postinjection via cardiac blood collection followed by centrifugation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Antitumor activity versus total weekly dosage in human xenograft cancer models. Line graphs = average tumor volumes over time. Error bars = SEM. Mice were randomized into groups on Day 0. Treatment started on Day 1. Tumor volume measurements were taken twice per week. Bar graphs = total weekly dose for each treatment arm. (a) Female Ncr/nude mice bearing HCT-116 tumors (∼200 mm<sup>3</sup> volume) were randomized into 5 groups (<i>n</i> = 8/group). Treatment started on Day 1. Tumor volumes were measured twice per week. Error bars represent SEM. (b) Total weekly dose administered to mice in each arm of the HCT-116 efficacy study (panel a) is calculated, demonstrating reduced compound required to achieve efficacy with TAK-981. (c) Female CB17 SCID mice bearing OCI-Ly10 tumors (∼200 mm<sup>3</sup> volume) were randomized into 5 groups (<i>n</i> = 8/group). Treatment started on Day 1. Tumor volumes were measured twice per week. Error bars represent SEM. (d) Total weekly dose administered to mice in each arm of the OCI-Ly10 efficacy study (panel c) is calculated, demonstrating reduced compound required to achieve efficacy with TAK-981. Dosing schedules: BID x21 = twice-per-day (Days 1–21); QD x2/week = twice per week (Days 1, 4, 8, 11, 15, 18); QD x21 = once-per-day (Days 1–21); QD x3/week = thrice-per-week (Days 1–21); QD x3/week = three consecutive dosing days followed by four nondosing days (Days 1, 2, 3, 8, 9, 10, 15, 16, 17).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrazolo Analogues Described in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes Employed for Pyrazolo-Substitution by Parallel Array</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Key Intermediates for Benzylic Alcohol and Benzylic Amines Described in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Key Intermediates for Alpha-Methyl Benzyl Amines</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Key Intermediates for Isochromane and Tetrahydroisoquinoline Compounds Described in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/medium/jm0c01491_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Crystal structure of TAK-981 solved by microelectron diffraction (microED) technique. Carbon is shown in gray; hydrogen, white; nitrogen, blue; oxygen, red; sulfur, yellow; chlorine, green. CCD accession code CCDC 2013738.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01491/20210409/images/large/jm0c01491_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01491&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 41 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geiss-Friedlander, R.</span></span> <span> </span><span class="NLM_article-title">Concepts in sumoylation: a decade on</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1038/nrm2293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnrm2293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=18000527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=947-956&issue=12&author=R.+Geiss-Friedlander&title=Concepts+in+sumoylation%3A+a+decade+on&doi=10.1038%2Fnrm2293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Concepts in sumoylation: a decade on</span></div><div class="casAuthors">Geiss-Friedlander, Ruth; Melchior, Frauke</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">947-956</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A decade has passed since SUMO (small ubiquitin-related modifier) was discovered to be a reversible post-translational protein modifier.  During this time many enzymes that participate in regulated SUMO conjugation and deconjugation pathways have been identified and characterized.  In parallel, the search for SUMO substrates has produced a long list of targets, which appear to be involved in most cellular functions.  Sumoylation is a highly dynamic process and its outcomes are extremely diverse, ranging from changes in localization to altered activity and, in some cases, stability of the modified protein.  At 1st glance, these effects have nothing in common; however, it seems that they all result from changes in the mol. interactions of the sumoylated proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXaaIwX1UoerVg90H21EOLACvtfcHk0lg1C_GmtxEvkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlCrsbrN&md5=aaab4fe48e4cff67e778648b5f416b1d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2293%26sid%3Dliteratum%253Aachs%26aulast%3DGeiss-Friedlander%26aufirst%3DR.%26atitle%3DConcepts%2520in%2520sumoylation%253A%2520a%2520decade%2520on%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26issue%3D12%26spage%3D947%26epage%3D956%26doi%3D10.1038%2Fnrm2293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. W.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1038/nrm2673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnrm2673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=19352404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFGrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=319-331&issue=5&author=B.+A.+Schulmanauthor=J.+W.+Harper&title=Ubiquitin-like+protein+activation+by+E1+enzymes%3A+the+apex+for+downstream+signalling+pathways&doi=10.1038%2Fnrm2673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signaling pathways</span></div><div class="casAuthors">Schulman, Brenda A.; Harper, J. Wade</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-331</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The attachment of ubiquitin or ubiquitin-like proteins (known as UBLs) to their targets through multienzyme cascades is a central mechanism in modulating protein functions.  This process is initiated by a family of mechanistically and structurally related E1 (or activating) enzymes.  These activate UBLs through C-terminal adenylylation and thiol transfer, and coordinate the use of UBLs in specific downstream pathways by charging cognate E2 (or conjugating) enzymes, which then interact with the downstream ubiquitination machinery to coordinate the modification of the target.  A broad understanding of how E1 enzymes activate UBLs and how they selectively coordinate UBLs with downstream function has come from enzymic, structural, and genetic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqRrsEHwtC8rVg90H21EOLACvtfcHk0lgRWwJHi38SGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFGrsL8%253D&md5=ac268f8312c97c2663ce89b54ea3d1ac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrm2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2673%26sid%3Dliteratum%253Aachs%26aulast%3DSchulman%26aufirst%3DB.%2BA.%26aulast%3DHarper%26aufirst%3DJ.%2BW.%26atitle%3DUbiquitin-like%2520protein%2520activation%2520by%2520E1%2520enzymes%253A%2520the%2520apex%2520for%2520downstream%2520signalling%2520pathways%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2009%26volume%3D10%26issue%3D5%26spage%3D319%26epage%3D331%26doi%3D10.1038%2Fnrm2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gareau, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. D.</span></span> <span> </span><span class="NLM_article-title">The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">871</span>, <span class="refDoi"> DOI: 10.1038/nrm3011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnrm3011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=21102611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGru7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=861-871&author=J.+R.+Gareauauthor=C.+D.+Lima&title=The+SUMO+pathway%3A+emerging+mechanisms+that+shape+specificity%2C+conjugation+and+recognition&doi=10.1038%2Fnrm3011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition</span></div><div class="casAuthors">Gareau, Jaclyn R.; Lima, Christopher D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">861-871</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Proteins of the small ubiquitin-related modifier (SUMO) family are conjugated to proteins to regulate such cellular processes as nuclear transport, transcription, chromosome segregation and DNA repair.  Recently, numerous insights into regulatory mechanisms of the SUMO modification pathway have emerged.  Although SUMO-conjugating enzymes can discriminate between SUMO targets, many substrates possess characteristics that facilitate their modification.  Other post-translational modifications also regulate SUMO conjugation, suggesting that SUMO signalling is integrated with other signal transduction pathways.  A better understanding of SUMO regulatory mechanisms will lead to improved approaches for analyzing the function of SUMO and substrate conjugation in distinct cellular pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN0COL6nhikLVg90H21EOLACvtfcHk0lgRWwJHi38SGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGru7zP&md5=48e56d75fa04204c8589a42746e21bf3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3011%26sid%3Dliteratum%253Aachs%26aulast%3DGareau%26aufirst%3DJ.%2BR.%26aulast%3DLima%26aufirst%3DC.%2BD.%26atitle%3DThe%2520SUMO%2520pathway%253A%2520emerging%2520mechanisms%2520that%2520shape%2520specificity%252C%2520conjugation%2520and%2520recognition%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D861%26epage%3D871%26doi%3D10.1038%2Fnrm3011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernier-Villamor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matunis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. D.</span></span> <span> </span><span class="NLM_article-title">Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00630-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2FS0092-8674%2802%2900630-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=11853669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVSksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2002&pages=345-356&issue=3&author=V.+Bernier-Villamorauthor=D.+A.+Sampsonauthor=M.+J.+Matunisauthor=C.+D.+Lima&title=Structural+basis+for+E2-mediated+SUMO+conjugation+revealed+by+a+complex+between+ubiquitin-conjugating+enzyme+Ubc9+and+RanGAP1&doi=10.1016%2FS0092-8674%2802%2900630-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1</span></div><div class="casAuthors">Bernier-Villamor, Victor; Sampson, Deborah A.; Matunis, Michael J.; Lima, Christopher D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-356</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">E2 enzymes catalyze attachment of ubiquitin and ubiquitin-like proteins to lysine residues directly or through E3-mediated reactions.  The small ubiquitin-like modifier SUMO regulates nuclear transport, stress response, and signal transduction in eukaryotes and is essential for cell-cycle progression in yeast.  In contrast to most ubiquitin conjugation, the SUMO E2 enzyme Ubc9 is sufficient for substrate recognition and lysine modification of known SUMO targets.  Crystallog. anal. of a complex between mammalian Ubc9 and a C-terminal domain of RanGAP1 at 2.5 Å reveals structural determinants for recognition of consensus SUMO modification sequences found within SUMO-conjugated proteins.  Structure-based mutagenesis and biochem. anal. of Ubc9 and RanGAP1 reveal distinct motifs required for substrate binding and SUMO modification of p53, IκBα, and RanGAP1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEE-4uiRTY97Vg90H21EOLACvtfcHk0lh9xR6BNeXnrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVSksbw%253D&md5=b774c5af1eff7415654ba378b1ceeee6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900630-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900630-X%26sid%3Dliteratum%253Aachs%26aulast%3DBernier-Villamor%26aufirst%3DV.%26aulast%3DSampson%26aufirst%3DD.%2BA.%26aulast%3DMatunis%26aufirst%3DM.%2BJ.%26aulast%3DLima%26aufirst%3DC.%2BD.%26atitle%3DStructural%2520basis%2520for%2520E2-mediated%2520SUMO%2520conjugation%2520revealed%2520by%2520a%2520complex%2520between%2520ubiquitin-conjugating%2520enzyme%2520Ubc9%2520and%2520RanGAP1%26jtitle%3DCell%26date%3D2002%26volume%3D108%26issue%3D3%26spage%3D345%26epage%3D356%26doi%3D10.1016%2FS0092-8674%2802%2900630-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. S.</span></span> <span> </span><span class="NLM_article-title">Protein modification by SUMO</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">382</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.074118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1146%2Fannurev.biochem.73.011303.074118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=15189146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslags7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=355-382&author=E.+S.+Johnson&title=Protein+modification+by+SUMO&doi=10.1146%2Fannurev.biochem.73.011303.074118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Protein modification by SUMO</span></div><div class="casAuthors">Johnson, Erica S.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">355-382</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Small ubiquitin-related modifier (SUMO) family proteins function by becoming covalently attached to other proteins as post-translational modifications.  SUMO modifies many proteins that participate in diverse cellular processes, including transcriptional regulation, nuclear transport, maintenance of genome integrity, and signal transduction.  Reversible attachment of SUMO is controlled by an enzyme pathway that is analogous to the ubiquitin pathway.  The functional consequences of SUMO attachment vary greatly from substrate to substrate, and in many cases are not understood at the mol. level.  Frequently SUMO alters interactions of substrates with other proteins or with DNA, but SUMO can also act by blocking ubiquitin attachment sites.  An unusual feature of SUMO modification is that, for most substrates, only a small fraction of the substrate is sumoylated at any given time.  This review discusses our current understanding of how SUMO conjugation is controlled, as well as the roles of SUMO in a no. of biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2cgvMqPC8f7Vg90H21EOLACvtfcHk0lh9xR6BNeXnrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslags7k%253D&md5=2a78d67692e278552125c4da373c0cc2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.074118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.074118%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DE.%2BS.%26atitle%3DProtein%2520modification%2520by%2520SUMO%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D355%26epage%3D382%26doi%3D10.1146%2Fannurev.biochem.73.011303.074118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hershko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciechanover, A.</span></span> <span> </span><span class="NLM_article-title">The ubiquitin system</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.67.1.425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1146%2Fannurev.biochem.67.1.425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=9759494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADyaK1cXlsFOmsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1998&pages=425-479&author=A.+Hershkoauthor=A.+Ciechanover&title=The+ubiquitin+system&doi=10.1146%2Fannurev.biochem.67.1.425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The ubiquitin system</span></div><div class="casAuthors">Hershko, Avram; Ciechanover, Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">425-479</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with ∼298 refs.  The selective degrdn. of many short-lived proteins in eukaryotic cells is carried out by the ubiquitin system.  In this pathway, proteins are targeted for degrdn. by covalent ligation to ubiquitin, a highly conserved small protein.  Ubiquitin-mediated degrdn. of regulatory proteins plays important roles in the control of numerous processes, including cell-cycle progression, signal transduction, transcriptional regulation, receptor down-regulation, and endocytosis.  The ubiquitin system has been implicated in the immune response, development, and programmed cell death.  Abnormalities in ubiquitin-mediated processes have been shown to cause pathol. conditions, including malignant transformation.  In this review we discuss recent information on functions and mechanisms of the ubiquitin system.  Since the selectivity of protein degrdn. is detd. mainly at the stage of ligation to ubiquitin, special attention is focused on what we know, and would like to know, about the mode of action of ubiquitin-protein ligation systems and about signals in proteins recognized by these systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqo5VhDx0kSLVg90H21EOLACvtfcHk0lh9xR6BNeXnrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlsFOmsLc%253D&md5=7c3c0a6df9c07baf55b5000eae13ef49</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.67.1.425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.67.1.425%26sid%3Dliteratum%253Aachs%26aulast%3DHershko%26aufirst%3DA.%26aulast%3DCiechanover%26aufirst%3DA.%26atitle%3DThe%2520ubiquitin%2520system%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1998%26volume%3D67%26spage%3D425%26epage%3D479%26doi%3D10.1146%2Fannurev.biochem.67.1.425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, E. T.</span></span> <span> </span><span class="NLM_article-title">Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">12036</span>– <span class="NLM_lpage">12042</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.17.12036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1074%2Fjbc.274.17.12036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10207026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADyaK1MXislGltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=12036-12042&issue=17&author=L.+Gongauthor=E.+T.+Yeh&title=Identification+of+the+activating+and+conjugating+enzymes+of+the+NEDD8+conjugation+pathway&doi=10.1074%2Fjbc.274.17.12036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway</span></div><div class="casAuthors">Gong, Limin; Yeh, Edward T. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">12036-12042</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">NEDD8 is a ubiquitin-like mol. that can be covalently conjugated to a limited no. of cellular proteins, such as Cdc53/cullin.  We have previously reported that the C terminus of NEDD8 is efficiently processed to expose Gly-76, which is required for conjugation to target proteins.  A combination of data base searches and polymerase chain reaction cloning was used to identify a cDNA encoding human UBA3, which is 38% identical to the yeast homolog, 22% identical to human UBA2, and 19% identical to the C-terminal region of human UBE1.  The human UBA3 gene is located on chromosome 3p13 and gave rise to a 2.2-kilobase pair transcript that was detected in all tissues.  Human UBA3 could be pptd. with glutathione S-transferase (GST)-NEDD8, but not with GST-ubiquitin or GST-sentrin-1.  Moreover, human UBA3 could form a β-mercaptoethanol-sensitive conjugate with NEDD8 in the presence of APP-BP1, a protein with sequence homol. to the N-terminal half of ubiquitin-activating enzyme.  We have also cloned human UBC12 and demonstrated that it could form a thiol ester linkage with NEDD8 in the presence of the activating enzyme complex.  Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway should allow for a more detailed study of the role of NEDD8 modification in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvNB8GF3Q9j7Vg90H21EOLACvtfcHk0licHiQePdd6_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXislGltrg%253D&md5=2fa85c6110831986455948a921c79bc7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.17.12036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.17.12036%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DL.%26aulast%3DYeh%26aufirst%3DE.%2BT.%26atitle%3DIdentification%2520of%2520the%2520activating%2520and%2520conjugating%2520enzymes%2520of%2520the%2520NEDD8%2520conjugation%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26issue%3D17%26spage%3D12036%26epage%3D12042%26doi%3D10.1074%2Fjbc.274.17.12036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergink, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jentsch, S.</span></span> <span> </span><span class="NLM_article-title">Principles of ubiquitin and SUMO modifications in DNA repair</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>458</i></span> (<span class="NLM_issue">7237</span>),  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1038/nature07963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnature07963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=19325626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1KltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=461-467&issue=7237&author=S.+Berginkauthor=S.+Jentsch&title=Principles+of+ubiquitin+and+SUMO+modifications+in+DNA+repair&doi=10.1038%2Fnature07963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of ubiquitin and SUMO modifications in DNA repair</span></div><div class="casAuthors">Bergink, Steven; Jentsch, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">7237</span>),
    <span class="NLM_cas:pages">461-467</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  With the discovery in the late 1980s that the DNA-repair gene RAD6 encodes a ubiquitin-conjugating enzyme, it became clear that protein modification by ubiquitin conjugation has a much broader significance than had previously been assumed.  Now, two decades later, ubiquitin and its cousin SUMO are implicated in a range of human diseases, including breast cancer and Fanconi anemia, giving fresh momentum to studies focused on the relationships between ubiquitin, SUMO and DNA-repair pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt4pGq8VIfgrVg90H21EOLACvtfcHk0licHiQePdd6_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1KltLY%253D&md5=22fdbf1b69d65a9b7a846816654e976e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature07963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07963%26sid%3Dliteratum%253Aachs%26aulast%3DBergink%26aufirst%3DS.%26aulast%3DJentsch%26aufirst%3DS.%26atitle%3DPrinciples%2520of%2520ubiquitin%2520and%2520SUMO%2520modifications%2520in%2520DNA%2520repair%26jtitle%3DNature%26date%3D2009%26volume%3D458%26issue%3D7237%26spage%3D461%26epage%3D467%26doi%3D10.1038%2Fnature07963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F. X.</span></span> <span> </span><span class="NLM_article-title">Ubc9 expression predicts chemoresistance in breast cancer</span>. <i>Aizheng</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.5732/cjc.011.10084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.5732%2Fcjc.011.10084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=21880185" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=638-644&issue=9&author=S.+F.+Chenauthor=C.+Gongauthor=M.+Luoauthor=H.+R.+Yaoauthor=Y.+J.+Zengauthor=F.+X.+Su&title=Ubc9+expression+predicts+chemoresistance+in+breast+cancer&doi=10.5732%2Fcjc.011.10084"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.5732%2Fcjc.011.10084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5732%252Fcjc.011.10084%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DGong%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DH.%2BR.%26aulast%3DZeng%26aufirst%3DY.%2BJ.%26aulast%3DSu%26aufirst%3DF.%2BX.%26atitle%3DUbc9%2520expression%2520predicts%2520chemoresistance%2520in%2520breast%2520cancer%26jtitle%3DAizheng%26date%3D2011%26volume%3D30%26issue%3D9%26spage%3D638%26epage%3D644%26doi%3D10.5732%2Fcjc.011.10084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seeler, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejean, A.</span></span> <span> </span><span class="NLM_article-title">SUMO and the robustness of cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnrc.2016.143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=28134258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVaru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=184-197&issue=3&author=J.+S.+Seelerauthor=A.+Dejean&title=SUMO+and+the+robustness+of+cancer&doi=10.1038%2Fnrc.2016.143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">SUMO and the robustness of cancer</span></div><div class="casAuthors">Seeler, Jacob-Sebastian; Dejean, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-197</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Post-translational protein modification by small ubiquitin-like modifier (SUMO), termed sumoylation, is an important mechanism in cellular responses to stress and one that appears to be upregulated in many cancers.  Here, we examine the role of sumoylation in tumorigenesis as a possibly necessary safeguard that protects the stability and functionality of otherwise easily misregulated gene expression programs and signalling pathways of cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquyShx1EBV0LVg90H21EOLACvtfcHk0licHiQePdd6_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVaru78%253D&md5=1dbd9cf2e98fa41ee2319bd8056d9dc8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.143%26sid%3Dliteratum%253Aachs%26aulast%3DSeeler%26aufirst%3DJ.%2BS.%26aulast%3DDejean%26aufirst%3DA.%26atitle%3DSUMO%2520and%2520the%2520robustness%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26issue%3D3%26spage%3D184%26epage%3D197%26doi%3D10.1038%2Fnrc.2016.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahle, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerbrey, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlabach, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez-Vidana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solimini, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilsenbeck, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, T. F.</span></span> <span> </span><span class="NLM_article-title">A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>335</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1126/science.1212728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1126%2Fscience.1212728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=22157079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC38XntlGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2012&pages=348-353&author=J.+D.+Kesslerauthor=K.+T.+Kahleauthor=T.+Sunauthor=K.+L.+Meerbreyauthor=M.+R.+Schlabachauthor=E.+M.+Schmittauthor=S.+O.+Skinnerauthor=Q.+Xuauthor=M.+Z.+Liauthor=Z.+C.+Hartmanauthor=M.+Raoauthor=P.+Yuauthor=R.+Dominguez-Vidanaauthor=A.+C.+Liangauthor=N.+L.+Soliminiauthor=R.+J.+Bernardiauthor=B.+Yuauthor=T.+Hsuauthor=I.+Goldingauthor=J.+Luoauthor=C.+K.+Osborneauthor=C.+J.+Creightonauthor=S.+G.+Hilsenbeckauthor=R.+Schiffauthor=C.+A.+Shawauthor=S.+J.+Elledgeauthor=T.+F.+Westbrook&title=A+SUMOylation-dependent+transcriptional+subprogram+is+required+for+Myc-driven+tumorigenesis&doi=10.1126%2Fscience.1212728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis</span></div><div class="casAuthors">Kessler, Jessica D.; Kahle, Kristopher T.; Sun, Tingting; Meerbrey, Kristen L.; Schlabach, Michael R.; Schmitt, Earlene M.; Skinner, Samuel O.; Xu, Qikai; Li, Mamie Z.; Hartman, Zachary C.; Rao, Mitchell; Yu, Peng; Dominguez-Vidana, Rocio; Liang, Anthony C.; Solimini, Nicole L.; Bernardi, Ronald J.; Yu, Bing; Hsu, Tiffany; Golding, Ido; Luo, Ji; Osborne, C. Kent; Creighton, Chad J.; Hilsenbeck, Susan G.; Schiff, Rachel; Shaw, Chad A.; Elledge, Stephen J.; Westbrook, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">6066</span>),
    <span class="NLM_cas:pages">348-353</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Myc is an oncogenic transcription factor frequently dysregulated in human cancer.  To identify pathways supporting the Myc oncogenic program, we used a genome-wide RNA interference screen to search for Myc-synthetic lethal genes and uncovered a role for the SUMO-activating enzyme (SAE1/2).  Loss of SAE1/2 enzymic activity drives synthetic lethality with Myc.  Inactivation of SAE2 leads to mitotic catastrophe and cell death upon Myc hyperactivation.  Mechanistically, SAE2 inhibition switches a transcriptional subprogram of Myc from activated to repressed.  A subset of these SUMOylation-dependent Myc switchers (SMS genes) is required for mitotic spindle function and to support the Myc oncogenic program.  SAE2 is required for growth of Myc-dependent tumors in mice, and gene expression analyses of Myc-high human breast cancers suggest that low SAE1 and SAE2 abundance in the tumors correlates with longer metastasis-free survival of the patients.  Thus, inhibition of SUMOylation may merit investigation as a possible therapy for Myc-driven human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTfA0iuQ_f_7Vg90H21EOLACvtfcHk0lh3jmeFEqG1Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntlGhtg%253D%253D&md5=b25fdbcaae0d4c96d01876ed3d00bb65</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.1212728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1212728%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DJ.%2BD.%26aulast%3DKahle%26aufirst%3DK.%2BT.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DMeerbrey%26aufirst%3DK.%2BL.%26aulast%3DSchlabach%26aufirst%3DM.%2BR.%26aulast%3DSchmitt%26aufirst%3DE.%2BM.%26aulast%3DSkinner%26aufirst%3DS.%2BO.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DM.%2BZ.%26aulast%3DHartman%26aufirst%3DZ.%2BC.%26aulast%3DRao%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DDominguez-Vidana%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DA.%2BC.%26aulast%3DSolimini%26aufirst%3DN.%2BL.%26aulast%3DBernardi%26aufirst%3DR.%2BJ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DHsu%26aufirst%3DT.%26aulast%3DGolding%26aufirst%3DI.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DHilsenbeck%26aufirst%3DS.%2BG.%26aulast%3DSchiff%26aufirst%3DR.%26aulast%3DShaw%26aufirst%3DC.%2BA.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26aulast%3DWestbrook%26aufirst%3DT.%2BF.%26atitle%3DA%2520SUMOylation-dependent%2520transcriptional%2520subprogram%2520is%2520required%2520for%2520Myc-driven%2520tumorigenesis%26jtitle%3DScience%26date%3D2012%26volume%3D335%26spage%3D348%26epage%3D353%26doi%3D10.1126%2Fscience.1212728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riceberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulukuri, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N.</span></span> <span> </span><span class="NLM_article-title">Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e0123882</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0123882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1371%2Fjournal.pone.0123882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=25860128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVylsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&issue=4&author=X.+Heauthor=J.+Ricebergauthor=S.+M.+Pulukuriauthor=S.+Grossmanauthor=V.+Shindeauthor=P.+Shahauthor=J.+E.+Brownellauthor=L.+Dickauthor=J.+Newcombauthor=N.+Bence&title=Characterization+of+the+loss+of+SUMO+pathway+function+on+cancer+cells+and+tumor+proliferation&doi=10.1371%2Fjournal.pone.0123882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the loss of sumo pathway function on cancer cells and tumor proliferation</span></div><div class="casAuthors">He, Xingyue; Riceberg, Jessica; Pulukuri, Sai M.; Grossman, Steve; Shinde, Vaishali; Shah, Pooja; Brownell, James E.; Dick, Larry; Newcomb, John; Bence, Neil</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0123882/1-e0123882/19</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">SUMOylation is a post-translational ubiquitin-like protein modification pathway that regulates important cellular processes including chromosome structure, kinetochore function, chromosome segregation, nuclear and sub-nuclear organization, transcription and DNA damage repair.  There is increasing evidence that the SUMO pathway is dysregulated in cancer, raising the possibility that modulation of this pathway may have therapeutic potential.  To investigate the importance of the SUMO pathway in the context of cancer cell proliferation and tumor growth, we applied lentivirus-based short hairpin RNAs (shRNA) to knockdown SUMO pathway genes in human cancer cells. shRNAs for SAE2 and UBC9 reduced SUMO conjugation activity and inhibited proliferation of human cancer cells.  To expand upon these observations, we generated doxycycline inducible conditional shRNA cell lines for SAE2 to achieve acute and reversible SAE2 knockdown.  Conditional SAE2 knockdown in U2OS and HCT116 cells slowed cell growth in vitro, and SAE2 knockdown induced multiple terminal outcomes including apoptosis, endoreduplication and senescence.  Multinucleated cells became senescent and stained pos. for the senescence marker, SA-β Gal, and displayed elevated levels of p53 and p21.  In an attempt to explain these phenotypes, we confirmed that loss of SUMO pathway activity leads to a loss of SUMOylated Topoisomerase IIα and the appearance of chromatin bridges which can impair proper cytokinesis and lead to multinucleation.  Furthermore, knockdown of SAE2 induces disruption of PML nuclear bodies which may further promote apoptosis or senescence.  In an in vivo HCT116 xenograft tumor model, conditional SAE2 knockdown strongly impaired tumor growth.  These data demonstrate that the SUMO pathway is required for cancer cell proliferation in vitro and tumor growth in vivo, implicating the SUMO pathway as a potential cancer therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7KVD_INIZILVg90H21EOLACvtfcHk0lh3jmeFEqG1Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVylsbvL&md5=1e7ac33d55c7df5cb1412df49c3e9338</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0123882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0123882%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DRiceberg%26aufirst%3DJ.%26aulast%3DPulukuri%26aufirst%3DS.%2BM.%26aulast%3DGrossman%26aufirst%3DS.%26aulast%3DShinde%26aufirst%3DV.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DDick%26aufirst%3DL.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DBence%26aufirst%3DN.%26atitle%3DCharacterization%2520of%2520the%2520loss%2520of%2520SUMO%2520pathway%2520function%2520on%2520cancer%2520cells%2520and%2520tumor%2520proliferation%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D4%26doi%3D10.1371%2Fjournal.pone.0123882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1186/s13045-015-0164-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1186%2Fs13045-015-0164-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=25622682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=1-10&author=X.+Liuauthor=Y.+Xuauthor=Z.+Pangauthor=F.+Guoauthor=Q.+Qinauthor=T.+Yinauthor=Y.+Sangauthor=C.+Fengauthor=X.+Liauthor=L.+Jiangauthor=P.+Shuauthor=Y.+Wang&title=Knockdown+of+SUMO-activating+enzyme+subunit+2+%28SAE2%29+suppresses+cancer+malignancy+and+enhances+chemotherapy+sensitivity+in+small+cell+lung+cancer&doi=10.1186%2Fs13045-015-0164-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy</span></div><div class="casAuthors">Wu, Jingjing; Fu, Jiaping; Zhang, Mingzhi; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-4</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Monoclonal antibodies against CD20 mol. have been leading the revolution of lymphoma treatment.  In addn. to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clin. development are being developed and are rapidly migrating to clin. application.  One area of active development is NK cell activators, such as AFM13.  This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDJHDzKZXTOrVg90H21EOLACvtfcHk0lisyMQf_s793Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFymtQ%253D%253D&md5=fd933124d358677979fc145146116b2c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1186%2Fs13045-015-0164-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-015-0164-y%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPang%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DSang%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DShu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DKnockdown%2520of%2520SUMO-activating%2520enzyme%2520subunit%25202%2520%2528SAE2%2529%2520suppresses%2520cancer%2520malignancy%2520and%2520enhances%2520chemotherapy%2520sensitivity%2520in%2520small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2015%26volume%3D8%26spage%3D1%26epage%3D10%26doi%3D10.1186%2Fs13045-015-0164-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biederstadt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneeweis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckenhuber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schunck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenhof, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orben, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, U.</span></span> <span> </span><span class="NLM_article-title">SUMO pathway inhibition targets an aggressive pancreatic cancer subtype</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1472</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2018-317856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1136%2Fgutjnl-2018-317856" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=1472-1482&author=A.+Biederstadtauthor=Z.+Hassanauthor=C.+Schneeweisauthor=M.+Schickauthor=L.+Schneiderauthor=A.+Muckenhuberauthor=Y.+Hongauthor=G.+Siegersauthor=L.+Nilssonauthor=M.+Wirthauthor=Z.+Dantesauthor=K.+Steigerauthor=K.+Schunckauthor=S.+Langstonauthor=H.+P.+Lenhofauthor=A.+Coluccioauthor=F.+Orbenauthor=J.+Slawskaauthor=A.+Schergerauthor=D.+Saurauthor=S.+Mullerauthor=R.+Radauthor=W.+Weichertauthor=J.+Nilssonauthor=M.+Reichertauthor=G.+Schneiderauthor=U.+Keller&title=SUMO+pathway+inhibition+targets+an+aggressive+pancreatic+cancer+subtype&doi=10.1136%2Fgutjnl-2018-317856"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2018-317856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2018-317856%26sid%3Dliteratum%253Aachs%26aulast%3DBiederstadt%26aufirst%3DA.%26aulast%3DHassan%26aufirst%3DZ.%26aulast%3DSchneeweis%26aufirst%3DC.%26aulast%3DSchick%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DL.%26aulast%3DMuckenhuber%26aufirst%3DA.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DSiegers%26aufirst%3DG.%26aulast%3DNilsson%26aufirst%3DL.%26aulast%3DWirth%26aufirst%3DM.%26aulast%3DDantes%26aufirst%3DZ.%26aulast%3DSteiger%26aufirst%3DK.%26aulast%3DSchunck%26aufirst%3DK.%26aulast%3DLangston%26aufirst%3DS.%26aulast%3DLenhof%26aufirst%3DH.%2BP.%26aulast%3DColuccio%26aufirst%3DA.%26aulast%3DOrben%26aufirst%3DF.%26aulast%3DSlawska%26aufirst%3DJ.%26aulast%3DScherger%26aufirst%3DA.%26aulast%3DSaur%26aufirst%3DD.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DRad%26aufirst%3DR.%26aulast%3DWeichert%26aufirst%3DW.%26aulast%3DNilsson%26aufirst%3DJ.%26aulast%3DReichert%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DKeller%26aufirst%3DU.%26atitle%3DSUMO%2520pathway%2520inhibition%2520targets%2520an%2520aggressive%2520pancreatic%2520cancer%2520subtype%26jtitle%3DGut%26date%3D2020%26volume%3D8%26spage%3D1472%26epage%3D1482%26doi%3D10.1136%2Fgutjnl-2018-317856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adorisio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fierabracci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muscari, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liberati, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayroldi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuy, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delfino, D. V.</span></span> <span> </span><span class="NLM_article-title">SUMO proteins: Guardians of immune system</span>. <i>J. Autoimmun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1016/j.jaut.2017.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.jaut.2017.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=28919255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWitrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2017&pages=21-28&author=S.+Adorisioauthor=A.+Fierabracciauthor=I.+Muscariauthor=A.+M.+Liberatiauthor=E.+Ayroldiauthor=G.+Miglioratiauthor=T.+T.+Thuyauthor=C.+Riccardiauthor=D.+V.+Delfino&title=SUMO+proteins%3A+Guardians+of+immune+system&doi=10.1016%2Fj.jaut.2017.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">SUMO proteins: Guardians of immune system</span></div><div class="casAuthors">Adorisio, Sabrina; Fierabracci, Alessandra; Muscari, Isabella; Liberati, Anna Marina; Ayroldi, Emira; Migliorati, Graziella; Thuy, Trinh Thi; Riccardi, Carlo; Delfino, Domenico V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Autoimmunity</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-28</span>CODEN:
                <span class="NLM_cas:coden">JOAUEP</span>;
        ISSN:<span class="NLM_cas:issn">0896-8411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Small ubiquitin-like modifier (SUMO) proteins belong to the ubiquitin-like family and act to change the function of target proteins through post-translational modifications.  Through their interactions with innate immune pathways, SUMOs promote an efficient immune response to pathogenic challenge avoiding, at the same time, an excess of immune response that could lead to the development of autoimmune diseases.  This report discusses the general functions of SUMO proteins; highlights SUMO involvement in the innate immune response through their role in NF-κB and interferon pathways; the involvement of SUMO proteins in autoimmune diseases; and reviews bacterial, viral, and parasitic interactions with SUMO pathways.  In conclusion, we speculate that targeting SUMOs could represent a new therapeutic strategy against infections and autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdivj0kCCqJLVg90H21EOLACvtfcHk0lgkCfnMgO9UUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWitrnJ&md5=29a6a2431f7aac67f1659e09cde2547c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jaut.2017.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaut.2017.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DAdorisio%26aufirst%3DS.%26aulast%3DFierabracci%26aufirst%3DA.%26aulast%3DMuscari%26aufirst%3DI.%26aulast%3DLiberati%26aufirst%3DA.%2BM.%26aulast%3DAyroldi%26aufirst%3DE.%26aulast%3DMigliorati%26aufirst%3DG.%26aulast%3DThuy%26aufirst%3DT.%2BT.%26aulast%3DRiccardi%26aufirst%3DC.%26aulast%3DDelfino%26aufirst%3DD.%2BV.%26atitle%3DSUMO%2520proteins%253A%2520Guardians%2520of%2520immune%2520system%26jtitle%3DJ.%2520Autoimmun.%26date%3D2017%26volume%3D84%26spage%3D21%26epage%3D28%26doi%3D10.1016%2Fj.jaut.2017.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Decque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joffre, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magalhaes, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossec, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blecher-Gonen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapaquette, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joubert, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeler, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amit, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amigorena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejean, A.</span></span> <span> </span><span class="NLM_article-title">Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1038/ni.3342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fni.3342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=26657003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSgtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=140-149&issue=2&author=A.+Decqueauthor=O.+Joffreauthor=J.+G.+Magalhaesauthor=J.+C.+Cossecauthor=R.+Blecher-Gonenauthor=P.+Lapaquetteauthor=A.+Silvinauthor=N.+Manelauthor=P.+E.+Joubertauthor=J.+S.+Seelerauthor=M.+L.+Albertauthor=I.+Amitauthor=S.+Amigorenaauthor=A.+Dejean&title=Sumoylation+coordinates+the+repression+of+inflammatory+and+anti-viral+gene-expression+programs+during+innate+sensing&doi=10.1038%2Fni.3342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing</span></div><div class="casAuthors">Decque, Adrien; Joffre, Olivier; Magalhaes, Joao G.; Cossec, Jack-Christophe; Blecher-Gonen, Ronnie; Lapaquette, Pierre; Silvin, Aymeric; Manel, Nicolas; Joubert, Pierre-Emmanuel; Seeler, Jacob-Sebastian; Albert, Matthew L.; Amit, Ido; Amigorena, Sebastian; Dejean, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-149</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Innate sensing of pathogens initiates inflammatory cytokine responses that need to be tightly controlled.  We found here that after engagement of Toll-like receptors (TLRs) in myeloid cells, deficient sumoylation caused increased secretion of transcription factor NF-κB-dependent inflammatory cytokines and a massive type I interferon signature.  In mice, diminished sumoylation conferred susceptibility to endotoxin shock and resistance to viral infection.  Overprodn. of several NF-κB-dependent inflammatory cytokines required expression of the type I interferon receptor, which identified type I interferon as a central sumoylation-controlled hub for inflammation.  Mechanistically, the small ubiquitin-like modifier SUMO operated from a distal enhancer of the gene encoding interferon-β (Ifnb1) to silence both basal and stimulus-induced activity of the Ifnb1 promoter.  Therefore, sumoylation restrained inflammation by silencing Ifnb1 expression and by strictly suppressing an unanticipated priming by type I interferons of the TLR-induced prodn. of inflammatory cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnGzeVo1dSU7Vg90H21EOLACvtfcHk0lgkCfnMgO9UUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSgtrfF&md5=d2f6be017daac62c3eeb57d167a13b8a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fni.3342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3342%26sid%3Dliteratum%253Aachs%26aulast%3DDecque%26aufirst%3DA.%26aulast%3DJoffre%26aufirst%3DO.%26aulast%3DMagalhaes%26aufirst%3DJ.%2BG.%26aulast%3DCossec%26aufirst%3DJ.%2BC.%26aulast%3DBlecher-Gonen%26aufirst%3DR.%26aulast%3DLapaquette%26aufirst%3DP.%26aulast%3DSilvin%26aufirst%3DA.%26aulast%3DManel%26aufirst%3DN.%26aulast%3DJoubert%26aufirst%3DP.%2BE.%26aulast%3DSeeler%26aufirst%3DJ.%2BS.%26aulast%3DAlbert%26aufirst%3DM.%2BL.%26aulast%3DAmit%26aufirst%3DI.%26aulast%3DAmigorena%26aufirst%3DS.%26aulast%3DDejean%26aufirst%3DA.%26atitle%3DSumoylation%2520coordinates%2520the%2520repression%2520of%2520inflammatory%2520and%2520anti-viral%2520gene-expression%2520programs%2520during%2520innate%2520sensing%26jtitle%3DNat.%2520Immunol.%26date%3D2016%26volume%3D17%26issue%3D2%26spage%3D140%26epage%3D149%26doi%3D10.1038%2Fni.3342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowl, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D. B.</span></span> <span> </span><span class="NLM_article-title">SUMO2 and SUMO3 redundantly prevent a noncanonical type I interferon response</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">6798</span>– <span class="NLM_lpage">6803</span>, <span class="refDoi"> DOI: 10.1073/pnas.1802114115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1073%2Fpnas.1802114115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=29891701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbmt1Crsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=6798-6803&issue=26&author=J.+T.+Crowlauthor=D.+B.+Stetson&title=SUMO2+and+SUMO3+redundantly+prevent+a+noncanonical+type+I+interferon+response&doi=10.1073%2Fpnas.1802114115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">SUMO2 and SUMO3 redundantly prevent a noncanonical type I interferon response</span></div><div class="casAuthors">Crowl John T; Stetson Daniel B</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6798-6803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Detection of nucleic acids by innate immune sensors triggers the production of type I interferons (IFNs).  While IFNs are essential for host defense against viral infection, dysregulated production of IFNs underlies numerous autoinflammatory diseases.  We have found that the loss of sumoylation results in a potent, spontaneous IFN response.  Vertebrates possess three small ubiquitin-like modifiers (SUMOs) that can be conjugated onto target proteins and alter protein function in diverse but still poorly characterized ways.  We demonstrate that regulation of IFN by sumoylation is redundantly mediated by both SUMO2 and SUMO3, but not SUMO1, revealing a previously unknown function of SUMO2/3.  Remarkably, this IFN response is independent of all known IFN-inducing pathways and does not require either of the canonical IFN-associated transcription factors IRF3 or IRF7.  Taken together, our findings demonstrate that SUMO2 and SUMO3 are specific and essential negative regulators of a noncanonical mechanism of IFN induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqfLtnKg3oakodMGTatQ7LfW6udTcc2eYO9p58615BDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbmt1Crsg%253D%253D&md5=9424d47505eb615f8eb86a2ab294ed35</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1802114115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1802114115%26sid%3Dliteratum%253Aachs%26aulast%3DCrowl%26aufirst%3DJ.%2BT.%26aulast%3DStetson%26aufirst%3DD.%2BB.%26atitle%3DSUMO2%2520and%2520SUMO3%2520redundantly%2520prevent%2520a%2520noncanonical%2520type%2520I%2520interferon%2520response%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D26%26spage%3D6798%26epage%3D6803%26doi%3D10.1073%2Fpnas.1802114115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhardt, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraj, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spelman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sells, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visiers, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span> <span> </span><span class="NLM_article-title">Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2009.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.molcel.2009.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=20129059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFKgsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=102-111&issue=1&author=J.+E.+Brownellauthor=M.+D.+Sintchakauthor=J.+M.+Gavinauthor=H.+Liaoauthor=F.+J.+Bruzzeseauthor=N.+J.+Bumpauthor=T.+A.+Soucyauthor=M.+A.+Milhollenauthor=X.+Yangauthor=A.+L.+Burkhardtauthor=J.+Maauthor=H.+K.+Lokeauthor=T.+Lingarajauthor=D.+Wuauthor=K.+B.+Hammanauthor=J.+J.+Spelmanauthor=C.+A.+Cullisauthor=S.+P.+Langstonauthor=S.+Vyskocilauthor=T.+B.+Sellsauthor=W.+D.+Mallenderauthor=I.+Visiersauthor=P.+Liauthor=C.+F.+Claiborneauthor=M.+Rolfeauthor=J.+B.+Bolenauthor=L.+R.+Dick&title=Substrate-assisted+inhibition+of+ubiquitin-like+protein-activating+enzymes%3A+the+NEDD8+E1+inhibitor+MLN4924+forms+a+NEDD8-AMP+mimetic+in+situ&doi=10.1016%2Fj.molcel.2009.12.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ</span></div><div class="casAuthors">Brownell, James E.; Sintchak, Michael D.; Gavin, James M.; Liao, Hua; Bruzzese, Frank J.; Bump, Nancy J.; Soucy, Teresa A.; Milhollen, Michael A.; Yang, Xiaofeng; Burkhardt, Anne L.; Ma, Jingya; Loke, Huay-Keng; Lingaraj, Trupti; Wu, Dongyun; Hamman, Kristin B.; Spelman, James J.; Cullis, Courtney A.; Langston, Steven P.; Vyskocil, Stepan; Sells, Todd B.; Mallender, William D.; Visiers, Irache; Li, Ping; Claiborne, Christopher F.; Rolfe, Mark; Bolen, Joseph B.; Dick, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The NEDD8-activating enzyme (NAE) initiates a protein homeostatic pathway essential for cancer cell growth and survival.  MLN4924 is a selective inhibitor of NAE currently in clin. trials for the treatment of cancer.  Here, we show that MLN4924 is a mechanism-based inhibitor of NAE and creates a covalent NEDD8-MLN4924 adduct catalyzed by the enzyme.  The NEDD8-MLN4924 adduct resembles NEDD8 adenylate, the first intermediate in the NAE reaction cycle, but cannot be further utilized in subsequent intraenzyme reactions.  The stability of the NEDD8-MLN4924 adduct within the NAE active site blocks enzyme activity, thereby accounting for the potent inhibition of the NEDD8 pathway by MLN4924.  Importantly, we have detd. that compds. resembling MLN4924 demonstrate the ability to form analogous adducts with other ubiquitin-like proteins (UBLs) catalyzed by their cognate-activating enzymes.  These findings reveal insights into the mechanism of E1s and suggest a general strategy for selective inhibition of UBL conjugation pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrGGYI7bTPerVg90H21EOLACvtfcHk0ljiKfp-BhBKfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFKgsbw%253D&md5=b080f6ec40864164ab2252f629975456</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2009.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2009.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DLiao%26aufirst%3DH.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DBump%26aufirst%3DN.%2BJ.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBurkhardt%26aufirst%3DA.%2BL.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLoke%26aufirst%3DH.%2BK.%26aulast%3DLingaraj%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DHamman%26aufirst%3DK.%2BB.%26aulast%3DSpelman%26aufirst%3DJ.%2BJ.%26aulast%3DCullis%26aufirst%3DC.%2BA.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DSells%26aufirst%3DT.%2BB.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DVisiers%26aufirst%3DI.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DDick%26aufirst%3DL.%2BR.%26atitle%3DSubstrate-assisted%2520inhibition%2520of%2520ubiquitin-like%2520protein-activating%2520enzymes%253A%2520the%2520NEDD8%2520E1%2520inhibitor%2520MLN4924%2520forms%2520a%2520NEDD8-AMP%2520mimetic%2520in%2520situ%26jtitle%3DMol.%2520Cell%26date%3D2010%26volume%3D37%26issue%3D1%26spage%3D102%26epage%3D111%26doi%3D10.1016%2Fj.molcel.2009.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsu, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallender, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span> <span> </span><span class="NLM_article-title">Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">40867</span>– <span class="NLM_lpage">40877</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.279984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1074%2Fjbc.M111.279984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=21969368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=40867-40877&issue=47&author=J.+J.+Chenauthor=C.+A.+Tsuauthor=J.+M.+Gavinauthor=M.+A.+Milhollenauthor=F.+J.+Bruzzeseauthor=W.+D.+Mallenderauthor=M.+D.+Sintchakauthor=N.+J.+Bumpauthor=X.+Yangauthor=J.+Maauthor=H.+K.+Lokeauthor=Q.+Xuauthor=P.+Liauthor=N.+F.+Benceauthor=J.+E.+Brownellauthor=L.+R.+Dick&title=Mechanistic+studies+of+substrate-assisted+inhibition+of+ubiquitin-activating+enzyme+by+adenosine+sulfamate+analogues&doi=10.1074%2Fjbc.M111.279984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues</span></div><div class="casAuthors">Chen, Jesse J.; Tsu, Christopher A.; Gavin, James M.; Milhollen, Michael A.; Bruzzese, Frank J.; Mallender, William D.; Sintchak, Michael D.; Bump, Nancy J.; Yang, Xiaofeng; Ma, Jingya; Loke, Huay-Keng; Xu, Qing; Li, Ping; Bence, Neil F.; Brownell, James E.; Dick, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">40867-40877</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ubiquitin-activating enzyme (UAE or E1) activates ubiquitin via an adenylate intermediate and catalyzes its transfer to a ubiquitin-conjugating enzyme (E2).  MLN4924 is an adenosine sulfamate analog that was identified as a selective, mechanism-based inhibitor of NEDD8-activating enzyme (NAE), another E1 enzyme, by forming a NEDD8-MLN4924 adduct that tightly binds at the active site of NAE, a novel mechanism termed substrate-assisted inhibition.  In the present study, substrate-assisted inhibition of human UAE (Ube1) by another adenosine sulfamate analog, 5'-O-sulfamoyl-N6-[(1S)-2,3-dihydro-1H-inden-1-yl]-adenosine (Compd. I), a nonselective E1 inhibitor, was characterized.  Compd. I inhibited UAE-dependent ATP-PPi exchange activity, caused loss of UAE thioester, and inhibited E1-E2 transthiolation in a dose-dependent manner.  Mechanistic studies on Compd. I and its purified ubiquitin adduct demonstrate that the proposed substrate-assisted inhibition via covalent adduct formation is entirely consistent with the three-step ubiquitin activation process and that the adduct is formed via nucleophilic attack of UAE thioester by the sulfamate group of Compd. I after completion of step 2.  Kinetic and affinity anal. of Compd. I, MLN4924, and their purified ubiquitin adducts suggest that both the rate of adduct formation and the affinity between the adduct and E1 contribute to the overall potency.  Because all E1s are thought to use a similar mechanism to activate their cognate ubiquitin-like proteins, the substrate-assisted inhibition by adenosine sulfamate analogs represents a promising strategy to develop potent and selective E1 inhibitors that can modulate diverse biol. pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiclhUT_b-7Vg90H21EOLACvtfcHk0lhzfOJzCoGnNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOqu7nE&md5=2362ac83bb8acf0de63162bac731c6e7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.279984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.279984%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DTsu%26aufirst%3DC.%2BA.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBruzzese%26aufirst%3DF.%2BJ.%26aulast%3DMallender%26aufirst%3DW.%2BD.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DBump%26aufirst%3DN.%2BJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLoke%26aufirst%3DH.%2BK.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBence%26aufirst%3DN.%2BF.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DDick%26aufirst%3DL.%2BR.%26atitle%3DMechanistic%2520studies%2520of%2520substrate-assisted%2520inhibition%2520of%2520ubiquitin-activating%2520enzyme%2520by%2520adenosine%2520sulfamate%2520analogues%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26issue%3D47%26spage%3D40867%26epage%3D40877%26doi%3D10.1074%2Fjbc.M111.279984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capili, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cisar, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S.</span></span> <span> </span><span class="NLM_article-title">Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1748</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1021/ja9088549</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9088549" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVSiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=1748-1749&issue=6&author=X.+Luauthor=S.+K.+Olsenauthor=A.+D.+Capiliauthor=J.+S.+Cisarauthor=C.+D.+Limaauthor=D.+S.+Tan&title=Designed+semisynthetic+protein+inhibitors+of+Ub%2FUbl+E1+activating+enzymes&doi=10.1021%2Fja9088549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Semisynthetic Protein Inhibitors of Ub/Ubl E1 Activating Enzymes</span></div><div class="casAuthors">Lu, Xuequan; Olsen, Shaun K.; Capili, Allan D.; Cisar, Justin S.; Lima, Christopher D.; Tan, Derek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1748-1749</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Semisynthetic, mechanism-based protein inhibitors of ubiquitin (Ub) and ubiquitin-like modifier (Ubl) activating enzymes (E1s) have been developed to target E1-catalyzed adenylation and thioesterification of the Ub/Ubl C-terminus during the processes of protein SUMOylation and ubiquitination.  The inhibitors were generated by intein-mediated expressed protein ligation using a truncated Ub/Ubl protein (SUMO residues 1-94; Ub residues 1-71) with a C-terminal thioester and synthetic tripeptides having a C-terminal adenosine analog and an N-terminal cysteine residue.  SUMO-AMSN (4a) and Ub-AMSN (4b) contain a sulfamide group as a nonhydrolyzable mimic of the phosphate group in the cognate Ub/Ubl-AMP adenylate intermediate in the first half-reaction, and these constructs selectively inhibit SUMO E1 and Ub E1, resp., in a dose-dependent manner.  SUMO-AVSN (5a) and Ub-AVSN (5b) contain an electrophilic vinyl sulfonamide designed to trap the incoming E1 cysteine nucleophile (Uba2 Cys173 in SUMO E1; Uba1 Cys593 in Ub E1) in the second half-reaction, and these constructs selectively, covalently, and stably cross-link to SUMO E1 and Ub E1, resp., in a cysteine nucleophile-dependent manner.  These inhibitors are powerful tools to probe outstanding mechanistic questions in E1 function and can also be used to study the biol. functions of E1 enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFrlstIrtwC7Vg90H21EOLACvtfcHk0ljFaBrqAwSKVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVSiurY%253D&md5=2c7015f7594aa5fb6f540c8679101fce</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fja9088549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9088549%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26aulast%3DCapili%26aufirst%3DA.%2BD.%26aulast%3DCisar%26aufirst%3DJ.%2BS.%26aulast%3DLima%26aufirst%3DC.%2BD.%26aulast%3DTan%26aufirst%3DD.%2BS.%26atitle%3DDesigned%2520semisynthetic%2520protein%2520inhibitors%2520of%2520Ub%252FUbl%2520E1%2520activating%2520enzymes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26issue%3D6%26spage%3D1748%26epage%3D1749%26doi%3D10.1021%2Fja9088549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capili, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. D.</span></span> <span> </span><span class="NLM_article-title">Active site remodelling accompanies thioester bond formation in the SUMO E1</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span> (<span class="NLM_issue">7283</span>),  <span class="NLM_fpage">906</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1038/nature08765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnature08765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=20164921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFemsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=906-912&issue=7283&author=S.+K.+Olsenauthor=A.+D.+Capiliauthor=X.+Luauthor=D.+S.+Tanauthor=C.+D.+Lima&title=Active+site+remodelling+accompanies+thioester+bond+formation+in+the+SUMO+E1&doi=10.1038%2Fnature08765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Active site remodelling accompanies thioester bond formation in the SUMO E1</span></div><div class="casAuthors">Olsen, Shaun K.; Capili, Allan D.; Lu, Xuequan; Tan, Derek S.; Lima, Christopher D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7283</span>),
    <span class="NLM_cas:pages">906-912</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">E1 enzymes activate ubiquitin (Ub) and ubiquitin-like (Ubl) proteins in two steps by carboxy-terminal adenylation and thioester bond formation to a conserved catalytic cysteine in the E1 Cys domain.  The structural basis for these intermediates remains unknown.  Here we report crystal structures for human SUMO E1 in complex with SUMO adenylate and tetrahedral intermediate analogs at 2.45 and 2.6 Å, resp.  These structures show that side chain contacts to ATP·Mg are released after adenylation to facilitate a 130 degree rotation of the Cys domain during thioester bond formation that is accompanied by remodeling of key structural elements including the helix that contains the E1 catalytic cysteine, the crossover and re-entry loops, and refolding of two helixes that are required for adenylation.  These changes displace side chains required for adenylation with side chains required for thioester bond formation.  Mutational and biochem. analyses indicate these mechanisms are conserved in other E1s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9k1BOu5nwaLVg90H21EOLACvtfcHk0ljFaBrqAwSKVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFemsr8%253D&md5=1c21dabaaa4d831db0bb9bb343ffe555</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature08765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08765%26sid%3Dliteratum%253Aachs%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26aulast%3DCapili%26aufirst%3DA.%2BD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DD.%2BS.%26aulast%3DLima%26aufirst%3DC.%2BD.%26atitle%3DActive%2520site%2520remodelling%2520accompanies%2520thioester%2520bond%2520formation%2520in%2520the%2520SUMO%2520E1%26jtitle%3DNature%26date%3D2010%26volume%3D463%26issue%3D7283%26spage%3D906%26epage%3D912%26doi%3D10.1038%2Fnature08765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixby, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faessel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedarati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezube, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span> <span> </span><span class="NLM_article-title">Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1111/bjh.13323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1111%2Fbjh.13323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=25733005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2015&pages=534-543&issue=4&author=R.+T.+Swordsauthor=H.+P.+Erbaauthor=D.+J.+DeAngeloauthor=D.+L.+Bixbyauthor=J.+K.+Altmanauthor=M.+Marisauthor=Z.+Huaauthor=S.+J.+Blakemoreauthor=H.+Faesselauthor=F.+Sedaratiauthor=B.+J.+Dezubeauthor=F.+J.+Gilesauthor=B.+C.+Medeiros&title=Pevonedistat+%28MLN4924%29%2C+a+First-in-Class+NEDD8-activating+enzyme+inhibitor%2C+in+patients+with+acute+myeloid+leukaemia+and+myelodysplastic+syndromes%3A+a+phase+1+study&doi=10.1111%2Fbjh.13323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study</span></div><div class="casAuthors">Swords, Ronan T.; Erba, Harry P.; DeAngelo, Daniel J.; Bixby, Dale L.; Altman, Jessica K.; Maris, Michael; Hua, Zhaowei; Blakemore, Stephen J.; Faessel, Helene; Sedarati, Farhad; Dezube, Bruce J.; Giles, Francis J.; Medeiros, Bruno C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">534-543</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : This trial was conducted to det. the dose-limiting toxicities (DLTs) and max. tolerated dose (MTD) of the first in class NEDD8-activating enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).  Pevonedistat was administered via a 60-min i.v. infusion on days 1, 3 and 5 (schedule A, n = 27), or days 1, 4, 8 and 11 (schedule B, n = 26) every 21-days.  Dose escalation proceeded using a std. '3 + 3' design.  Responses were assessed according to published guidelines.  The MTD for schedules A and B were 59 and 83 mg/m2, resp.  On schedule A, hepatotoxicity was dose limiting.  Multi-organ failure (MOF) was dose limiting on schedule B. The overall complete (CR) and partial (PR) response rate in patients treated at or below the MTD was 17% (4/23, 2 CRs, 2 PRs) for schedule A and 10% (2/19, 2 PRs) for schedule B. Pevonedistat plasma concns. peaked after infusion followed by elimination in a biphasic pattern.  Pharmacodynamic studies of biol. correlates of NAE inhibition demonstrated target-specific activity of pevonedistat.  In conclusion, administration of the first-in-class agent, pevonedistat, was feasible in patients with MDS and AML and modest clin. activity was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKvj57_N1VFrVg90H21EOLACvtfcHk0li55ajjpiTWAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOntLY%253D&md5=435529c5ec061a767d00a3feb6589bb1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fbjh.13323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.13323%26sid%3Dliteratum%253Aachs%26aulast%3DSwords%26aufirst%3DR.%2BT.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DMaris%26aufirst%3DM.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DBlakemore%26aufirst%3DS.%2BJ.%26aulast%3DFaessel%26aufirst%3DH.%26aulast%3DSedarati%26aufirst%3DF.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26atitle%3DPevonedistat%2520%2528MLN4924%2529%252C%2520a%2520First-in-Class%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukaemia%2520and%2520myelodysplastic%2520syndromes%253A%2520a%2520phase%25201%2520study%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2015%26volume%3D169%26issue%3D4%26spage%3D534%26epage%3D543%26doi%3D10.1111%2Fbjh.13323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span>; <span class="NLM_string-name">Langston, S. P.</span>; <span class="NLM_string-name">Vyskocil, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Potent NAE Inhibitor: Pevonedistat</span>. In  <i>Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Vol. 2</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, F. A.-M.</span>, <span class="NLM_string-name">Pesti, J. A..</span>, <span class="NLM_string-name">Vaidyanathan, R.</span></span>, Eds.; <span class="NLM_publisher-name">ACS Symposium Series</span>: <span class="NLM_year">2016</span>; Vol.  <span class="NLM_volume">1240</span>, pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1240.ch001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=1-11&author=H.+Mizutani&author=S.+P.+Langston&author=S.+Vyskocilauthor=F.+A.-M.+Ahmed&author=J.+A..+Pesti&author=R.+Vaidyanathan&title=Comprehensive+Accounts+of+Pharmaceutical+Research+and+Development%3A+From+Discovery+to+Late-Stage+Process+Development+Vol.+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1240.ch001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Fbk-2016-1240.ch001%26sid%3Dliteratum%253Aachs%26aulast%3DMizutani%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520a%2520Potent%2520NAE%2520Inhibitor%253A%2520Pevonedistat%26btitle%3DComprehensive%2520Accounts%2520of%2520Pharmaceutical%2520Research%2520and%2520Development%253A%2520From%2520Discovery%2520to%2520Late-Stage%2520Process%2520Development%2520Vol.%25202%26aulast%3DAhmed%26aufirst%3DF.%2BA.-M.%26pub%3DACS%2520Symposium%2520Series%26date%3D2016%26volume%3D1240%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams-Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span> <span> </span><span class="NLM_article-title">MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.1182/blood-2010-03-272567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1182%2Fblood-2010-03-272567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=20525923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2qsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=1515-1523&issue=9&author=M.+A.+Milhollenauthor=T.+Traoreauthor=J.+Adams-Duffyauthor=M.+P.+Thomasauthor=A.+J.+Bergerauthor=L.+Dangauthor=L.+R.+Dickauthor=J.+J.+Garnseyauthor=E.+Koenigauthor=S.+P.+Langstonauthor=M.+Manfrediauthor=U.+Narayananauthor=M.+Rolfeauthor=L.+M.+Staudtauthor=T.+A.+Soucyauthor=J.+Yuauthor=J.+Zhangauthor=J.+B.+Bolenauthor=P.+G.+Smith&title=MLN4924%2C+a+NEDD8-activating+enzyme+inhibitor%2C+is+active+in+diffuse+large+B-cell+lymphoma+models%3A+rationale+for+treatment+of+NF-%7Bkappa%7DB-dependent+lymphoma&doi=10.1182%2Fblood-2010-03-272567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma</span></div><div class="casAuthors">Milhollen, Michael A.; Traore, Tary; Adams-Duffy, Jennifer; Thomas, Michael P.; Berger, Allison J.; Dang, Lenny; Dick, Lawrence R.; Gamsey, James J.; Koenig, Erik; Langston, Steven P.; Manfredi, Mark; Narayanan, Usha; Rolfe, Mark; Staudt, Louis M.; Soucy, Teresa A.; Yu, Jie; Zhang, Julie; Bolen, Joseph B.; Smith, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1515-1523</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">MLN4924 is a potent and selective small mol. NEDD8-activating enzyme (NAE) inhibitor.  In most cancer cells tested, inhibition of NAE leads to induction of DNA rereplication, resulting in DNA damage and cell death.  However, in preclin. models of activated B cell-like (ABC) diffuse large B-cell lymphoma (DLBCL), we show that MLN4924 induces an alternative mechanism of action.  Treatment of ABC DLBCL cells with MLN4924 resulted in rapid accumulation of pIκBα, decrease in nuclear p65 content, redn. of nuclear factor-κB (NF-κB) transcriptional activity, and G1 arrest, ultimately resulting in apoptosis induction, events consistent with potent NF-κB pathway inhibition.  Treatment of germinal-center B cell-like (GCB) DLBCL cells resulted in an increase in cellular Cdt-1 and accumulation of cells in S-phase, consistent with cells undergoing DNA rereplication.  In vivo administration of MLN4924 to mice bearing human xenograft tumors of ABC- and GCB-DLBCL blocked NAE pathway biomarkers and resulted in complete tumor growth inhibition.  In primary human tumor models of ABC-DLBCL, MLN4924 treatment resulted in NF-κB pathway inhibition accompanied by tumor regressions.  This work describes a novel mechanism of targeted NF-κB pathway modulation in DLBCL and provides strong rationale for clin. development of MLN4924 against NF-κB-dependent lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Ez4BtgNx0LVg90H21EOLACvtfcHk0li55ajjpiTWAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2qsbzO&md5=6100194d48b30325e94b3b0cdb77fae0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-03-272567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-03-272567%26sid%3Dliteratum%253Aachs%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DAdams-Duffy%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DKoenig%26aufirst%3DE.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DNarayanan%26aufirst%3DU.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26atitle%3DMLN4924%252C%2520a%2520NEDD8-activating%2520enzyme%2520inhibitor%252C%2520is%2520active%2520in%2520diffuse%2520large%2520B-cell%2520lymphoma%2520models%253A%2520rationale%2520for%2520treatment%2520of%2520NF-%257Bkappa%257DB-dependent%2520lymphoma%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26issue%3D9%26spage%3D1515%26epage%3D1523%26doi%3D10.1182%2Fblood-2010-03-272567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doucette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershman, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talreja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyskocil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S. P.</span></span> <span> </span><span class="NLM_article-title">An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>458</i></span> (<span class="NLM_issue">7239</span>),  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1038/nature07884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnature07884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=19360080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=732-736&issue=7239&author=T.+A.+Soucyauthor=P.+G.+Smithauthor=M.+A.+Milhollenauthor=A.+J.+Bergerauthor=J.+M.+Gavinauthor=S.+Adhikariauthor=J.+E.+Brownellauthor=K.+E.+Burkeauthor=D.+P.+Cardinauthor=S.+Critchleyauthor=C.+A.+Cullisauthor=A.+Doucetteauthor=J.+J.+Garnseyauthor=J.+L.+Gaulinauthor=R.+E.+Gershmanauthor=A.+R.+Lublinskyauthor=A.+McDonaldauthor=H.+Mizutaniauthor=U.+Narayananauthor=E.+J.+Olhavaauthor=S.+Pelusoauthor=M.+Rezaeiauthor=M.+D.+Sintchakauthor=T.+Talrejaauthor=M.+P.+Thomasauthor=T.+Traoreauthor=S.+Vyskocilauthor=G.+S.+Weatherheadauthor=J.+Yuauthor=J.+Zhangauthor=L.+R.+Dickauthor=C.+F.+Claiborneauthor=M.+Rolfeauthor=J.+B.+Bolenauthor=S.+P.+Langston&title=An+inhibitor+of+NEDD8-activating+enzyme+as+a+new+approach+to+treat+cancer&doi=10.1038%2Fnature07884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer</span></div><div class="casAuthors">Soucy, Teresa A.; Smith, Peter G.; Milhollen, Michael A.; Berger, Allison J.; Gavin, James M.; Adhikari, Sharmila; Brownell, James E.; Burke, Kristine E.; Cardin, David P.; Critchley, Stephen; Cullis, Courtney A.; Doucette, Amanda; Garnsey, James J.; Gaulin, Jeffrey L.; Gershman, Rachel E.; Lublinsky, Anna R.; McDonald, Alice; Mizutani, Hirotake; Narayanan, Usha; Olhava, Edward J.; Peluso, Stephane; Rezaei, Mansoureh; Sintchak, Michael D.; Talreja, Tina; Thomas, Michael P.; Traore, Tary; Vyskocil, Stepan; Weatherhead, Gabriel S.; Yu, Jie; Zhang, Julie; Dick, Lawrence R.; Claiborne, Christopher F.; Rolfe, Mark; Bolen, Joseph B.; Langston, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">7239</span>),
    <span class="NLM_cas:pages">732-736</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. development of an inhibitor of cellular proteasome function suggests that compds. targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies.  NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome.  Substrates of cullin-RING ligases have important roles in cellular processes assocd. with cancer cell growth and survival pathways.  Here we describe MLN4924, a potent and selective inhibitor of NAE.  MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumor cells by a new mechanism of action, the deregulation of S-phase DNA synthesis.  MLN4924 suppressed the growth of human tumor xenografts in mice at compd. exposures that were well tolerated.  Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8fx7OnZtYjbVg90H21EOLACvtfcHk0lgt1nokl3jxJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVenu7Y%253D&md5=365d4b4feac3994849050e00f1aae5e0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature07884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07884%26sid%3Dliteratum%253Aachs%26aulast%3DSoucy%26aufirst%3DT.%2BA.%26aulast%3DSmith%26aufirst%3DP.%2BG.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBerger%26aufirst%3DA.%2BJ.%26aulast%3DGavin%26aufirst%3DJ.%2BM.%26aulast%3DAdhikari%26aufirst%3DS.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DK.%2BE.%26aulast%3DCardin%26aufirst%3DD.%2BP.%26aulast%3DCritchley%26aufirst%3DS.%26aulast%3DCullis%26aufirst%3DC.%2BA.%26aulast%3DDoucette%26aufirst%3DA.%26aulast%3DGarnsey%26aufirst%3DJ.%2BJ.%26aulast%3DGaulin%26aufirst%3DJ.%2BL.%26aulast%3DGershman%26aufirst%3DR.%2BE.%26aulast%3DLublinsky%26aufirst%3DA.%2BR.%26aulast%3DMcDonald%26aufirst%3DA.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DNarayanan%26aufirst%3DU.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DPeluso%26aufirst%3DS.%26aulast%3DRezaei%26aufirst%3DM.%26aulast%3DSintchak%26aufirst%3DM.%2BD.%26aulast%3DTalreja%26aufirst%3DT.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DVyskocil%26aufirst%3DS.%26aulast%3DWeatherhead%26aufirst%3DG.%2BS.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DClaiborne%26aufirst%3DC.%2BF.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DBolen%26aufirst%3DJ.%2BB.%26aulast%3DLangston%26aufirst%3DS.%2BP.%26atitle%3DAn%2520inhibitor%2520of%2520NEDD8-activating%2520enzyme%2520as%2520a%2520new%2520approach%2520to%2520treat%2520cancer%26jtitle%3DNature%26date%3D2009%26volume%3D458%26issue%3D7239%26spage%3D732%26epage%3D736%26doi%3D10.1038%2Fnature07884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyer, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhollen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciavarri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sappal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzzese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riceberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lublinsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bump, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulukuri, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuranda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiby, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenspan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N. F.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/nm.4474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnm.4474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=29334375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=186-193&issue=2&author=M.+L.+Hyerauthor=M.+A.+Milhollenauthor=J.+Ciavarriauthor=P.+Flemingauthor=T.+Traoreauthor=D.+Sappalauthor=J.+Huckauthor=J.+Shiauthor=J.+Gavinauthor=J.+Brownellauthor=Y.+Yangauthor=B.+Stringerauthor=R.+Griffinauthor=F.+Bruzzeseauthor=T.+Soucyauthor=J.+Duffyauthor=C.+Rabinoauthor=J.+Ricebergauthor=K.+Hoarauthor=A.+Lublinskyauthor=S.+Menonauthor=M.+Sintchakauthor=N.+Bumpauthor=S.+M.+Pulukuriauthor=S.+Langstonauthor=S.+Tirrellauthor=M.+Kurandaauthor=P.+Veibyauthor=J.+Newcombauthor=P.+Liauthor=J.+T.+Wuauthor=J.+Poweauthor=L.+R.+Dickauthor=P.+Greenspanauthor=K.+Galvinauthor=M.+Manfrediauthor=C.+Claiborneauthor=B.+S.+Amidonauthor=N.+F.+Bence&title=A+small-molecule+inhibitor+of+the+ubiquitin+activating+enzyme+for+cancer+treatment&doi=10.1038%2Fnm.4474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment</span></div><div class="casAuthors">Hyer, Marc L.; Milhollen, Michael A.; Ciavarri, Jeff; Fleming, Paul; Traore, Tary; Sappal, Darshan; Huck, Jessica; Shi, Judy; Gavin, James; Brownell, Jim; Yang, Yu; Stringer, Bradley; Griffin, Robert; Bruzzese, Frank; Soucy, Teresa; Duffy, Jennifer; Rabino, Claudia; Riceberg, Jessica; Hoar, Kara; Lublinsky, Anya; Menon, Saurabh; Sintchak, Michael; Bump, Nancy; Pulukuri, Sai M.; Langston, Steve; Tirrell, Stephen; Kuranda, Mike; Veiby, Petter; Newcomb, John; Li, Ping; Wu, Jing Tao; Powe, Josh; Dick, Lawrence R.; Greenspan, Paul; Galvin, Katherine; Manfredi, Mark; Claiborne, Chris; Amidon, Benjamin S.; Bence, Neil F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-193</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis.  The therapeutic potential of this pathway has been validated by the clin. successes of a no. of UPS modulators, including proteasome inhibitors and immunomodulatory imide drugs (IMiDs).  Here we identified TAK-243 (formerly known as MLN7243) as a potent, mechanism-based small-mol. inhibitor of the ubiquitin activating enzyme (UAE), the primary mammalian E1 enzyme that regulates the ubiquitin conjugation cascade.  TAK-243 treatment caused depletion of cellular ubiquitin conjugates, resulting in disruption of signaling events, induction of proteotoxic stress, and impairment of cell cycle progression and DNA damage repair pathways.  TAK-243 treatment caused death of cancer cells and, in primary human xenograft studies, demonstrated antitumor activity at tolerated doses.  Due to its specificity and potency, TAK-243 allows for interrogation of ubiquitin biol. and for assessment of UAE inhibition as a new approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0GCsna-MdUrVg90H21EOLACvtfcHk0lgYmLyiZIkf4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVChtA%253D%253D&md5=06010b7eb1cc59cf3687b9c52844eb96</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnm.4474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4474%26sid%3Dliteratum%253Aachs%26aulast%3DHyer%26aufirst%3DM.%2BL.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DCiavarri%26aufirst%3DJ.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DTraore%26aufirst%3DT.%26aulast%3DSappal%26aufirst%3DD.%26aulast%3DHuck%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DGavin%26aufirst%3DJ.%26aulast%3DBrownell%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DStringer%26aufirst%3DB.%26aulast%3DGriffin%26aufirst%3DR.%26aulast%3DBruzzese%26aufirst%3DF.%26aulast%3DSoucy%26aufirst%3DT.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DRabino%26aufirst%3DC.%26aulast%3DRiceberg%26aufirst%3DJ.%26aulast%3DHoar%26aufirst%3DK.%26aulast%3DLublinsky%26aufirst%3DA.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DBump%26aufirst%3DN.%26aulast%3DPulukuri%26aufirst%3DS.%2BM.%26aulast%3DLangston%26aufirst%3DS.%26aulast%3DTirrell%26aufirst%3DS.%26aulast%3DKuranda%26aufirst%3DM.%26aulast%3DVeiby%26aufirst%3DP.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%2BT.%26aulast%3DPowe%26aufirst%3DJ.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGreenspan%26aufirst%3DP.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DClaiborne%26aufirst%3DC.%26aulast%3DAmidon%26aufirst%3DB.%2BS.%26aulast%3DBence%26aufirst%3DN.%2BF.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520the%2520ubiquitin%2520activating%2520enzyme%2520for%2520cancer%2520treatment%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26issue%3D2%26spage%3D186%26epage%3D193%26doi%3D10.1038%2Fnm.4474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciavarri, J.</span>; <span class="NLM_string-name">Langston, S.</span></span>, <span> </span><span class="NLM_article-title">The Discovery of First-in-Class Inhibitors of the Nedd8-Activating Enzyme (NAE) and the Ubiquitin-Activating Enzyme (UAE)</span>. In  <i>Comprehensive Medicinal Chemistry III</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span>, <span class="NLM_string-name">Rotella, D.</span>, <span class="NLM_string-name">Ward, S.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Oxford</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">8</span>, pp  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">112</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2FB978-0-12-409547-2.12459-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=95-112&author=J.+Ciavarri&author=S.+Langstonauthor=S.+Chackalamannil&author=D.+Rotella&author=S.+Ward&title=Comprehensive+Medicinal+Chemistry+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-409547-2.12459-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-409547-2.12459-X%26sid%3Dliteratum%253Aachs%26aulast%3DCiavarri%26aufirst%3DJ.%26atitle%3DThe%2520Discovery%2520of%2520First-in-Class%2520Inhibitors%2520of%2520the%2520Nedd8-Activating%2520Enzyme%2520%2528NAE%2529%2520and%2520the%2520Ubiquitin-Activating%2520Enzyme%2520%2528UAE%2529%26btitle%3DComprehensive%2520Medicinal%2520Chemistry%2520III%26aulast%3DChackalamannil%26aufirst%3DS.%26pub%3DElsevier%26date%3D2017%26volume%3D8%26spage%3D95%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statsyuk, A. V.</span></span> <span> </span><span class="NLM_article-title">Development of activity-based probes for ubiquitin and ubiquitin-like protein signaling pathways</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">16948</span>– <span class="NLM_lpage">16962</span>, <span class="refDoi"> DOI: 10.1021/ja4099643</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja4099643" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=16948-16962&issue=45&author=H.+Anauthor=A.+V.+Statsyuk&title=Development+of+activity-based+probes+for+ubiquitin+and+ubiquitin-like+protein+signaling+pathways&doi=10.1021%2Fja4099643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Activity-Based Probes for Ubiquitin and Ubiquitin-like Protein Signaling Pathways</span></div><div class="casAuthors">An, Heeseon; Statsyuk, Alexander V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">16948-16962</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ubiquitin and ubiquitin-like (UBL) proteins regulate a vast variety of cellular functions.  Some UBL proteins are present in all cell types, while others are expressed only in certain cells or under certain environmental conditions.  This highlights the central role of UBL systems in regulation of ubiquitous as well as specific cellular functions.  UBL proteins share little amino acid sequence identity to each other, yet they share similar 3D shapes, which is exemplified by the β-grasp fold.  Central to UBL protein signaling pathways are UBL protein-activating E1 enzymes that activate the C-terminus of UBL proteins for subsequent conjugation to the protein substrates.  Due to their crit. roles in biol., E1 enzymes have been recognized as emerging drug targets to treat human diseases.  In spite of their biol. significance, however, methods to discover UBL proteins and to monitor the intracellular activity of E1 enzymes are lacking.  Thus, there is a crit. need for methods to evaluate the intracellular mechanisms of action of E1 enzyme inhibitors.  Here we describe the development of a mechanism-based small-mol. probe, ABP1, that can be used to discover and to detect active UBL proteins, and to monitor the intracellular activity of E1 enzymes inside intact cells.  The developed probe can also be used to profile the selectivity of E1 enzyme-targeting drugs in vitro and inside intact cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodWCWohwWsNrVg90H21EOLACvtfcHk0lgYmLyiZIkf4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrrM&md5=d6e53c87761a79d3ac8636a44d09b017</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fja4099643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja4099643%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DH.%26aulast%3DStatsyuk%26aufirst%3DA.%2BV.%26atitle%3DDevelopment%2520of%2520activity-based%2520probes%2520for%2520ubiquitin%2520and%2520ubiquitin-like%2520protein%2520signaling%2520pathways%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26issue%3D45%26spage%3D16948%26epage%3D16962%26doi%3D10.1021%2Fja4099643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Statsyuk, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotriffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindelin, H.</span></span> <span> </span><span class="NLM_article-title">Dissecting the Specificity of Adenosyl Sulfamate Inhibitors Targeting the Ubiquitin-Activating Enzyme</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1120</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1016/j.str.2017.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.str.2017.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=28578874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptFClurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1120-1129&issue=7&author=M.+Misraauthor=M.+Kuhnauthor=M.+Lobelauthor=H.+Anauthor=A.+V.+Statsyukauthor=C.+Sotrifferauthor=H.+Schindelin&title=Dissecting+the+Specificity+of+Adenosyl+Sulfamate+Inhibitors+Targeting+the+Ubiquitin-Activating+Enzyme&doi=10.1016%2Fj.str.2017.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting the Specificity of Adenosyl Sulfamate Inhibitors Targeting the Ubiquitin-Activating Enzyme</span></div><div class="casAuthors">Misra, Mohit; Kuhn, Maximilian; Loebel, Mark; An, Heeseon; Statsyuk, Alexander V.; Sotriffer, Christoph; Schindelin, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1120-1129.e3</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Targeting the activating enzymes (E1) of ubiquitin (Ub) and ubiquitin-like modifiers (Ubls) has emerged as a promising anti-cancer strategy, possibly overcoming the ineffectiveness of proteasome inhibitors against solid tumors.  Here, we report crystal structures of the yeast ubiquitin E1 (Uba1) with three adenosyl sulfamate inhibitors exhibiting different E1 specificities, which are all covalently linked to ubiquitin.  The structures illustrate how the chem. diverse inhibitors are accommodated within the adenylation active site.  When compared with the previously reported structures of various E1 enzymes, our structures provide the basis of the preferences of these inhibitors for different Ub/Ubl-activating enzymes.  In vitro inhibition assays and mol. dynamics simulations validated the specificities of the inhibitors as deduced from the structures.  Taken together, the structures establish a framework for the development of addnl. compds. targeting E1 enzymes, which will display higher potency and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRazXmQXgL4LVg90H21EOLACvtfcHk0lj5l21X_zIGYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptFClurc%253D&md5=78ff180520852f9baab732964a09d613</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2017.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2017.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DM.%26aulast%3DLobel%26aufirst%3DM.%26aulast%3DAn%26aufirst%3DH.%26aulast%3DStatsyuk%26aufirst%3DA.%2BV.%26aulast%3DSotriffer%26aufirst%3DC.%26aulast%3DSchindelin%26aufirst%3DH.%26atitle%3DDissecting%2520the%2520Specificity%2520of%2520Adenosyl%2520Sulfamate%2520Inhibitors%2520Targeting%2520the%2520Ubiquitin-Activating%2520Enzyme%26jtitle%3DStructure%26date%3D2017%26volume%3D25%26issue%3D7%26spage%3D1120%26epage%3D1129%26doi%3D10.1016%2Fj.str.2017.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodeoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span> <span> </span><span class="NLM_article-title">Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2009.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.chembiol.2009.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=19246003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFagtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=133-140&issue=2&author=I.+Fukudaauthor=A.+Itoauthor=G.+Hiraiauthor=S.+Nishimuraauthor=H.+Kawasakiauthor=H.+Saitohauthor=K.+Kimuraauthor=M.+Sodeokaauthor=M.+Yoshida&title=Ginkgolic+acid+inhibits+protein+SUMOylation+by+blocking+formation+of+the+E1-SUMO+intermediate&doi=10.1016%2Fj.chembiol.2009.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Ginkgolic Acid Inhibits Protein SUMOylation by Blocking Formation of the E1-SUMO Intermediate</span></div><div class="casAuthors">Fukuda, Isao; Ito, Akihiro; Hirai, Go; Nishimura, Shinichi; Kawasaki, Hisashi; Saitoh, Hisato; Kimura, Ken-ichi; Sodeoka, Mikiko; Yoshida, Minoru</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-140</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Protein modification by small ubiquitin-related modifier proteins (SUMOs) controls diverse cellular functions.  Dysregulation of SUMOylation or deSUMOylation processes has been implicated in the development of cancer and neurodegenerative diseases.  However, no small-mol. inhibiting protein SUMOylation has been reported so far.  Here, we report inhibition of SUMOylation by ginkgolic acid and its analog, anacardic acid.  Ginkgolic acid and anacardic acid inhibit protein SUMOylation both in vitro and in vivo without affecting in vivo ubiquitination.  Binding assays with a fluorescently labeled probe showed that ginkgolic acid directly binds E1 and inhibits the formation of the E1-SUMO intermediate.  These studies will provide not only a useful tool for investigating the roles of SUMO conjugations in a variety of pathways in cells, but also a basis for the development of drugs targeted against diseases involving aberrant SUMOylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoilR5o6aqeKrVg90H21EOLACvtfcHk0lj5l21X_zIGYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFagtbw%253D&md5=64eca326e5b3426a8d1b807bea9a5b48</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2009.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2009.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DI.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DHirai%26aufirst%3DG.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DSaitoh%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DSodeoka%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DM.%26atitle%3DGinkgolic%2520acid%2520inhibits%2520protein%2520SUMOylation%2520by%2520blocking%2520formation%2520of%2520the%2520E1-SUMO%2520intermediate%26jtitle%3DChem.%2520Biol.%26date%3D2009%26volume%3D16%26issue%3D2%26spage%3D133%26epage%3D140%26doi%3D10.1016%2Fj.chembiol.2009.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirohama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koshino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of protein SUMOylation by davidiin, an ellagitannin from Davidia involucrata</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1038/ja.2013.142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fja.2013.142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=24424345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvV2ltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2014&pages=335-338&issue=4&author=M.+Takemotoauthor=Y.+Kawamuraauthor=M.+Hirohamaauthor=Y.+Yamaguchiauthor=H.+Handaauthor=H.+Saitohauthor=Y.+Nakaoauthor=M.+Kawadaauthor=K.+Khalidauthor=H.+Koshinoauthor=K.+Kimuraauthor=A.+Itoauthor=M.+Yoshida&title=Inhibition+of+protein+SUMOylation+by+davidiin%2C+an+ellagitannin+from+Davidia+involucrata&doi=10.1038%2Fja.2013.142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of protein SUMOylation by davidiin, an ellagitannin from Davidia involucrata</span></div><div class="casAuthors">Takemoto, Misao; Kawamura, Yumi; Hirohama, Mikako; Yamaguchi, Yuki; Handa, Hiroshi; Saitoh, Hisato; Nakao, Yoichi; Kawada, Manabu; Khalid, Khan; Koshino, Hiroyuki; Kimura, Ken-ichi; Ito, Akihiro; Yoshida, Minoru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-338</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein sumoylation regulates numerous biol. processes including transcription, the cell cycle, DNA repair, and innate immunity.  Like ubiquitination, sumoylation is reversible; the desumoylation process is mediated by SUMO-specific proteases.  Abnormal sumoylation is implicated in various diseases including neurodegenerative disease, viral infection, and cancer.  Therefore, enzymes responsible for the SUMO conjugation pathway represent potential targets for drug discovery.  To date, several natural products including ginkgolic acid, anacardic acid, kerriamycin B7, and spectromycin B18, as well as synthetic compds. have been reported to inhibit protein sumoylation.  Here, the authors report another natural product that functions as a sumoylation inhibitor: davidiin (I), an ellagitannin purified from the plant D. involucrata.  Although most known sumoylation inhibitors function in the micromolar range, I was particularly potent, inhibiting at sub-micromolar concns.  Purified I inhibited the in vitro sumoylation of RanGAP1-C2 protein in a dose-dependent manner, and its IC50 value was 0.15 μM.  In addn., I reduced the level of sumoylation of p53 protein in a dose-dependent manner.  Importantly, I did not influence the cellular level of ubiquitinated proteins.  These results indicated that I inhibits protein sumoylation both in vitro and in vivo without affecting protein ubiquitination.  Next, the authors sought to identify the target of I.  High-level expression of genes involved in sumoylation is frequently obsd. in cancer.  In addn., SUMO E1 has an important role in Myc-driven tumorigenesis.  Accordingly, the authors tested the effects of I on the proliferation of cancer cells.  I inhibited cell proliferation of several cancer cells in a dose-dependent manner with similar GI50 values (gastric cancer MKN-45 cells: 8.3 μM, prostate cancer DU-145 cells: 11.6 μM, and lung cancer NCI-H460 cells: 16.4 μM).  Recent studies showed that I inhibited the growth of hepatocellular carcinoma cells by down-regulating EZH2 (enhancer of zeste homolog 2), the enzymic subunit of the Polycomb-repressive complex 2 that catalyzes histone H3 Lys-27 methylation, which is highly expressed in a variety of human cancers.  Importantly in this regard, EZH2 is SUMOylated in cells.  Here, the authors showed that I inhibited the cell growth of several cancer cells including DU-145 cells, in which EZH2 is overexpressed.  Thus, although the mol. mechanism by which I inhibits cancer cell growth remains to be elucidated, these observations suggest that the antitumor activity of I is mediated, at least in part, by inhibition of sumoylation of proteins, including EZH2.  Analyses of the structure-activity relations of I should facilitate development of novel anti-cancer agents targeting protein sumoylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLeUTKQAnSALVg90H21EOLACvtfcHk0lj5l21X_zIGYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvV2ltrc%253D&md5=51ec85a5148b6e6fb68a28bf923c5e65</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fja.2013.142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2013.142%26sid%3Dliteratum%253Aachs%26aulast%3DTakemoto%26aufirst%3DM.%26aulast%3DKawamura%26aufirst%3DY.%26aulast%3DHirohama%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DSaitoh%26aufirst%3DH.%26aulast%3DNakao%26aufirst%3DY.%26aulast%3DKawada%26aufirst%3DM.%26aulast%3DKhalid%26aufirst%3DK.%26aulast%3DKoshino%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520protein%2520SUMOylation%2520by%2520davidiin%252C%2520an%2520ellagitannin%2520from%2520Davidia%2520involucrata%26jtitle%3DJ.%2520Antibiot.%26date%3D2014%26volume%3D67%26issue%3D4%26spage%3D335%26epage%3D338%26doi%3D10.1038%2Fja.2013.142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uramoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span> <span> </span><span class="NLM_article-title">Kerriamycin B inhibits protein SUMOylation</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1038/ja.2009.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fja.2009.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=19265871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlt1Smtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2009&pages=221-224&issue=4&author=I.+Fukudaauthor=A.+Itoauthor=M.+Uramotoauthor=H.+Saitohauthor=H.+Kawasakiauthor=H.+Osadaauthor=M.+Yoshida&title=Kerriamycin+B+inhibits+protein+SUMOylation&doi=10.1038%2Fja.2009.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Kerriamycin B inhibits protein SUMOylation</span></div><div class="casAuthors">Fukuda, Isao; Ito, Akihiro; Uramoto, Masakazu; Saitoh, Hisato; Kawasaki, Hisashi; Osada, Hiroyuki; Yoshida, Minoru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-224</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors report a novel activity of kerriamycin B that inhibits protein SUMOylation, which will provide useful information about the role of SUMOylation in cells and drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4vd7M4mI--bVg90H21EOLACvtfcHk0liDFooh4f8QoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlt1Smtr8%253D&md5=267d0861d4124ce1dc926fa9eb2d0dde</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fja.2009.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2009.10%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DI.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DUramoto%26aufirst%3DM.%26aulast%3DSaitoh%26aufirst%3DH.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DOsada%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26atitle%3DKerriamycin%2520B%2520inhibits%2520protein%2520SUMOylation%26jtitle%3DJ.%2520Antibiot.%26date%3D2009%26volume%3D62%26issue%3D4%26spage%3D221%26epage%3D224%26doi%3D10.1038%2Fja.2009.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riceberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minissale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xega, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sintchak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightcap, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulukuri, S. M.</span></span> <span> </span><span class="NLM_article-title">Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1164</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fnchembio.2463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=28892090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKltbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=1164-1171&issue=11&author=X.+Heauthor=J.+Ricebergauthor=T.+Soucyauthor=E.+Koenigauthor=J.+Minissaleauthor=M.+Galleryauthor=H.+Bernardauthor=X.+Yangauthor=H.+Liaoauthor=C.+Rabinoauthor=P.+Shahauthor=K.+Xegaauthor=Z.+H.+Yanauthor=M.+Sintchakauthor=J.+Bradleyauthor=H.+Xuauthor=M.+Duffeyauthor=D.+Englandauthor=H.+Mizutaniauthor=Z.+Huauthor=J.+Guoauthor=R.+Chauauthor=L.+R.+Dickauthor=J.+E.+Brownellauthor=J.+Newcombauthor=S.+Langstonauthor=E.+S.+Lightcapauthor=N.+Benceauthor=S.+M.+Pulukuri&title=Probing+the+roles+of+SUMOylation+in+cancer+cell+biology+by+using+a+selective+SAE+inhibitor&doi=10.1038%2Fnchembio.2463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor</span></div><div class="casAuthors">He, Xingyue; Riceberg, Jessica; Soucy, Teresa; Koenig, Erik; Minissale, James; Gallery, Melissa; Bernard, Hugues; Yang, Xiaofeng; Liao, Hua; Rabino, Claudia; Shah, Pooja; Xega, Kristina; Yan, Zhong-hua; Sintchak, Mike; Bradley, John; Xu, He; Duffey, Matt; England, Dylan; Mizutani, Hirotake; Hu, Zhigen; Guo, Jianping; Chau, Ryan; Dick, Lawrence R.; Brownell, James E.; Newcomb, John; Langston, Steve; Lightcap, Eric S.; Bence, Neil; Pulukuri, Sai M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1164-1171</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Small ubiquitin-like modifier (SUMO) family proteins regulate target-protein functions by post-translational modification.  However, a potent and selective inhibitor targeting the SUMO pathway has been lacking.  Here we describe ML-792, a mechanism-based SUMO-activating enzyme (SAE) inhibitor with nanomolar potency in cellular assays.  ML-792 selectively blocks SAE enzyme activity and total SUMOylation, thus decreasing cancer cell proliferation.  Moreover, we found that induction of the MYC oncogene increased the ML-792-mediated viability effect in cancer cells, thus indicating a potential application of SAE inhibitors in treating MYC-amplified tumors.  Using ML-792, we further explored the crit. roles of SUMOylation in mitotic progression and chromosome segregation.  Furthermore, expression of an SAE catalytic-subunit (UBA2) S95N M97T mutant rescued SUMOylation loss and the mitotic defect induced by ML-792, thus confirming the selectivity of ML-792.  As a potent and selective SAE inhibitor, ML-792 provides rapid loss of endogenously SUMOylated proteins, thereby facilitating novel insights into SUMO biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNkvcAW2wXqLVg90H21EOLACvtfcHk0liDFooh4f8QoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKltbfJ&md5=62ee63218ec5f40923370294780a0f7f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2463%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DRiceberg%26aufirst%3DJ.%26aulast%3DSoucy%26aufirst%3DT.%26aulast%3DKoenig%26aufirst%3DE.%26aulast%3DMinissale%26aufirst%3DJ.%26aulast%3DGallery%26aufirst%3DM.%26aulast%3DBernard%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiao%26aufirst%3DH.%26aulast%3DRabino%26aufirst%3DC.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DXega%26aufirst%3DK.%26aulast%3DYan%26aufirst%3DZ.%2BH.%26aulast%3DSintchak%26aufirst%3DM.%26aulast%3DBradley%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DDuffey%26aufirst%3DM.%26aulast%3DEngland%26aufirst%3DD.%26aulast%3DMizutani%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DChau%26aufirst%3DR.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DBrownell%26aufirst%3DJ.%2BE.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DLangston%26aufirst%3DS.%26aulast%3DLightcap%26aufirst%3DE.%2BS.%26aulast%3DBence%26aufirst%3DN.%26aulast%3DPulukuri%26aufirst%3DS.%2BM.%26atitle%3DProbing%2520the%2520roles%2520of%2520SUMOylation%2520in%2520cancer%2520cell%2520biology%2520by%2520using%2520a%2520selective%2520SAE%2520inhibitor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26issue%3D11%26spage%3D1164%26epage%3D1171%26doi%3D10.1038%2Fnchembio.2463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkison, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of a human ubiquitin E1-ubiquitin complex reveals conserved functional elements essential for activity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span> (<span class="NLM_issue">47</span>),  <span class="NLM_fpage">18337</span>– <span class="NLM_lpage">18352</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA118.003975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1074%2Fjbc.RA118.003975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=30279270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12ksrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=18337-18352&issue=47&author=Z.+Lvauthor=K.+M.+Williamsauthor=L.+Yuanauthor=J.+H.+Atkisonauthor=S.+K.+Olsen&title=Crystal+structure+of+a+human+ubiquitin+E1-ubiquitin+complex+reveals+conserved+functional+elements+essential+for+activity&doi=10.1074%2Fjbc.RA118.003975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a human ubiquitin E1-ubiquitin complex reveals conserved functional elements essential for activity</span></div><div class="casAuthors">Lv, Zongyang; Williams, Katelyn M.; Yuan, Lingmin; Atkison, James H.; Olsen, Shaun K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">18337-18352</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ubiquitin (Ub) signaling plays a key regulatory role in nearly every aspect of eukaryotic biol. and is initiated by E1 enzymes that activate and transfer Ub to E2 Ub-conjugating enzymes.  Despite Ub E1's fundamental importance to the cell and its attractiveness as a target for therapeutic intervention in cancer and other diseases, its only available structural information is derived from yeast orthologs of human ubiquitin-like modifier-activating enzyme 1 (hUBA1).  To illuminate structural differences between yeast and hUBA1 structures that might be exploited for the development of small-mol. therapeutics, we detd. the first crystal structure of a hUBA1-Ub complex.  Using structural anal., mol. modeling, and biochem. anal., we demonstrate that hUBA1 shares a conserved overall structure and mechanism with previously characterized yeast orthologs, but displays subtle structural differences, particularly within the active site.  Computational anal. revealed four potential ligand-binding hot spots on the surface of hUBA1 that might serve as targets to inhibit hUBA1 at the level of Ub activation or E2 recruitment or that might potentially be used in approaches such as protein-targeting chimeric mols.  Taken together, our work enhances our understanding of the hUBA1 mechanism, provides an improved framework for the development of small-mol. inhibitors of UBA1, and serves as a stepping stone for structural studies that involve the enzymes of the human Ub system at the level of both E1 and E2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRhwD_aDGQ4rVg90H21EOLACvtfcHk0lhLuEur9w3Uag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12ksrzO&md5=760049e734451c2ed5b4aa1bbf8ce54c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.003975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.003975%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DZ.%26aulast%3DWilliams%26aufirst%3DK.%2BM.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DAtkison%26aufirst%3DJ.%2BH.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520a%2520human%2520ubiquitin%2520E1-ubiquitin%2520complex%2520reveals%2520conserved%2520functional%2520elements%2520essential%2520for%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26issue%3D47%26spage%3D18337%26epage%3D18352%26doi%3D10.1074%2Fjbc.RA118.003975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minissale, J.</span>; <span class="NLM_string-name">Burkhardt, A.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Minissale%2C+J.%3B+Burkhardt%2C+A.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DMinissale%26aufirst%3DJ." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shank, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doose, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streeter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialer, M.</span></span> <span> </span><span class="NLM_article-title">Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase</span>. <i>Epilepsy Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">2–3</span>),  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1016/j.eplepsyres.2005.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.eplepsyres.2005.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=15715969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtF2hsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2005&pages=103-112&issue=2%E2%80%933&author=R.+P.+Shankauthor=D.+R.+Dooseauthor=A.+J.+Streeterauthor=M.+Bialer&title=Plasma+and+whole+blood+pharmacokinetics+of+topiramate%3A+the+role+of+carbonic+anhydrase&doi=10.1016%2Fj.eplepsyres.2005.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase</span></div><div class="casAuthors">Shank, Richard P.; Doose, Dennis R.; Streeter, Anthony J.; Bialer, Meir</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">103-112</span>CODEN:
                <span class="NLM_cas:coden">EPIRE8</span>;
        ISSN:<span class="NLM_cas:issn">0920-1211</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Topiramate (TPM) is a broad-spectrum antiepileptic drug with various mechanisms of action including an inhibitory effect on some isoenzymes of carbonic anhydrase (CA).  Binding to CA-I and CA-II, which are highly concd. in erythrocytes, may affect drug pharmacokinetics.  Consequently, the objectives of this study were: (a) to comparatively assess TPM pharmacokinetics in healthy subjects, based on plasma and whole blood data, by simultaneously measuring TPM concns. in plasma and whole blood following different therapeutic doses; (b) to rigorously establish the affinity of TPM for CA-I and CA-II in order to gain insight into how binding to these isoenzymes in erythrocytes influences TPM pharmacokinetics.  TPM (100, 200 and 400 mg, single dose) was given in a randomized three-way crossover design to 27 healthy subjects and the drug concns. in plasma and whole blood were simultaneously measured for 168 h after dosing.  The pharmacokinetics of TPM in plasma was linear, but TPM clearance from whole blood increased with increasing dose.  At low therapeutic concns., the blood-to-plasma ratio for TPM decreased from 8 to 2 as its concn. increased, indicating a substantial and saturable binding of TPM to erythrocytes.  The kinetics (dissocn. binding const. -Kd and max. binding rate -Bmax) of the binding of TPM to erythrocytes was detd. from the measured concns. of TPM in whole blood and plasma.  This anal. indicated the existence of two binding sites with Kd values of 0.54 and 140 μM, and Bmax values of 22 and 124 μmol/L of erythrocyte vol., resp.  These Bmax values are similar to literature values for the molar concn. of human CA-II (14-25 μmol/L) and CA-I (115-125 μmol/L).  TPM inhibition const. (Ki) values for the inhibition of purified human CA obtained using assays based on CO2 hydration or 4-nitrophenylacetate hydrolysis were 0.62 and 0.49 μM for CA-II, and 91 and 93 μM for CA-I.  The results of these studies indicate that virtually all of the binding of TPM to erythrocytes is attributable to CA-I and CA-II.  Because CA-I and CA-II are highly concd. in erythrocytes, a large portion of TPM in whole blood is bound and serves as a depot.  This contributes to the lower oral clearance (CL/F), apparent vol. of distribution (Vss/F) and longer half-life (t 1/2) that TPM has in blood compared to the CL/F, Vss/F and t 1/2, estd. from plasma data.  The difference between TPM blood and plasma pharmacokinetics was more profound at low doses (≤100 mg/day).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEtCEepha3NLVg90H21EOLACvtfcHk0lhLuEur9w3Uag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtF2hsrk%253D&md5=c0691a2ff9425f452f04539c1988038c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.eplepsyres.2005.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eplepsyres.2005.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DShank%26aufirst%3DR.%2BP.%26aulast%3DDoose%26aufirst%3DD.%2BR.%26aulast%3DStreeter%26aufirst%3DA.%2BJ.%26aulast%3DBialer%26aufirst%3DM.%26atitle%3DPlasma%2520and%2520whole%2520blood%2520pharmacokinetics%2520of%2520topiramate%253A%2520the%2520role%2520of%2520carbonic%2520anhydrase%26jtitle%3DEpilepsy%2520Res.%26date%3D2005%26volume%3D63%26issue%3D2%25E2%2580%25933%26spage%3D103%26epage%3D112%26doi%3D10.1016%2Fj.eplepsyres.2005.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winum, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scozzafava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supuran, C. T.</span></span> <span> </span><span class="NLM_article-title">Sulfamates and their therapeutic potential</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1002/med.20021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1002%2Fmed.20021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=15478125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlWhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=186-228&issue=2&author=J.+Y.+Winumauthor=A.+Scozzafavaauthor=J.+L.+Monteroauthor=C.+T.+Supuran&title=Sulfamates+and+their+therapeutic+potential&doi=10.1002%2Fmed.20021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfamates and their therapeutic potential</span></div><div class="casAuthors">Winum, Jean-Yves; Scozzafava, Andrea; Montero, Jean-Louis; Supuran, Claudiu T.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-228</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Starting from the very simple mol. sulfamic acid, O-substituted-, N-substituted-, or di-/tri-substituted sulfamates may be obtained, which show specific biol. activities which were or started to be exploited for the design of many types of therapeutic agents.  Among them, sulfamate inhibitors of aminoacyl-tRNA synthetases (aaRSs) were recently reported, constituting completely new classes of antibiotics, useful in the fight of drug-resistant infections.  Anti-viral agents incorporating sulfamate moieties have also been obtained, with at least two types of such derivs. investigated: the nucleoside/nucleotide human immunodeficiency virus (HIV) reverse transcriptase inhibitors, and the HIV protease inhibitors (PIs).  In the increasing armamentarium of anti-cancer drugs, the sulfamates occupy a special position, with at least two important targets evidenced so far: the steroid sulfatases (STSs) and the carbonic anhydrases (CAs).  An impressing no. of inhibitors of STSs of the sulfamate type have been reported in the last years, with several compds., such as 667 COUMATE among others, progressing to clin. trials for the treatment of hormone-dependent tumors (breast and prostate cancers).  This field is rapidly evolving, with many types of new inhibitors being constantly reported and designed in such a way as to increase their anti-tumor properties, and decrease undesired features (for example, estrogenicity, a problem encountered with the first generation such inhibitors, such as EMATE).  Among the many isoenzymes of CAs, at least two, CA IX and CA XII, are highly overexpressed in tumors, being generally absent in the normal tissues.  Inhibition of tumor-assocd. CAs was hypothesized to lead to novel therapeutic approaches for the treatment of cancer.  Many sulfamates act as very potent (low nanomolar) CA inhibitors.  The x-ray crystal structure of the best-studied isoenzyme, CA II, with three sulfamates (sulfamic acid, topiramate, and EMATE) has recently been reported, which allowed for a rationale drug design of new inhibitors.  Indeed, low nanomolar CA IX inhibitors of the sulfamate type have been reported, although such compds. also act as efficient inhibitors of isoenzymes CA I and II, which are not assocd. with tumors.  A large no. of anti-convulsant sulfamates have been described, with one such compd., topiramate, being widely used clin. as anti-epileptic drug.  By taking into consideration a side effect of topiramate, an anti-epileptic drug leading to wt. loss in some patients, it has recently been proposed to use this drug and related sulfamates for the treatment of obesity.  The rationale of this use is based on the inhibition of the mitochondrial CA isoenzyme, CA V, involved in lipogenesis.  Some sulfamates were also shown to possess potent inhibitory activity against acyl CoA:cholesterol acyltransferase, an enzyme involved in cholesterol metab.  One such agent, avasimibe, is in advanced clin. trials for the treatment of hyperlipidemia and atherosclerosis.  Thus, the sulfamate moiety offers very attractive possibilities for the drug design of various pharmacol. agents, which are on one hand due to the relative ease with which such compds. are synthesized, and on the other one, due to the fact that biol. activity of most of them is impressive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIqLDcmtZep7Vg90H21EOLACvtfcHk0lhLuEur9w3Uag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlWhsL4%253D&md5=d9d2f31b7cdf47a11d204227813c0f2a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fmed.20021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20021%26sid%3Dliteratum%253Aachs%26aulast%3DWinum%26aufirst%3DJ.%2BY.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DMontero%26aufirst%3DJ.%2BL.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DSulfamates%2520and%2520their%2520therapeutic%2520potential%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2005%26volume%3D25%26issue%3D2%26spage%3D186%26epage%3D228%26doi%3D10.1002%2Fmed.20021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lightcap, Y. P.</span>; <span class="NLM_string-name">Grossman, S.</span>; <span class="NLM_string-name">Song, K.</span>; <span class="NLM_string-name">Khattar, M.</span>; <span class="NLM_string-name">Xega, K.</span>; <span class="NLM_string-name">He, X.</span>; <span class="NLM_string-name">Gavin, J. G.</span>; <span class="NLM_string-name">Imaichi, H.</span>; <span class="NLM_string-name">Garnsey, J. J.</span>; <span class="NLM_string-name">Koenig, E.</span>; <span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Lu, Z.</span>; <span class="NLM_string-name">Shah, P.</span>; <span class="NLM_string-name">Hatton, B. A.</span>; <span class="NLM_string-name">Riceberg, J.</span>; <span class="NLM_string-name">Shinde, V.</span>; <span class="NLM_string-name">Li, C.</span>; <span class="NLM_string-name">Minissale, J.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">England, D.</span>; <span class="NLM_string-name">Klinghoffer, R. A.</span>; <span class="NLM_string-name">Langston, S.</span>; <span class="NLM_string-name">Galvin, K.</span>; <span class="NLM_string-name">Shapiro, G.</span>; <span class="NLM_string-name">Pulukuri, S. M.</span>; <span class="NLM_string-name">Fuchs, S. Y.</span>; <span class="NLM_string-name">Huszar, D.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lightcap%2C+Y.+P.%3B+Grossman%2C+S.%3B+Song%2C+K.%3B+Khattar%2C+M.%3B+Xega%2C+K.%3B+He%2C+X.%3B+Gavin%2C+J.+G.%3B+Imaichi%2C+H.%3B+Garnsey%2C+J.+J.%3B+Koenig%2C+E.%3B+Zhang%2C+H.%3B+Lu%2C+Z.%3B+Shah%2C+P.%3B+Hatton%2C+B.+A.%3B+Riceberg%2C+J.%3B+Shinde%2C+V.%3B+Li%2C+C.%3B+Minissale%2C+J.%3B+Yang%2C+X.%3B+England%2C+D.%3B+Klinghoffer%2C+R.+A.%3B+Langston%2C+S.%3B+Galvin%2C+K.%3B+Shapiro%2C+G.%3B+Pulukuri%2C+S.+M.%3B+Fuchs%2C+S.+Y.%3B+Huszar%2C+D.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DLightcap%26aufirst%3DY.%2BP." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span> <i>TAK-981: A first-in-class SUMOylation inhibitor in phase 1 clinical trials promotes a Type I interferon response and antitumor immunity in preclinical models</i>, Session DDT01; <span class="NLM_publisher-name">American Association for Cancer Research</span>: <span class="NLM_publisher-loc">Atlanta, GA</span>, Mar 29–Apr 03, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+Huszar&title=TAK-981%3A+A+first-in-class+SUMOylation+inhibitor+in+phase+1+clinical+trials+promotes+a+Type+I+interferon+response+and+antitumor+immunity+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHuszar%26aufirst%3DD.%26btitle%3DTAK-981%253A%2520A%2520first-in-class%2520SUMOylation%2520inhibitor%2520in%2520phase%25201%2520clinical%2520trials%2520promotes%2520a%2520Type%2520I%2520interferon%2520response%2520and%2520antitumor%2520immunity%2520in%2520preclinical%2520models%26pub%3DAmerican%2520Association%2520for%2520Cancer%2520Research%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldana-Masangkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colayco, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobkova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divlianska, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergienko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakih, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1016%2Fj.chembiol.2018.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=30581133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2ksL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=278-288&issue=2&author=Y.+J.+Liauthor=L.+Duauthor=J.+Wangauthor=R.+Vegaauthor=T.+D.+Leeauthor=Y.+Miaoauthor=G.+Aldana-Masangkayauthor=E.+R.+Samuelsauthor=B.+Liauthor=S.+X.+Ouyangauthor=S.+A.+Colaycoauthor=E.+V.+Bobkovaauthor=D.+B.+Divlianskaauthor=E.+Sergienkoauthor=T.+D.+Y.+Chungauthor=M.+Fakihauthor=Y.+Chen&title=Allosteric+Inhibition+of+Ubiquitin-like+Modifications+by+a+Class+of+Inhibitor+of+SUMO-Activating+Enzyme&doi=10.1016%2Fj.chembiol.2018.10.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme</span></div><div class="casAuthors">Li, Yi-Jia; Du, Li; Wang, Jianghai; Vega, Ramir; Lee, Terry D.; Miao, Yunan; Aldana-Masangkay, Grace; Samuels, Eric R.; Li, Baozong; Ouyang, S. Xiaohu; Colayco, Sharon A.; Bobkova, Ekaterina V.; Divlianska, Daniela B.; Sergienko, Eduard; Chung, Thomas D. Y.; Fakih, Marwan; Chen, Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-288.e6</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ubiquitin-like (Ubl) post-translational modifications are potential targets for therapeutics.  However, the only known mechanism for inhibiting a Ubl-activating enzyme is through targeting its ATP-binding site.  Here we identify an allosteric inhibitory site in the small ubiquitin-like modifier (SUMO)-activating enzyme (E1).  This site was unexpected because both it and analogous sites are deeply buried in all previously solved structures of E1s of ubiquitin-like modifiers (Ubl).  The inhibitor not only suppresses SUMO E1 activity, but also enhances its degrdn. in vivo, presumably due to a conformational change induced by the compd.  In addn., the lead compd. increased the expression of miR-34b and reduced c-Myc levels in lymphoma and colorectal cancer cell lines and a colorectal cancer xenograft mouse model.  Identification of this first-in-class inhibitor of SUMO E1 is a major advance in modulating Ubl modifications for therapeutic aims.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiIbJhcJwpzrVg90H21EOLACvtfcHk0lhhAYgiMsmgOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2ksL7N&md5=ec87586d0834746bfdd8521d7a11725a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DVega%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DAldana-Masangkay%26aufirst%3DG.%26aulast%3DSamuels%26aufirst%3DE.%2BR.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DS.%2BX.%26aulast%3DColayco%26aufirst%3DS.%2BA.%26aulast%3DBobkova%26aufirst%3DE.%2BV.%26aulast%3DDivlianska%26aufirst%3DD.%2BB.%26aulast%3DSergienko%26aufirst%3DE.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DFakih%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DAllosteric%2520Inhibition%2520of%2520Ubiquitin-like%2520Modifications%2520by%2520a%2520Class%2520of%2520Inhibitor%2520of%2520SUMO-Activating%2520Enzyme%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D2%26spage%3D278%26epage%3D288%26doi%3D10.1016%2Fj.chembiol.2018.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkison, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessions, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divlianska, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-07015-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=10.1038%2Fs41467-018-07015-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=29317637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVakur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-12&author=Z.+Lvauthor=L.+Yuanauthor=J.+H.+Atkisonauthor=K.+M.+Williamsauthor=R.+Vegaauthor=E.+H.+Sessionsauthor=D.+B.+Divlianskaauthor=C.+Daviesauthor=Y.+Chenauthor=S.+K.+Olsen&title=Molecular+mechanism+of+a+covalent+allosteric+inhibitor+of+SUMO+E1+activating+enzyme&doi=10.1038%2Fs41467-018-07015-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme</span></div><div class="casAuthors">Lv, Zongyang; Yuan, Lingmin; Atkison, James H.; Williams, Katelyn M.; Vega, Ramir; Sessions, E. Hampton; Divlianska, Daniela B.; Davies, Christopher; Chen, Yuan; Olsen, Shaun K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">E1 enzymes activate ubiquitin (Ub) and ubiquitin-like modifiers (Ubls) in the first step of Ub/Ubl conjugation cascades and represent potential targets for therapeutic intervention in cancer and other life-threatening diseases.  Here, we report the crystal structure of the E1 enzyme for the Ubl SUMO in complex with a recently discovered and highly specific covalent allosteric inhibitor (COH000).  The structure reveals that COH000 targets a cryptic pocket distinct from the active site that is completely buried in all previous SUMO E1 structures and that COH000 binding to SUMO E1 is accompanied by a network of structural changes that altogether lock the enzyme in a previously unobserved inactive conformation.  These structural changes include disassembly of the active site and a 180° rotation of the catalytic cysteine-contg. SCCH domain, relative to conformational snapshots of SUMO E1 poised to catalyze adenylation.  Altogether, our study provides a mol. basis for the inhibitory mechanism of COH000 and its SUMO E1 specificity, and also establishes a framework for potential development of mols. targeting E1 enzymes for other Ubls at a cryptic allosteric site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmPuzjKgi2DrVg90H21EOLACvtfcHk0lhhAYgiMsmgOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVakur3O&md5=b86e1882ba6f772e9477a1fe3431f342</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-07015-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-07015-1%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DZ.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DAtkison%26aufirst%3DJ.%2BH.%26aulast%3DWilliams%26aufirst%3DK.%2BM.%26aulast%3DVega%26aufirst%3DR.%26aulast%3DSessions%26aufirst%3DE.%2BH.%26aulast%3DDivlianska%26aufirst%3DD.%2BB.%26aulast%3DDavies%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26atitle%3DMolecular%2520mechanism%2520of%2520a%2520covalent%2520allosteric%2520inhibitor%2520of%2520SUMO%2520E1%2520activating%2520enzyme%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fs41467-018-07015-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOI','PDB','6XOI'); return false;">PDB: 6XOI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOG','PDB','6XOG'); return false;">PDB: 6XOG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XOH','PDB','6XOH'); return false;">PDB: 6XOH</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i44"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01491">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_21102"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01491?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01491</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings file and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01491/suppl_file/jm0c01491_si_001.csv">CSV</a>)</p></li><li><p class="inline">Protocols for the in vitro and cell assays and in vivo experiments, synthetic methods for the remaining examples, HPLC traces of final compound, protein synthesis and purification methodology, and X-ray crystallographic and microelectron diffraction protocols (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01491/suppl_file/jm0c01491_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01491/suppl_file/jm0c01491_si_001.csv">jm0c01491_si_001.csv (6.99 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01491/suppl_file/jm0c01491_si_002.pdf">jm0c01491_si_002.pdf (4.33 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB depositions are available for SAE SUMO adducts of compounds <b>2</b>, <b>46</b>, <b>49</b>, and TAK-981. The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01491&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01491%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01491" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679943bc8f2fd93e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
